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Abstract  
  Pulmonary arterial hypertension (PAH) is a rare but devastating disease 
characterised by the progressive remodelling of the small pulmonary vessels. 
Although the causes may vary, similar pathobiological features are shared 
among different forms of PAH, with endothelial dysfunction, the 
hyperproliferation of smooth muscle cells and mesenchymal cells in the 
vascular wall, as well as inflammation contributing to this process. Despite the 
availability of licensed therapies, 5-year survival for patients remains less than 
60%. To uncover additional fundamental mechanisms of PAH pathobiology, our 
group undertook whole genome sequencing in 1038 idiopathic or heritable PAH 
patients and identified disease-associated heterozygous mutations in 
ATP13A3, a P5B-type ATPase. P5 ATPases, namely ATP13A1-5, are putative 
transmembrane proteins that generate and maintain significant chemical 
gradients across biological membranes by active transport of cations. However, 
to date, studies of their functions are sparse. Therefore, the focus of my project 
was to characterise ATP13A3 in the pulmonary vasculature and to uncover the 
underlying mechanism of how mutations in this gene contribute to PAH 
pathogenesis.  
  Although the biological functions of ATP13A3 are elusive, its homologue 
(CATP-5) in C. elegans was previously reported as a polyamine transporter. 
Polyamines are a group of naturally existing polycations essential for many 
cellular processes. Therefore, my working hypothesis was that ATP13A3 loss 
of function might disrupt the polyamine homeostasis and hence contribute to 
the abnormal vascular remodelling in PAH. To address this, I first confirmed 




localisation of ATP13A3 suggested it might be related to polyamine transport 
since the endocytic pathway was recognised as a crucial route for polyamine 
trafficking. To expand this finding, I developed molecular tools to knockdown or 
to overexpress ATP13A3 in vascular cells and analysed how these affected 
polyamine transport. This led to the discovery of putrescine as the preferred 
substrate for ATP13A3 and also revealed a basal reduction of other polyamines 
in endothelial cells.  
  Further investigation highlighted an essential role of ATP13A3 in pulmonary 
vasculature with its deficiency restrained cell growth and predisposed 
endothelial cells to apoptosis. To validate these findings, blood outgrowth 
endothelial cells (BOECs) were isolated from a PAH patient bearing an 
ATP13A3 frameshift mutation (LK726X). Intriguingly, ATP13A3LK726X, by 
causing ATP13A3 reduction, impaired polyamine uptake and induced 
apoptosis in BOECs. This provides the first evidence for the pathogenic effects 
of a PAH associated ATP13A3 mutation. In addition, using a lentiviral 
overexpression system, I also demonstrated impairments of other PAH-
associated mutations on ATP13A3 mediated polyamine uptake, reinforcing the 
involvement of ATP13A3 in PAH pathobiology. To explore whether ATP13A3 
mutations can cause PAH, our laboratory has generated a mouse model 
harbouring a human ATP13A3 mutation (P452Lfs) via the MRC Harwell Gene 
editing service. My colleague, Dr Ekaterina Legchenko and I have discovered 
that the Atp13a3P452Lfs/P452Lfs mice spontaneously develop PAH-like 
hemodynamic changes at 6-months of age. Preliminary data also revealed 
lower Atp13a3 level and reduced polyamine content in the lungs of the mutant 
mice, suggesting that Atp13a3 frameshift mutation (P452L) may contribute to 
PAH pathogenesis via the disruption of polyamine homeostasis in vivo. 
  In conclusion, my work characterises for the first time that ATP13A3 is a 
polyamine transporter in vascular cells with putrescine as its preferable 
transport substrate. ATP13A3 mutations identified from PAH patients are highly 




These findings open up a new field for investigating PAH pathobiology and also 
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1.1 Pulmonary Hypertension 
1.1.1 Clinical definition and classification  
  Pulmonary hypertension (PH) is a clinical condition characterised by elevated 
blood pressure in the pulmonary arteries. It was first defined by the WHO group 
as mean pulmonary arterial pressure (mPAP) ≥ 25mmHg measured at rest [1] 
and this definition has been used for decades. In 2009, a meta-analysis of the 
published data suggested that 20mmHg is the upper limit of the mPAP in the  
healthy population [2]. This makes mPAP between 21-24mmHg a “grey area”, 
although studies have suggested an increased risk of disease progression in 
patients with mPAP in this range [3-5]. Therefore, to address these recent 
findings, renewed PH definitions were proposed by the 6th World Symposium 
on Pulmonary Hypertension (WSPH) task force to redefine this clinical 
condition [6] (Table 1-1). However prospective studies are warranted to 
evaluate the benefits of management in this PH population. The updated 
clinical classification of PH was also released with minor changes while 
maintaining the 5 core groups [6] (Table 1-2). 
Table 1-1 Hemodynamic definitions of pulmonary hypertension (PH) 
 
mPAP: mean pulmonary arterial pressure; PAWP: pulmonary arterial wedge pressure; 
PVR: pulmonary vascular resistance; WU: Wood Units; # Group 1-5 PAH refer to the 
classification in Table1-2 [6]. 
Definitions Characteristics Clinical groups# 
Pre-capillary PH mPAP >20 mmHg 
PAWP ⩽15 mmHg 
PVR ⩾3 WU 
1, 3, 4 and 5 
Isolated post-capillary PH (IpcPH) mPAP >20 mmHg 
PAWP >15 mmHg
PVR <3 WU 
2 and 5 
Combined pre- and post-capillary PH (CpcPH) mPAP >20 mmHg 
PAWP >15 mmHg 
PVR ⩾3 WU 
2 and 5 
mPAP: mean pulmonary arterial pressure; PAWP: pulmonary arterial wedge pressure; PVR: pulmonary vascular
resistance; WU: Wood Units. #: group 1: PAH; group 2: PH due to left heart disease; group 3: PH due to lung
diseases and/or hypoxia; group 4: PH due to pulmonary artery obstructions; group 5: PH with unclear and/or
multifactorial mechanisms.




Table 1-2 Updated clinical classification of pulmonary hypertension (PH)  
 
PAH: pulmonary arterial hypertension; PVOD: pulmonary veno-occlusive disease; 





1.3 Drug- and toxin-induced PAH
1.4 PAH associated with: 
1.4.1 Connective tissue disease 
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease 
1.4.5 Schistosomiasis 
1.5 PAH long-term responders to calcium channel blockers
1.6 PAH with overt features of venous/capillaries (PVOD/PCH) involvement
1.7 Persistent PH of the newborn syndrome 
2 PH due to left heart disease 
2.1 PH due to heart failure with preserved LVEF
2.2 PH due to heart failure with reduced LVEF
2.3 Valvular heart disease
2.4 Congenital/acquired cardiovascular conditions leading to post-capillary PH 
3 PH due to lung diseases and/or hypoxia 
3.1 Obstructive lung disease
3.2 Restrictive lung disease
3.3 Other lung disease with mixed restrictive/obstructive pattern 
3.4 Hypoxia without lung disease
3.5 Developmental lung disorders 
4 PH due to pulmonary artery obstructions
4.1 Chronic thromboembolic PH 
4.2 Other pulmonary artery obstructions 
5 PH with unclear and/or multifactorial mechanisms
5.1 Haematological disorders
5.2 Systemic and metabolic disorders 
5.3 Others
5.4 Complex congenital heart disease 
PAH: pulmonary arterial hypertension; PVOD: pulmonary veno-occlusive disease; 
PCH: l onary capillary haemangiomat sis; L EF: left ventricular ej cti n fraction. 




1.1.2 Pulmonary arterial hypertension 
1.1.2.1 Overview 
  Pulmonary arterial hypertension (PAH) belongs to the group 1 pulmonary 
hypertension which is characterised by the progressive expansion of the 
muscle wall of small pulmonary arteries and the muscularisation of previously 
non-muscular arterioles. The resulting narrowing and occlusion of these 
vessels increases the pressures required to maintain blood flow and PAH is 
eventually lethal due to right heart failure if left untreated. Group 1 PAH can be 
idiopathic/heritable (I/HPAH), induced by drug/toxin, or secondary to other 
disease conditions. PAH patients who have a long-term response to calcium 
channel blockers were recently incorporated into group 1 PH (Table 1-2) to 
reflect the involvement of vasoconstriction in PAH pathophysiology. PAH is a 
rare disease with an incidence of 2.5-7.1 cases/million and a prevalence 
between 5-52/million in the adult population [7, 8]. Idiopathic and heritable PAH 
are the most common forms of PAH, accounting for approximately half of the 
patient population. This is followed by PAH secondary to other diseases, with 
connective tissue disease reported as the most prevalent aetiology [7, 9, 10].  
 
1.1.2.2 Pathology 
  PAH mainly affects the small distal muscularised pulmonary vessels ranging 
from 70µm to 500µm in diameter [11]. The pathology of PAH typically manifests 
as a series of remodelling events in the vessel wall, including hyperplasic or 
fibrotic intima, hypertrophic media, hyperproliferative adventitia, and/or in situ 
thrombosis [11-16]. These histological changes can either occur alone in mild 
cases or together to form concentric lesions in severe cases (Figure1-1 g-j [11], 
Figure 1-2 [16]) or eventually developed into plexiform lesions in end-stage 
conditions (Figure 1-1 a-c [11]; Figure 1-2 [16]), which completely block the 
vessels. PAH can also be characterised by abnormal muscularisation and 
fibrosis in the microvasculature, leading to obliteration and ultimately loss of 




pre-capillary arteries (Figure 1-3 [11]). Recent evidence has demonstrated 
perivascular infiltration and accumulation of inflammatory cells in the pathology 
of PAH (Figure 1-3 [11]), suggesting an important role for inflammation in 
disease development.  
 
Figure 1-1 Representative vascular lesions typically detected in lungs of 
patients with pulmonary arterial hypertension (PAH) 
a–c) Plexiform lesions. d) Atypical fibrovascular lesions e) Thrombotic lesion 
with fresh fibrin and fibroblasts involvement (arrows). f) Fully organised 
thrombotic lesion g) Concentric the intima with mild media thickening (arrows) 
h) Eccentric (cushion-like) intima i) media hyperplasia and adventitia fibrosis 
(arrows). Images adapted from Humbert, Marc, et al. European Respiratory 
Journal 2019 [11]. 





Figure 1-2 Pathology of vascular lesions in idiopathic pulmonary arterial 
hypertension Immunostaining of CD31 and α-smooth muscle actin (arrowed) 
demonstrating concentric intimal lesions and plexiform lesions in lung sections of idiopathic 
pulmonary arterial hypertension patients [16]. 
 
Figure 1-3 Lesions of the microvasculature in lungs of PAH or PVOD 
patients a) Inflammatory infiltration of micro-arteries or -venules b) Muscularised 
pulmonary vasculature (highlighted by α-SMA) in lungs of a PVOD patient. c) Patchy lung 
interstitial thickening in a PVOD patient d) Haemangiomatosis-like foci. e) Muscular 
hyperplasia and fibrous remodelling in pulmonary septal veins of a PAH patient. f) Fibrous 
intima thickening of small septal veins in a PVOD patient. Images readapted from Humbert, 
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1.1.2.3 The genetics of PAH 
  Though familial occurrence was initially described in 1891 [17], Dresdale 
highlighted a family with primary pulmonary hypertension (currently referred to 
as IPAH) in 1954. More extensive families with primary pulmonary hypertension 
were described in 1984, with 6-10% of the cases found to be familial and 
exhibiting an autosomal dominant inheritance with incomplete penetrance [18]. 
Later in 2000, heterozygous germline mutations were identified in BMPR2 [19] 
and since then, our understanding of the genetic architecture of PAH has 
steadily grown. It is now well established that mutations in BMPR2 cause nearly 
80% of familial PAH and approximately 20% of sporadic cases with reduced 
penetrance. In addition to BMPR2, mutations in genes encoding two other 
receptors of the TGFβ/BMP family, ALK1 and endoglin (ENG) were discovered 
in HHT families manifesting severe PAH symptoms [20, 21]. Later, DNA 
sequencing screening of genes downstream of the BMP signalling revealed 
rare variants in Smad-1, -4 and -9 in PAH patients [22, 23]. Interestingly, the 
initial genetic findings were mainly confined to TGF/BMP signalling, indicating 
an important role for disruption of this pathway in the pathogenesis of PAH. 
Over the last decade, advances in genetic techniques have substantially 
expanded our knowledge in the genetic causes of PAH. For example, whole 
exosome sequencing of blood samples uncovered rare mutations in caveolin-
1 (CAV-1) and potassium channel subfamily K member 3 (KCNK3) in familial 
PAH cases [24, 25]. Mutations in T-box 4 (TBX4), a gene, previously reported 
in small patella syndrome, were also associated with childhood cases of PAH 
[26]. In 2014, mutations in EIF2AK4, the gene encoding eukaryotic translation 
initiation factor 2 alpha kinase 4 were reported in PVOD and PCH cases. 
Recently, whole genome sequencing of a European-wide cohort consists of 
over 1000 I/HPAH cased revealed rare variants in four novel genes, namely 
ATP13A3, SOX17, AQP1 and GDF2 [27]. In addition, two BMP10 loss-of-
function mutations were also identified in severe PAH cases, further expanding 
the spectrum of BMP signalling in PAH molecular genetic framework [28, 29]. 




In summary, 16 genes (Table1-3) to date have been identified as contributing 
to the genetic architecture of PAH. Mutations in these genes are inherited 
predominantly in an autosomal dominant manner with incomplete penetrance 
[30, 31]. 
Table 1-3 Genetic features of 16 PAH associated genes 
 
AD, autosomal dominant; AR, autosomal recessive; MOI, mode of inheritance; NK, not 
known; Allelic series: number of distinct mutations, excluding recurrent variations. 
Mutation number: the total number of independent alleles reported, excluding related 
individuals. For biallelic mutations in EIF2AK4 and GDF2, each allele was counted as 
independent (that is, n = 2), except for five patients with documented consanguinity [31]. 
1.1.2.4 Pathogenesis of PAH 
1.1.2.4.1 Dysfunctional pulmonary vascular endothelium  
  The pulmonary vascular endothelium is the inner layer of the pulmonary 
vasculature. This monolayer ‘barrier” is formed mainly by the pulmonary 
vascular endothelial cells (ECs), separating the bloodstream from lung tissue 
and playing a pivotal role in maintaining vascular-tissue homeostasis. 
Gene Allelic series Mutation number MOI Molecular mechanism
BMPR2 486 806 AD Haploinsufficiency 
EIF2AK4 58 101 AR/AD Loss of function
ACVRL1 54 76 AD Haploinsufficiency
TBX4 55 48 AD NK
GDF2 30 34 AD/AR Haploinsufficiency
SOX17 24 26 AD NK
ENG 16 17 AD NK
KCNK3 15 16 AD Haploinsufficiency
ABCC8 12 12 AD Haploinsufficiency
ATP13A3 11 11 AD NK
SMAD9 10 11 AD Haploinsufficiency
AQP1 5 9 AD NK
CAV1 3 4 AD Gain of function;Dominant negative
BMP10 2 2 AD NK
SMAD4 2 2 AD NK
SMAD1 1 1 AD NK




Endothelial dysfunction was first recognised in the pathogenesis of PAH for 
mediating elevated vascular tone [32, 33]. Under physiological conditions, a low 
pulmonary vascular tone is maintained by a dynamic balance between 
vasoconstrictors and vasodilators. Pulmonary vascular ECs synthesise 
vasodilators, such as Nitric oxide (NO) and prostacyclin (PGI2), to favour vaso-
relaxation. However, under disease conditions (e.g. PAH), the production of 
vasodilators is suppressed [34] while vasoconstrictors including Endothelin-1 
(ET-1), Thromboxane A2 [35], Serotonin (5-HT) [36] are elevated, resulting in 
a high vascular tone. These findings led to the development of the current PAH 
specific therapies which mainly target the calcium channels, nitric oxide 
pathway, endothelin pathway and also prostacyclin pathway for promoting 
vasodilatation [32]. However, as vasoconstriction only accounts for disease in 
a small proportion of PAH patients [37, 38], whereas vascular remodelling 
remains the predominant pathogenic cause, new therapeutic strategies are 
required.  
  Apart from causing abnormal vascular tone, endothelial dysfunction also 
leads to an impairment of endothelial integrity, manifesting as increases of EC 
apoptosis and permeability [39]. Several lines of evidence have linked the 
initiation of pulmonary arterial hypertension to endothelial cell apoptosis [40-
43]. The plant alkaloid monocrotaline (MCT), after being metabolised into MCT 
pyrrole, causes PH in rats, at least in part, via endothelial injury [44]. Vascular 
endothelial growth factor (VEGF) is a potent survival factor protecting 
endothelial cells from apoptosis. SU5416, a semi-selective tyrosine kinase 
VEGFR2 inhibitor, combined with hypoxia can also establish PH in rats by 
mediating EC apoptosis [45]. Gene-based VEGF overexpression [46, 47] 
attenuated both MCT- and Sugen/hypoxia-induced PH by decreasing EC 
caspase activities, further implicating EC apoptosis as a pivotal cause of 
disease development. Increased endothelial apoptosis is also linked to the 
dysregulation of PAH associated genes. Teichert-Kuliszewska et al. [48] 
showed that BMPR2 loss-of-function predisposes hPAECs to apoptosis. In the 




same study, BOECs derived from patients bearing BMPR2 mutations failed to 
respond to the antiapoptotic effect of BMP2 under serum withdrawal. Our group 
also demonstrated that BMP9, by selectively targeting PAECs, prevented TNF-
α induced apoptosis via BMPR2 and reversed experimental PAH related to 
endothelial injury [39]. Similar to BMPR2, preliminary data also suggest that 
ATP13A3 silencing by small interfering RNA predisposed BOECs to apoptosis 
[27]. Interestingly, contrary to disease initiation, hyper-proliferative, apoptosis-
resistant EC populations are also evident in PAH, mostly during the late stage 
of disease progression. Masri et al. [49] demonstrated that hPAECs isolated 
from PAH patients were more proliferative and inhibition of Janus Kinase (JAK) 
could attenuate their proliferation. Decreased miRNA-124 via affecting PTBP1 
and PKM1/PKM2 in PAH patient-derived endothelial cells was recently 
demonstrated to be associated with abnormal pulmonary artery endothelial cell 
proliferation and glycolysis [50]. These hyper-proliferative, anti-apoptotic ECs 
arise as a result of the initial endothelial injury, as continuous apoptosis and 
renewal of endothelial cells may favour the selection of such a population [51]. 
However, the full mechanism underlying these divergent observations is still 
unclear as multiple factors including the genetic background, hypoxia and 
inflammation may be involved. Increased endothelial permeability has also 
been documented in PAH. BMP signalling holds great importance to endothelial 
homeostasis. siBMPR2 was shown to mediate leakage and promote leukocytes 
transmigration in hPAECs under both static- and flow-based conditions [52]. 
Mice bearing a PAH associated mutation Bmpr2-R899X exhibited increased 
vascular leakage and spontaneously developed PAH at 6-months of age [39]. 
Recently, other than the BMP signalling, researchers have also demonstrated 
a transient receptor potential channel 4 (TRPC4)-dependent pulmonary 
vascular leakage, indicating a role of Ca2+ in endothelial permeability. These 
together suggest that increased endothelial permeability could be an important 
contributor to pulmonary vascular remodelling. 




  The pathobiology of PAH is also characterised by dysregulated angiogenesis. 
This is evidenced by the elevated plasma VEGF observed in severe PAH cases 
[53] and also the abundant expression of VEGF and its cognate receptor 
(VEGFR2) in complex PAH associated lung lesions [54]. BMP9 was also 
demonstrated to promote endothelial stability by suppressing this pathological 
angiogenesis [39]. These lines of evidence suggest PAH might be a 
proangiogenic disorder. However, the fact that combining SU4516 with chronic 
hypoxia can induce experimental PH, and loss of pre-capillary arteries is a 
feature of the pathology of PAH [40] suggest an anti-angiogenic mechanism 
underlies the disease pathogenesis. These seemingly paradoxical findings 
indicate that the pro- or anti-angiogenic events in the pathogenesis of PAH may 
be context-dependent and involve multiple pathways. For example, Bmpr2 
knockout mice exhibit impaired angiogenesis in the uterine decidua via 
repression of VEGF signalling [55]. On the other hand, the VEGFR3 receptor 
facilitates BMP signalling by promoting BMPR2 internalisation. In mice, 
endothelial-specific knockdown of Vegfr3 exaggerated hypoxia-induced PH 
phenotypes by impairing the BMP signalling [56]. These findings provide 
evidence for an aberrant interplay between BMP and VEGF signalling in the 
context of angiogenesis, possibly contributing to the pathogenesis of PAH.  
  It has also been reported that endothelial dysfunction in the pathobiology of 
PAH is accompanied by an abnormal immune response. Overproduction of 
inflammatory cytokines or chemokines were observed in endothelial cells in 
hypoxia or with a genetic predisposition [57, 58]. The acquisition of pro-
inflammatory phenotypes by PAECs has recently been described in PAH. 
Under disease-promoting conditions, endothelial cells upregulate the 
expression of E-selectin, intercellular adhesion molecule 1 (ICAM1) and 
vascular cell adhesion molecule 1 (VCAM1), resulting in the recruitment of 
leukocytes and the promotion of vascular remodelling [59]. In PAH, endothelial 
dysfunction, by mediating IL-6 and FGF2 overproduction, also leads to 
increased pericyte coverage of distal pre-capillary pulmonary arteries [60]. This 




underpins the importance of communication between endothelial cells and 
other cells resident in the vessel wall for the maintenance of vascular 
homeostasis. 
 
1.1.2.4.2 Dysfunctional smooth muscle cells and adventitial fibroblasts 
  Pulmonary vascular remodelling in PAH is also hallmarked by 
hyperproliferative and apoptosis-resistant pulmonary artery smooth muscle 
cells. hPASMCs harvested from PAH patients with BMPR2 mutations were 
insensitive to the normal growth inhibitory response to BMP4 due to impairment 
of Smad1/5 signalling [61]. Moreover, TNF repressed BMPR2 expression and 
promoted BMP6 mediated hPASMC proliferation via dysregulated Src family 
signalling [62]. FoxO1, a critical transcription factor that regulates cell 
proliferation, was demonstrated to be downregulated in PAH patients. Inhibition 
of FoxO1 with the inhibitor, AS1842856, or transduction of cells with a 
constitutively active FoxO1 mutant increased PASMC proliferation [63]. 
Excessive levels of several growth factors have been demonstrated in vascular 
lesions in PAH and are suggested to contribute to vascular cell abnormalities. 
Factors produced by PAECs, such as serotonin [64] and endothelin-1 [65], also 
induce PASMC proliferation. Moreover, proliferation of PASMCs could be 
triggered by other growth factors, namely fibroblast growth factor 2 (FGF2), 
epidermal growth factor (EGF) and platelet derived growth factor (PDGF) [66, 
67]. Among these, PDGF is a potent stimulus for pulmonary vascular 
abnormalities with both PDGF-A and PDGF-B found to be upregulated in the 
pulmonary arteries of severe PAH cases [68]. In addition, treating patients with 
Imatinib, a receptor tyrosine kinase inhibitor initially designed to target Abl 
kinase, but with activity towards PDGF receptors, improved pulmonary vascular 
resistance (PVR) and cardiac output (CO) in PAH patients, implying an 
important contribution of PDGF signalling to the pathology of PAH [69]. 
Moreover, other cancer-related signalling pathways are also implicated in the 




hyperproliferative responses of PASMCs in PAH. Mammalian target of 
rapamycin 2(mTORC2) has been shown to activate mTORC1 via AMPK and 
contributes to PASMC proliferation [70]. Pulmonary artery adventitial 
hypertrophy, dominated by dysfunctional fibroblasts, is another hallmark of the 
pathological changes in PAH, contributing to increased pulmonary artery 
stiffness. Pulmonary artery adventitial fibroblasts, particularly under hypoxia, 
secrete a series of adhesion molecules and cytokines e.g. ICAM-1, VCAM-1, 
TGF-β which promote the recruitment of leukocytes into the adventitial 
compartment and together trigger subsequent inflammatory responses leading 
to vascular remodelling [71]. 
 
1.1.2.4.3 Immune disturbance 
  Inflammation and dysregulated immune responses have been implicated in 
the pathogenesis of PAH. Histological analysis revealed perivascular infiltration 
of inflammatory cells and lymphoid neogenesis in the precapillary arteries of 
PAH patients [72, 73]. Increased plasma cytokines and chemokines were also 
reported in PAH patients, with higher levels of IL1α/β, IL2, IL6, IL10, IL12 or 
TNFα associating with a poorer prognosis [74]. Overproduction of these 
inflammatory mediators leads to endothelial injury [75], abnormal recruitment 
of leukocytes [59] and smooth muscle/fibroblast proliferation [76, 77], thus 
contributing to vascular remodelling in PAH. Aberrant inflammatory responses 
also happen when BMP signalling is disrupted. LPS exposure promotes IL-6 
and IL-8 production in both Bmpr2-/+ mice and PASMCs isolated from BMPR2 
mutation carriers [58]. Moreover, loss of BMPR2 increases the phosphorylated-
p38 pathway, resulting in the overproduction of IL-6 [78]. Apart from being 
affected by BMP signalling, inflammatory factors also mediate the regulation of 
BMPR2. Our group has previously reported that TNFα promotes the 
development of PAH by transcriptionally suppressing BMPR2 while enhancing 
its cleavage in hPASMCs [62]. The elevation of circulating TNFα in PAH 




patients suggests an important role for TNFα as a modifier of disease 
penetrance. 
 
1.1.2.4.4 Genetic mechanisms of PAH pathobiology 
TGFβ/BMP signalling pathway It is recognised that the TGFβ/BMP signalling 
pathway is central to the molecular genetic framework of PAH, with mutations 
in BMPR2, the gene encoding the BMP type II receptor as the most common 
cause of HPAH [30, 31]. BMPR2 is widely expressed in different tissues and 
plays pivotal roles in the functions of several BMP ligands [79]. To mediate 
signal transduction, BMPR2 forms a heteromeric receptor complex with one of 
four type I receptors, ALK1, ALK2, ALK3 or ALK6 that dictate the selectivity of 
the receptor complex for particular BMP ligands. Upon binding of a dimeric BMP 
ligand, the constitutively active kinase domain of BMPR2 then 
transphosphorylates the kinase domain of the type I receptor, which in turn 
catalyses C-terminal phosphorylation of the downstream canonical Smad1/5/8 
(receptor-regulated Smads(R-Smads)) proteins [80, 81]. Once activated, the R-
Smads form a complex with the nuclear chaperone Smad4, and this complex 
then translocates into the nucleus to they control the transcriptional regulation 
of target genes [82]. BMPR2 is highly expressed on the cell surface of the 
pulmonary endothelial cells and mediates BMP9 and BMP10 signalling with the 
endothelial-specific type I receptor (ALK1) and co-receptor (ENG) [79]. 
Mutations in these genes cause aberrant BMP signalling, contributing to the 
endothelial dysfunction underlying PAH [31]. However, only 20-30% of the 
BMPR2 mutation carriers develop PAH, indicating that other factors may 
contribute to the disease penetrance. Indeed, dysregulated oestrogen 
metabolism may account for the higher penetrance in female patients [83]. 
TNFα, a potent inflammatory cytokine, disrupts BMP signalling by suppressing 
the expression of BMPR2. This provides evidence for the potential involvement 
of inflammation as a factor in driving disease [62]. More recently, somatic 




mutations acquired in PAH patients were reported as causing DNA damage 
and are a possible contributor to the disease penetrance of BMPR2 mutations 
[84]. In addition to disrupting endothelial cell functions, hPASMCs bearing PAH-
related BMPR2 mutations also exhibit disease-associated phenotypes [85], 
suggesting that BMPR2 dysfunction contributes to disease by affecting multiple 
cell types. Apart from the receptors, mutations were also identified in the 
SMAD1, SMAD9 and SMAD4 genes, which encode the proteins responsible 
for canonical BMP signal transduction. Recently, mutations in GDF2, the gene 
encoding BMP9, were also identified in HPAH cases [27]. A follow-up study 
demonstrated that these GDF2 mutations impair BMP9 processing and 
secretion and lead to reduced circulating levels of BMP9 and BMP10 [29].  
Caveolin-1 (CAV1) CAV1 encodes the scaffolding protein caveolin-1, which is 
the main component of the invaginations of the plasma membrane. So far, three 
protein truncated variants have been reported in PAH patients [24, 86, 87], 
suggesting that CAV-1 loss of function leads to the pathogenesis of PAH. 
Indeed, reduced CAV-1 levels were reported in the lung tissues of PAH patients 
[88], and CAV-1 deficiency perturbs BMP signalling by affecting BMPR2 
localisation [89]. Cav1 knockout mice also exhibit an absence of caveolae in 
the pulmonary vasculature and an increased mPAP [90]. Taken together, these 
suggest a role for caveolin-1 in maintaining pulmonary homeostasis.  
Potassium channel subfamily K member 3 (KCNK3) Ion channels play an 
important role in the regulation of vascular homeostasis. An aberrant resting 
membrane potential resulting from dysregulated ion channels could lead to 
vascular remodelling [91]. A genetic association of KCNK3 mutations with PAH 
were first identified in 2013 [25] and further validated by other studies [92]. 
Mutations in KCNK3 caused variable impairment of the potassium-channel 
current, causing membrane depolarisation in hPASMCs. These genetic 
changes affect vascular tone and hence contribute to the pathogenesis of PAH.  
Eukaryotic Translation Initiation Factor 2 Alpha Kinase 4 (EIF2AK4) Unlike 
the other types of PAH, pulmonary veno-occlusive disease (PVOD) and 




pulmonary capillary haemangiomatosis (PCH) exhibit autosomal recessive 
inheritance [30]. Genetic analysis in these patients revealed homozygous 
mutations in EIFAK4. Nearly 25% of the sporadic cases also harbour mutations 
in this gene, further suggesting a pathogenic role of EIF2AK4 in PVOD [93]. 
The biological functions of EIF2AK4 mainly involve regulating the response to 
cellular stress [94]. Interestingly, EIF2AK4 mutations were also seen in HPAH 
patients, characterised by early onset of disease and poor clinical outcomes, 
and likely to represent cases of PVOD without typical clinical features [95].  
T-box transcription factor 4 (TBX4) TBX4 is a transcription factor responsible 
for the regulation of mesoderm differentiation and embryogenesis. Genetic 
analysis revealed TBX4 as the predominant cause of childhood-onset PAH [96]. 
Interestingly, mutations identified from early-onset PAH cases clustered in the 
critical T-box domain, resulting in deleterious amino acid substitutions or 
premature stop codons [31]. These findings, at least in part, suggest TBX4 loss-
of-function defects may contribute to the pathobiology of disease by affecting 
developmental progression. 
Novel genes associated with PAH Aquaporin 1 (AQP1) is a water channel 
widely expressed in tissues and predominantly functions in maintaining the 
homeostasis of the kidney. Recently, inhibition of AQP1 was shown to alleviate 
hypoxia-induced PAH in mice [97]. Reduced angiogenesis was also observed 
in Aqp1 knockout mice [98]. Conversely, aquaporin 1 overproduction induced 
proliferation and migration of PASMC [99]. Collectively, these findings suggest 
an essential role of AQP1 in vascular homeostasis.  
  Sox17 is an endothelial transcriptional factor essential for development. Rare 
variants were recently identified in an I/HPAH cohort with the missense 
mutations clustering in the high-mobility group box of SOX17 [27]. This 
suggests a potential pathogenic link between SOX17 mutations and the 
regulation of developmental transcriptional programs in endothelial cells. 
Recently, a comprehensive GWAS study of over 2000 PAH patients of 
European ancestry revealed a significant association with the upstream region 




of SOX17 [100]. The same study also demonstrated an impairment of enhancer 
activity in the SOX17 gene promoter by these PAH risk variants [100]. This, 
together with the previous findings [27] indicate that both common and rare 
variants in SOX17 predispose to PAH. Later, two independent cohorts further 
revealed SOX17 as a major risk factor accounting for PAH associated with 
congenital heart diseases [96, 101]. Collectively, these findings strongly 
suggest a potential role of SOX17 in the pathobiology of PAH. 
 
Figure 1-4 Schematic of the major pathway and associated genes in HPAH, 
PVOD and PCH  
BMP9 and BMP10 signalling pathways centre the genetic causes of HPAH, with 
mutation identified in BMPR2, ACVRL1 (also known as ALK1), ENG, SMAD4 and 
SMAD9. Caveolin 1 (CAV1) mutations also potentially disrupt BMP signalling by 
affecting BMPR2. KCNK3 encodes the potassium channel and ABCC8 encodes a 
subunit of the ATP-sensitive potassium channel. ATP13A3 is a putative cation 
transporter resides on the endosomal compartment. SOX17 and TBX4 encode 




transcription factors critical for organogenesis. Biallelic mutations in EIF2AK4, which 
encodes an important kinase essential for sensing cellular stress response, are 
implicated in the PVOD and PCH pathogenesis. ACVRL1, activin receptor-like 1; 
ATP13A3, probable cation-transporting ATPase 13A3; BRE, BMP-responsive element; 
BMPR2, bone morphogenetic protein receptor type 2; GCN2, eIF2α kinase GCN2; 
SMAD, mothers against decapentaplegic homologue. Schematic readapted from 
Southgate, Laura, et al. Nature Reviews Cardiology 2019 [31]. 
 
ATP13A3 
  Following whole genome sequencing and rare variant analysis, ATP13A3 
was recently identified as a novel PAH-associated gene, accounting for 1.1% 
of the I/HPAH cohort [27]. Later, additional variants were reported in whole-
exome sequencing studies [102, 103]. To date, 26 unique ATP13A3 variants 
have been identified in PAH patients (Table 1-4). Of these, the missense 
mutations are enriched within the catalytic domains, suggesting a potential 
disruption of normal ATP13A3 functions (Figure 1-5). Moreover, an 
overrepresentation of protein truncated variants was reported in a PAH cohort 
[27] suggesting that loss-of-function of ATP13A3 could contribute to the 
pathogenesis of PAH. 
 
  ATP13A3 is a P5B ATPase that is widely expressed in different cell types. 
The biological functions of this putative cation transporter are still unknown as 
very few studies of ATP13A3 have been reported. Some lines of evidence 
suggest a link between ATP13A3 and the levels of polyamines, a group of small 
cations essential for cell growth, apoptosis [104-106]. Preliminary data I 
generated in BOECs showed that ATP13A3 deficiency reduces cell 
proliferation and increases the rates of apoptosis under serum-deprivation [27]. 
As shown in my studies described in this Thesis, this is likely owing to the 
perturbation of endothelial polyamine homeostasis [107, 108] and indicates a 
pathogenic role of ATP13A3 loss-of-function in the pathobiology of PAH.   




Table 1-4 ATP13A3 rare variants identified in different PAH cohorts 
 
HGVS: Human Genome Variation Society nomenclature APAH: Associated pulmonary 
arterial hypertension CTD: Connective tissue disease CHD: Congenital heart disease 












ATP13A3 frameshift c.1367delC p.Pro456LeufsTer7 IPAH [27]
ATP13A3 missense c.2867T>C p.Leu956Pro IPAH [27]
ATP13A3 missense c.2573G>A p.Arg858His IPAH [27]
ATP13A3 missense c.2550G>A p.Met850Ile IPAH [27]
ATP13A3 missense c.2023T>G p.Leu675Val IPAH [27]
ATP13A3 Splice donor c.3402+1G>T NA IPAH [27]
ATP13A3 Stop gained&Splice region c.1558C>T p.Arg520Ter IPAH [27]
ATP13A3 Splice region&Synonymous variant c.1149A>G
c.1149A>G(p.
%3D) IPAH [27]






















ATP13A3 missense c.G3653A p.G1218E IPAH [102]
ATP13A3 missense c.T2755G p.S919A IPAH [102]
ATP13A3 missense c.G2686A p.G896R IPAH [102]
ATP13A3 missense c.T1427C p.I476T IPAH [102]
ATP13A3 missense c.G1228T p.A410S IPAH [102]
ATP13A3 missense c.T869C p.V290A IPAH [102]
ATP13A3 missense c.A511G p.I171V IPAH [102]
ATP13A3 nonsense c.1540C>T p.Glu514* APAH-MS(INFβ treatment) [109]





Figure 1-5 Summary of the reported PAH associated mutations in 
ATP13A3 
Reported ATP13A3 mutations found in PAH patients were plotted on ATP13A3 
topology simulated from Protter (http://wlab.ethz.ch/protter). Residues affected by 
missense mutations are highlighted by a light blue square while protein truncated 
variants are marked by a red square. Cytosolic domains of ATP13A3, namely actuator 
“A”, phosphorylation “P” and nucleotide-binding “N” domains are also marked in 
responding colours. The N-terminal Ma domain (Figure 1-6) is not shown as the actual 






























































































































































1.2 P-type ATPase 
1.2.1 P-type ATPases 
  The P-type ATPases are a group of highly versatile membrane transporters. 
These may reside in the plasma membrane, facilitating transport between the 
extracellular space and the cytoplasm, or maybe present in organelle 
membranes, transporting substrates between the lumen of the organelle and 
the cytoplasm. By hydrolysing ATP to ADP, they serve as pumps for 
translocating ions, lipids or heavy metals across cell membranes or among 
cellular compartments [110]. The nomenclature of this superfamily, as “P-type”, 
comes from the phosphorylation intermediate formed during a catalytic cycle 
[110]. The first P-type ATPase was described by Skou [111] in 1956 as a 
sodium/potassium ATPase that transports ions across the shore crab nerve 
membrane. Later, more P-type ATPases were discovered and to date, five 
distinct subfamilies, namely the P1-P5 ATPases, have been characterised with 
respect to their sequence homology and substrate preferences. 
 
  Despite the low overall sequence conservation among P-type ATPases, they 
share highly conserved topology, probably owing to the sophisticated coupling 
of the cytoplasmic domains during substrate transport. P-type ATPases are 
transmembrane proteins, typically containing 10 membrane-spanning 
segments (Figure 1-6). The cytosolic domains of P-type ATPases are 
responsible for the coordination of protein phosphorylation and subsequent 
conformation change during the transport cycle. The transmembrane domains, 
on the other hand, contribute towards forming the substrate-binding sites, 
providing structural support for the P-type ATPase domains and mediating 
transport activities together with the cytosolic domains [110]. P-type ATPases 
generally consist of three cytosolic domains (Figure 1-6), the actuator domain 
(A), nucleotide domain (N) and the phosphorylation domain (P). The N domain, 
marked by a signature KGAPE motif, is linked to the P-domain and mainly 




responsible for ATP binding. Following substrate binding to the transmembrane 
domains, the N domain mediates the phosphorylation of the P domain by 
exposing the γ-phosphate of ATP to the DKTG motif in the P domain. This 
highly conserved DKTG motif is the hallmark of the P-type ATPases and is 
crucial for their transport activity. Consequently, the A domain, which is a 
flexible phosphatase, contacts the first two (P1 ATPase) or three (P2-5 ATPase) 
transmembrane segments and dephosphorylates the P domain during the 
catalytic cycle. A signature TGE motif is conserved among the P-type ATPases 
in this domain, suggesting a shared catalytic function across these transporters.  
 
Figure 1-6 General topology of P-type ATPases 
P-type ATPases consist of three cytosolic domains including the Actuator domain (A, 
yellow), nucleotide domain (N, red) and the phosphorylation domain (P, Navy). The 
transmembrane domain of the pump typically contains 10 membrane-spanning 
segments, responsible for substrate binding and provision of structural support. For 
P5B-ATPases, there is an additional N-terminal segment (Ma) embedded but not span 
across membrane. 




1.2.2 General catalytic mechanism of P-type ATPase activity 
  P-type ATPases share high structural conservation and hence utilise a 
similar catalytic mechanism for moving substrates across membrane. A 
counter-transport theory ((Post-Albers cycle) was proposed based on the study 
of sodium, potassium-ATPases [112, 113]. 
  In general, the P-type ATPases adopt two conformations, namely E1 and E2, 
that face the opposite sides of the membrane during a cycle (Figure 1-7). In the 
E1 state, substrate-binding site on the transmembrane domain of the P-type 
ATPases is faced to the cytosol, with a high affinity to the cytosolic substrate. 
Upon binding of the cytosolic substrate, the pump undergoes a structural 
rearrangement exposing an Mg2+ binding site near the conserved Asp site of 
the P domain. The binding of Mg2+ is crucial for the subsequent phosphorylation 
reaction, as it neutralises the electrostatic repulsion between ATP and the Asp 
residue in the P domain, facilitating the N-domain mediated phosphorylation of 
Asp residue (E1-P state). The phosphorylation of the P-domain leads to a 
forward bending, which in turn rotates the A domain by stretching the hinge 
between the transmembrane segments and the A domain. This conformational 
change reduces the affinity of the cytoplasmic substrate binding, releasing this 
cytosolic substrate to the extracellular/luminal side of the membrane (E2-P 
state). This step happens slowly and is recognised as the rate-limiting step of 
the catalytic cycle. The release of the cytosolic substrate triggers the binding of 
a counterion (extracellular/luminal substrate) on the extracellular/luminal side 
of the membrane and facilitates the dephosphorylation of the P-domain by the 
A-domain (E2). This is accompanied by a conformational shift from E2 back to 
E1, resulting in reduced affinity for the counterion substrate. There, the 
counterions are released into the cytosol, and the catalytic cycle can start again 
(Figure 1-7). However, it is noteworthy that not all the P-type ATPases function 
in a counter-transporting manner. Such examples are the heavy metal 
transporter P1 ATPase and the proton transporter P2 ATPase which are 




responsible for single-direction transport [110]. Moreover, the transport 
mechanism of the P5-ATPases have yet to be characterised.  
 
Figure 1-7 General catalytic mechanism of P-type ATPases during substrate 
transport 
The catalytic cycle begins at the E1 conformation when the P-type ATPases have a 
high affinity for the cytosolic substrate (S1). The binding of this substrate induces a 
conformational change and initiates the phosphorylation of the P-type ATPase (E1-P). 
This leads to a decreased affinity and subsequent release of the cytosolic substrate 
while favouring a high affinity to the extracellular/luminal substrate (S2) (E2-P). The 
binding of the counterion triggers the dephosphorylation of the P-type ATPase (E2), 
subsequently resulting in the release of the counterion into the cytosol. The P-type 
ATPase then returns to the E1 state and is ready for the start of a new catalytic cycle. 




1.2.3 P-type ATPase classification 
  As mentioned above, five subtypes of P-type ATPases exist in nature and 
participate in a set of biological functions by translocating substrates across 
membranes. So far, 36 P-type ATPases human homologues have been 
identified. Phylogenetic clustering of these cation transporters per their 
ancestry is detailed in figure 1-8. 
 
Figure 1-8 Phylogenetic clustering of human P-type ATPases Sequences of 36 
mammalian P-type ATPases obtained from UniProt (https://www.uniprot.org) were 
further phylogenetically analysed with the iTOL (https://itol.embl.de) platform and 
























































































1.2.3.1 P1-ATPases  
  P1-ATPases are recognised as the most ancient P-type ATPase subtype and 
can be further classified into the P1A and P1B subfamily. The P1A-ATPases 
are mainly found in bacteria with KdpFABC representing the most well-
characterised ion pump responsible for K+ transport [114]. This Kdp-like K+ 
transporter complex is composed of 4 subunits (F, A, B, C). Among them, KdpB 
is the smallest P-ATPase identified so far, possessing all the core structures of 
a typical P-type ATPase. The P1B-ATPases, on the other hand, are a group of 
heavy metal pumps transporting monovalent and bivalent metals across the 
cell membrane [114-116]. They are essential in bacteria and animal cells as 
efflux transporters, preventing the intracellular accumulation of heavy metal 
ions. Two human homologues, namely ATP7A and ATP7B, were identified as 
copper exporters. Mutations in ATP7A were shown to cause Cu+ deficiency in 
Menkes disease[117] while genetic defects in ATP7B lead to Wilson disease 
by inducing excessive Cu2+ accumulation [118].  
1.2.3.2 P2-ATPases 
  To date the P2-ATPases are most extensively characterised P-type ATPases, 
also known as Sarco(endo)plasmic Reticulum Ca2+-ATPases (SERCA) (P2A-
ATPases), calmodulin-binding Ca2+-ATPases (P2B-ATPases) and sodium-
potassium channels (P2C-ATPases). P2A-ATPases, namely ATP2A1-3, are 
calcium pumps responsible for recycling cytoplasmic calcium back to the 
sarcoplasmic reticulum during muscle relaxation [119]. This cation transport 
process is generally characterised by the efflux of two Ca2+ per catalytic cycle 
while counter-transporting H+ (less than four) into the cytosol. ATP2A1 
(SERCA1) is predominantly expressed in skeletal muscle, while ATP2A2 
(SERCA2) also exists in cardiac muscle (SERCA2a) and other types of tissue 
(SERCA2b) [120]. Loss-of-function mutations in ATP2A1 have been found in 
patients with Brody myopathy. These mutations, by reducing ATP2A1 
expression, impair skeletal muscle relaxation and hence cause muscle 




cramping and stiffening during childhood (Table 1-5) [121]. ATP2A3 was initially 
identified in non-muscle cells, such as platelets, human lymphoblastoid Jurkat 
cells and rat mucosal mast cells [122]. However, a recent study also 
demonstrated its expression in cardiomyocytes [123]. P2B-ATPases, by 
binding to calmodulin, regulate cellular calcium homeostasis. In humans, four 
isoforms have been identified so far (ATP2B1-4) (Figure 1-8) [110]. These P-
type ATPases reside on the plasma membrane of animal cells while localising 
to the vacuolar membrane or other intracellular compartments in plants or fungi 
[110]. A regulatory domain (R-domain) is typically present in the C-termini of 
these calcium pumps, and this negatively regulates their transport activity. 
Binding of calmodulin to the R-domain of a P2B-ATPase reduces this inhibition, 
substantially increasing the affinity for Ca2+ and hence facilitating calcium efflux 
[124].Unlike the P2A/B-ATPases, P2C-ATPases mainly mediate the 
translocation of sodium and potassium. ATP1A1, the first identified P-type 
ATPase, belongs to this subfamily [111]. A classic substrate transport process 
mediated by P2C-ATPases involves the efflux of three Na+ while importing two 
K+ into the cytoplasm [125]. This creates an electrochemical gradient across 
the plasma membrane and is pivotal for the formation of action potentials and 
other biological processes [126]. P3-ATPases do not exist in humans, with P3A 
functioning as membrane H+-ATPases in plants [127] and P3B as Mg2+-
ATPases in bacteria [128].  
1.2.3.3 P4-ATPase 
  P4-ATPases comprise the largest subfamily of P-type ATPases and are 
functionally distinct from the P1-3 subfamily, identified only in eukaryotes as 
phospholipid flippases [129]. P4-ATPases are physiologically important as they 
promote inward phospholipid translocation in the cell membrane [130]. So far, 
fourteen P4-ATPases have been identified in humans and are widely 
expressed across different human tissues. Among these, ATP8B1 is the most 
studied P4-ATPase, with mutations in ATP8A1 causing severe cholestatic 




disorders (Table 1-5) [131]. Both in vitro and in vivo data have shown that 
ATP8B1 translocates phosphatidylserine (PS) in the plasma membrane [132]. 
Interestingly, this requires the CDC50 protein to promote the release of 
ATP8A1 from the endoplasmic reticulum. P4-ATPases also mediate the 
trafficking of signalling lipids on cellular organelle membranes, regulating 
apoptosis, blood coagulation, cell fusion and other biological processes [132]. 
1.2.3.4 P5-ATPase  
  In the late 1990s, a fifth subtype of the P-type ATPases (P5-ATPases) 
existing exclusively in eukaryotes, were identified by phylogenetic analysis of 
the conserved sequence motif across genomes [129].  
  P5-ATPases are characterised by a signature PPxxP motif in the M4 
transmembrane segment, distinguishing them from the conserved Pxxx(P/L) 
motif found in other P-type ATPases [133]. Moreover, sequencing analysis 
revealed that the subfamily could be further divided into P5A- and P5B-
ATPases based on the conserved PP(E/D) x Px(E/D) motif and PP(A/V) x 
P(A/V) x motifs, respectively [134]. In humans, five distinct P5-ATPases have 
been identified, with ATP13A1 belonging to the P5A subfamily while ATP13A2-
5 fall in the P5B- subgroup. It has been demonstrated in other P-type ATPases 
that residues in the Pxxx(P/L) motif play a pivotal role in unwinding the M4 
segment and hence coordinating substrate binding during the catalytic cycle 
[134]. Due to the differences in this motif, it is rational to hypothesise that the 
substrate specificities may differ between P5A- and P5B-ATPases. Additionally, 
the P5-ATPases are also marked by the additional helices present in the N-
termini of these pumps. Topology prediction indicates two N-terminal helices 
(Ma, Mb) in the P5A-ATPase while only one (Ma) is present in the P5B-
ATPases [134]. Considering the fact that the N-terminal domain regulates the 
catalytic cycle of P1B-ATPases [135], these additional N-terminal helices may 
be functionally important for the P5-ATPases. Indeed, a recent study in Hela 
cells suggests that the N-terminal helix (Ma) of ATP13A2, by binding to 




Phosphatidic Acid (PA) and Phosphatidylinositol (3,5) bisphosphate (PI (3,5) 
P2), regulates the autophosphorylation of the transporter [136].  
  Apart from the structural divergence, P5A- and P5B-ATPases also exhibit 
different cellular localisation. Studies in different species revealed an exclusive 
localisation of the P5A-ATPase to the endoplasmic reticulum (ER) [137, 138]. 
Unlike the P5A-ATPase, the P5B subgroup show a diverse cellular localisation. 
CATP5, the P5B orthologue in C.elegans, was demonstrated to localise to the 
apical membranes of intestinal cells [139], whereas the P5B-ATPase in yeast 
(Ypk9p) resides in the vacuole [140]. Recently, overexpression of the human 
P5-ATPases in Hela cells confirmed the ER localisation of P5A-ATPase 
(ATP13A1), while the P5B-ATPases (ATP13A2-5) localised to the 
endo/lysosome compartments, corresponding to the vacuole localisation in 
yeast [141].  
  Unlike other P-type ATPases, the substrate specificity of the fifth subgroup 
had not been fully elucidated, though several candidates were proposed. P5A-
ATPase loss of function was shown to affect calcium homeostasis in yeast 
(Spf1p) [142] and in barley (HvP5A1) [143]. However, it is still unclear whether 
the pump is directly involved in the transport of Ca2+. The substrate preferences 
of the P5B subgroup is even more elusive. ATP13A2, a human P5B-ATPase 
homolog, was reported to governing Zn2+ and Mn2+ homeostasis while its 
deficiency leads to lysosomal and mitochondrial dysfunction in mammalian 
cells [144, 145]. Moreover, deletion of YPK9p sensitised yeast to Cd2+, Ni2+ 
and Se2+ toxicity, indicating a role of P5B-ATPases in the transport of heavy 
metal ions [146]. However, no mechanistic evidence was provided with respect 
to how P5B-ATPases mediate the translocation of these substrates across the 
membrane. Polyamines, a group of polycations essential for cellular functions, 
have recently been proposed as potential substrates for P5B-ATPase. CATP-
5 deletion increased the tolerance to nor-spermidine in C. Elegans [139]. 
Additionally, in pancreatic cancer cells, the expression level of ATP13A3 
correlates to the 3H Spermidine uptake capacity [147]. Most recently, a 




comprehensive study revealed that ATP13A2, another human P5B-ATPase, is 
an endo/lysosomal polyamine transporter, primarily responsible for releasing 
spermine into the cytosol. Incubation with spermine increases the ATPase 
activity while reducing the phospho-intermediate of ATP13A2 [148]. This study 
described, for the first time, the transport mechanism of human P5B-ATPases 
with polyamines as the preferable substrate. Functional disruption of the P5-
ATPases has been linked to several different diseases (Table 1-5). ATP13A2 
is predominantly expressed in brain tissues, and loss-of-function mutations in 
this gene have been implicated in Kufor-Rakeb syndrome [149] and early-onset 
Parkinson’s disease [150]. Mutations in ATP13A4 were linked to specific 
language impairment [151, 152] and autism spectrum disorders (ASD) [153], 
though its functions are still unclear. Recently, several lines of evidence have 
also revealed ATP13A3 as a novel disease-associated gene mutated in 
pulmonary arterial hypertension, further expanding the spectrum of the disease 
association of P5-ATPases [27, 103, 109]. 
1.2.3.4.1 ATP13A3 overview 
  ATP13A3 is a human homologue of the P5B-ATPases with unknown function. 
Even though ATP13A3 has been identified for decades, it remains one of the 
least characterised of the P-type ATPases. The gene encoding ATP13A3 is 
located on chromosome 3q29 in close proximity to the other two P5B members, 
ATP13A4 and ATP13A5 [141]. Phylogenetic analysis based on the primary 
amino acid sequences indicates ATP13A4 and ATP13A5 are closely related to 
ATP13A3 (Figure 1-8). ATP13A3 is a single-chain protein consisted of 1226 
amino acids, though the protein structure of ATP13A3 has not been elucidated. 
Previously, in silico prediction of the topology of the P5B-ATPases proposed a 
transmembrane (TM) domain consisting of 11 TM segments [134]. However, 
by overexpressing human P5B-ATPases in Hela cells, Sørensen et al. have 
demonstrated that ATP13A2-4 share a topology consisting of 10 
transmembrane helices [141]. Instead of spanning across the membrane, the 




N-terminal helix was shown to be embedded in the membrane and regulates 
the autophosphorylation of ATP13A2 [136]. As discussed earlier, the 
transmembrane domains of the P-type ATPase are responsible for substrate 
binding. Considering the highly similar TM domain topology shared by 
ATP13A3 and ATP13A2, it is highly likely that ATP13A3 may also function as 
a polyamine transporter in cells. 
Table 1-5 Transport substrates and disease involvement of the human P-type 
ATPase 
 
Protein name Substrate Involvement in disease
P1B-ATPase
ATP7A (Q04656) Cu2+ Menkes disease (MNKD)
ATP7B (P35670) Cu2+ Wilson disease (WD)
P2A-ATPase
ATP2A1 (O14983) Ca2+ Brody myopathy (BRM)
ATP2A2 (P16615) Ca2+ Acrokeratosis verruciformis (AKV)
ATP2A3 (Q93084) Ca2+




ATP2B2 (Q01814) Ca2+ Heriditary deafness
ATP2B3 (Q16720) Ca2+ Spinocerebellar ataxia, X-linked 1 (SCAX1)
ATP2B4 (P23634) Ca2+
P2C-ATPase
ATP1A1 (P05023) Na+/K+ Charcot-Marie-Tooth disease 2DD (CMT2DD) 
ATP1A2 (P50993) Na+/K+ Migraine, familial hemiplegic, 2 (FHM2)






 ATP8A2 (Q9NTI2) Phospholipid Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 4 (CMARQ4)
ATP8B1 (O43520) Phospholipid Cholestasis, progressive familial intrahepatic, 1 (PFIC1)











ATP11C (Q8NB49) Phospholipid Hemolytic anemia, congenital, X-linked (HAXL) 
P5-ATPase
ATP13A1 (Q9HD20) unkown
ATP13A2(Q9NQ11) polyamine Kufor-Rakeb syndrome (KRS)
Neuronal ceroid lipofuscinosis (NCL)
ATP13A3 (Q9H7F0) unkown Pulmonary arterial hypertension (PAH)
ATP13A4 (Q4VNC1) unkown specific language impairment (SLI)
Autism spectrum disorders (ASD)
ATP13A5 (Q4VNC0) unkown




1.2.3.4.2 Expression of ATP13A3 
Human 
  RNAseq data from the GTEX platform (https://www.gtexportal.org/home/) 
indicates ATP13A3 is widely expressed across human tissues. Interestingly, 
apart from the thyroid gland, a relatively high level of ATP13A3 gene expression 
is observed in systemic arteries and lung tissues (Figure 1-9). Single-cell 
RNAseq using lung tissues from healthy subjects indicated that ATP13A3 
expression is abundant in pulmonary macrophages, dendritic cells and vascular 
endothelial cells [154] (Figure 1-10). Our group also confirmed the expression 
of ATP13A3 in primary cultures of pulmonary artery smooth muscle cells 
(PASMCs), pulmonary artery endothelial cells (PAECs) and blood outgrowth 
endothelial cells (BOECs) [27]. Collectively, these suggest a potential link 
between ATP13A3 and the human pulmonary vasculature. 
 
Mouse 
  Similar to the human, Atp13a3 is also widely expressed in different mouse 
tissues, with the highest mRNA expression observed in the liver. A later 
developmental study in mice [155] demonstrated the existence of two Atp13a3 
transcript variants, with variant 1 highly expressed in brain, heart and lung and 
variant 2 in the kidney. Atp13a3 was also shown to be highly expressed at early 
developmental stages, with a peak of expression at E7 [156]. This observation 
suggested a potential role of Atp13a3 in organogenesis. More recently, single-
cell transcriptome analysis of various mouse organs revealed enriched Atp13a3 
expression in the lung epithelial cells [157], again suggesting Atp13a3 has a 










Figure 1-9 Gene expression of ATP13A3 in human cell and tissue samples 
Gene expression of ATP13A3 across 53 different types of human tissues was 
generated the RNA-seq data from the Genotype-Tissue Expression Consortium (GTEx 
V7) (https://www.gtexportal.org/home/). Expression level was presented as 
Transcripts per Million (TPM).  
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Figure 1-10 ATP13A3 expression pattern in single-cell RNAseq data from 
human lung tissues from healthy subjects 
(A) ATP13A3 expression clustering in 21 different types of human pulmonary 
cells. Data were generated from Lungconnectome [154] 
(http://www.lungconnectome.net.). The relative gene expression level is 
indicated by the colour intensity. (B) ATP13A3 relative expression was plotted 








1.2.3.4.3 Biological functions of ATP13A3 
  To date, studies of the biological functions of ATP13A3 are sparse.  P-type 
ATPase activation is characterised by the phosphorylation of an aspartyl 
residue during the catalytic cycle. In Cos-8 cells, overexpressed human 
ATP13A3 was shown to be autophosphorylated at the conserved Asp498 site 
[141]. Classified as a P5B-ATPase, ATP13A3 is predicted to be a cation 
transporter, though the substrate specificity is still unclear. CATP-5, a C. 
elegans orthologue of three human P5B-ATPases (ATP13A3, ATP13A2, 
ATP13A4), localised to the apical membranes of intestinal cells and was linked 
to polyamine transport. CATP-5 loss of function led to reduced polyamine 
content and hence suppressed postembryonic development [139]. A recent 
study in human pancreatic cancer cells also revealed a positive correlation 
between the levels of ATP13A3 expression and spermidine uptake [147]. 
These findings suggest polyamines may be potential substrates for ATP13A3. 
However, direct studies are necessary to establish the transport preference for 
particular polyamines and the mechanism of this transport. 
  In silico analysis, using a publicly available human gene expression database 
[158] (PathwayNet platform http://pathwaynet.princeton.edu) reveals a 
potential interaction between ATP13A3 and several candidate genes. Among 
these, hypoxia inducible factor-1 α-unit (HIF-1α) has the highest confidence 
(0.95) of interacting with ATP13A3 (Figure 1-11). HIF1α is a subunit of the 
transcriptional factor hypoxia-induced factor 1 (HIF1). In normoxia, HIF1α is 
constantly degraded through ubiquitin-mediated proteasomal degradation [159]. 
Hypoxia stabilises HIF1α expression by suppressing this ubiquitination [160]. 
By then dimerising with HIF1β and mediating transcription, a set of HIF1 target 
genes are transactivated [161]. Intriguingly, it has been reported that HIF1α can 
bind to the promoter region of ATP13A2 [162], another P5B ATPase sharing 
high homology to ATP13A3. Pharmacological inhibition of HIF1α hydroxylation 
increases ATP13A2 expression by preserving HIF1α levels [163]. Therefore, 
studies to explore a potential regulatory link between HIF1α and ATP13A3 are 




warranted. Moreover, by using subtractive suppression hybridisation, 
Habtemichael and co-workers showed upregulation of a homologous gene of 
the ATPase family (AFURS1) in senescent human parenchymal kidney cells 
[164]. AFURS1, localised to chromosome 3q26, encodes a 701 amino acids 
isoform with a high degree of homology to ATP13A3. Again, this suggests that 
a possible link between ATP13A3 and ageing might warrant further study. 
 
 
Figure 1-11 In silico prediction of the potential interactions between 
ATP13A3 and other genes. 
Top 5 candidate genes potentially may interact with ATP13A3 
(confidence>0.94), as revealed by in silico analysis using the PathwayNet [158] 
platform (http://pathwaynet.princeton.edu). 




1.2.3.4.4 ATP13A3 and PAH 
  Recently a large European-wide genetic study identified rare ATP13A3 
variants in blood samples from I/HPAH patients. These variants were inherited 
in an autosomal dominant manner with incomplete penetrance [27]. PAH 
patients with ATP13A3 mutations were predominantly female (90.9%), with a 
similar age at diagnosis to those without mutations (47.5 years vs 52.6 years). 
The disease severity of ATP13A3 mutation carriers was comparable to those 
bearing BMPR2 mutations [27]. Later, other PAH genetic studies revealed 
additional variants in ATP13A3, further strengthening the link between 
ATP13A3 mutations and the pathogenesis of PAH [102, 103]. Interestingly, an 
IFNβ-induced PAH case was reported recently in a multiple sclerosis patient 
bearing a nonsense mutation in ATP13A3 [109]. This observation suggests the 
possibility that an additional pathological stimulus may be required to induce 
PAH on the background of ATP13A3 mutations, explaining the reduced 
penetrance. In addition, ATP13A3 is potentially linked to dysregulated TGFβ 
signalling in PAH. Microarray analysis following 4-hour TGFβ incubation 
revealed upregulated ATP13A3 expression in hPASMCs from HPAH patients 
bearing BMPR2 mutations, but not in control cells [165]. However, no functional 
studies have been undertaken with respect to the role of ATP13A3 in the 
pulmonary vasculature.  
 
1.2.3.4.5 ATP13A3 and cancer 
  Aside from PAH, ATP13A3 has also been implicated in cancer biology. As 
described above, ATP13A3 is associated with spermidine uptake in pancreatic 
cancer cells, with cells expressing higher levels of ATP13A3 showing high 
sensitivity to difluoromethylornithine (DFMO), an irreversible ODC inhibitor 
which binds to the ornithine substrate binding site. This suggests that cells with 
higher ATP13A3 expression are more committed to polyamine transport. 
Therefore, plasma ATP13A3 levels were proposed as a clinical indicator for the 




efficiency of DFMO treatment in pancreatic cancer patients [147]. ATP13A3 
was also demonstrated as a prognostic marker in head and neck cancer, with 
those patients having higher ATP13A3 overexpression in the tumour sites 
showing a lower overall survival rate (HR=1.45) [166]. However, no mechanistic 
insights were described in this study with respect to how increased levels of 
ATP13A3 may affect the prognosis in head and neck cancer. To assess a 
potential link between ATP13A3 and survival of cancer cases in general, I have 
used the TCGA database to compare the overall survival between ATP13A3 
somatic mutation carriers and non-mutation carriers. In total, 10843 cancer 
cases were studied, including 1744 cases with mutations in ATP13A3. The 
overall survival rate between the two groups was statistically analysed by a log-
rank test. Interestingly, without further cancer type stratification, ATP13A3 
mutation carriers showed an overall poorer survival rate than those non-
mutation carriers (Figure 1-12). This suggests a potential link between 




Figure 1-12 Overall survival rate of cancer cases with or without ATP13A3 
mutations Survival rate of cancer cases with (1744 cases) or without (9099 cases) 
ATP13A3 mutations were extracted from the TCGA database followed by log-Rank 
test (P-Value=2.09e-8). 
Overall survival plot
Log-Rank Test P-Value = 2.09e-8




1.3 Polyamines in Biology 
1.3.1 Polyamines 
  Polyamines are a group of highly charged aliphatic polycations ubiquitously 
existing in nature. The first report of polyamines dates back to 1678 when 
Leeuwenhoek observed crystals forming in seminal fluid [167], which were later 
demonstrated to be spermine phosphate [168]. Putrescine (PUT), spermidine 
(SPD) and spermine (SPM) are the three most common polyamines present in 
mammalian cells while cadaverine (CAD) is mainly found in bacteria and plant 
[169]. Though they are small molecules, these polycations are essential for 
many cellular processes, and their dysregulation could affect cell functions [104, 
170, 171]. Therefore, to maintain a homeostatic balance, cellular polyamine 
levels are fine-tuned by two sophisticated pathways, polyamine biosynthesis 
and the polyamine transport system. 
 
1.3.2 Polyamine biosynthesis 
  De novo polyamine biosynthesis is essential for maintaining the stable level 
of cellular polyamines. A detailed summary of polyamine biosynthesis is listed 
in Figure 1-13. Arginine, a substrate for several pathways including the nitric 
oxide synthase pathway, is converted to ornithine by Arginase 1. Putrescine, 
the first mammalian polyamine is synthesised from ornithine by the catalysis of 
ornithine decarboxylase (ODC). This is the rate-limiting step for polyamine 
biosynthesis[172]. Upon formation, putrescine is converted to spermidine by 
the addition of an aminopropyl group. This step is catalysed by spermidine 
synthase, with the aminopropyl group donated via the decarboxylation of S-
adenosylmethionine by S-adenosylmethionine decarboxylase (encoded by 
AMD1). Spermine is formed in a similar manner, with spermine synthase 
catalysing the addition of an aminopropyl group to spermidine (Figure 1-13).  
 




1.3.2.1 Transcriptional regulation of Ornithine decarboxylase (ODC)  
  As the key enzyme for the polyamine biosynthesis pathway, ODC is 
regulated at multiple levels to maintain a stable cellular polyamine level. 
Increased synthesis of ODC mRNA is seen in response to stimuli such as 
tumour promoters and hormones in a cell-context dependent manner. This is 
largely owing to the complexity of ODC promoter region which contains a 
binding motif for SP-1, a CAAT site, an LSF site, a cyclic AMP (cAMP) response 
element (CRE), multiple GC- boxes, and a TATA box (Figure 1-14). For 
example, the transcription factor SP-1 was shown to promote basal Odc 
expression in rat H35 hepatoma cells [173]. 17b-estra- diol (E2) was also 
reported to induce ODC expression in human breast cancer cells [174], 
whereas 12-O-tetradecanoylphorbol-13-acetate (TPA) upregulated Odc levels 
in mouse fibroblasts by binding to the TATA box in the promoter region [175]. 
Additionally, ODC is also well recognised as a downstream target of c-Myc, the 
potent oncogene which in tumour cells increases ODC expression by 
dimerising with Max to form a transcription complex (Figure 1-14). The myc/Max 
complex binds to the CACGTG E-boxes within the first intron of ODC gene and 
transactivates ODC mRNA overproduction. Interestingly, in BALB/c-3T3 
fibroblasts under quiescent conditions, the CACGTG E-boxes is occupied by 
Mnt/Max, resulting in a lower level of Odc expression. Serum stimulation in 
these cells triggers the displacement of Mnt/Max by the Myc/Max complex and 
increases Odc expression [172].  
 
1.3.2.2 Translational regulation of Ornithine decarboxylase (ODC)  
  ODC is also regulated at the translational level through a cap-dependent or 
independent internal ribosome entry site (IRES) mechanism. The ODC mRNA 
possesses a long 5’-UTR and hence needs eIF4E to unwind the extensive 
secondary structure for cap-dependent translation initiation. pMV7-4E cells 
(derived from NIH-3T3 cell) overexpressing eIF4E express high levels of Odc1 




[176]. This long 5’-UTR also contains an inhibitory open reading frame (ORF) 
which suppresses ODC translation [172]. Apart from cap-dependent translation, 
ODC was also demonstrated to be translated via the internal ribosome entry 
site (IRES). It was shown in Hela cells that ODC translation alternates between 
cap-dependent and cap-independent mechanisms over the cell cycle. During 
the G2/M phase, Hela cells utilise the IRES for ODC translation and hence are 
insensitive to translational inhibition by rapamycin [177].  
 
1.3.2.3 Post-translational regulation of Ornithine decarboxylase (ODC)  
  Although ODC regulation happens at both the transcriptional and 
translational level, the most extensively studied process is post-translational 
regulation. ODC protein is rapidly turned over, with a half-life of less than 30 
minutes in mammalian tissues [178]. Upon synthesis, ODC is rapidly degraded 
via a ubiquitination-free 26S proteasomal degradation. This process is 
mediated by antizyme, which forms a non-covalent heterodimer with ODC and 
directs it to the proteasome [179] (Figure 1-15 A). The binding of antizyme 
(residue 106 –212) to ODC (residue 117– 140) prevents its enzymatic activity. 
However, this region is not sufficient for mediating ODC degradation, and the 
additional residues at positions 55-105 are required for directing ODC to the 
26S proteasome [180]. Antizyme enhances the interaction of ODC with the 
proteasome without affecting the processing rate [181]. On the other hand, 
degradation of ODC does not induce the breakdown of antizyme. Instead, 
antizyme is released and binds to other ODC monomers to mediate their 
degradation [182]. Post-translational regulation of ODC is achieved by tightly 
controlled antizyme expression (encoded by OAZ1). The synthesis of antizyme 
is regulated through a unique frameshifting event caused by ribosome skipping 
during scanning of the antizyme mRNA (Figure 1-15 B). The antizyme mRNA 
has two overlapping open reading frames (ORF1 and ORF2). Typically, ORF1 
can encode 68 amino acids and is terminated by a UGA stop codon (UCC UGA). 




ORF2, which encodes the main part of antizyme, is in the +1 frame with respect 
to ORF1 and starts before the end of ORF1. ORF2 is only accessed by 
ribosomes that first translate ORF1 and is only translated when the ribosome 
skips to the +1 reading frame for translation. This frameshift event is induced 
by an increase in cellular polyamine levels, thus inducing the production of the 
full-length functional antizyme (Figure 1-15 B) [179, 183]. Increased cellular 
polyamine levels also block antizyme degradation by inhibiting ubiquitination 
[184] while polyamine depletion in Balb/C 3T3 cells via DFMO represses 
antizyme mRNA expression [185]. In 1982, another protein, antizyme inhibitor, 
was discovered in rat liver and heart tissues. This shares a high degree of 
homology to ODC but lacks enzymatic activity [186]. The antizyme inhibitor has 
a higher affinity for antizyme than ODC and hence can preserve ODC by 
releasing it from the antizyme-ODC heterodimer [187, 188]. The expression of 
antizyme inhibitor is also actively regulated by polyamines, with high levels 
repressing the production of the antizyme inhibitor [189] (Figure 1-15 A). Taken 
together, ODC expression is tightly controlled by the cellular polyamine level 
through the post-translational regulation orchestrated by antizyme and 
antizyme inhibitor. 
1.3.3 Polyamine catabolism 
  In opposition to synthesis, spermine and spermidine can be metabolised to 
their precursors through acetylation and oxidation reactions mediated by 
polyamine catabolic enzymes. Spermine and spermidine are firstly acetylated 
by spermidine/spermine acetyltransferase (SSAT). The resulting metabolites, 
acetyl-spermidine/spermine, are then either excreted from cells or oxidised by 
polyamine oxidase (PAO) to form spermidine and putrescine, respectively 
(Figure 1-13). In addition, spermine can be directly oxidised by spermine 
oxidase (SMOX) to form spermidine (Figure 1-13).  These oxidative reactions 
also produce amino aldehyde and H2O2, which can be cytotoxic when 
excessive quantities accumulate [170]. Similar to polyamine biosynthesis, the 




catabolic pathway is tightly regulated by polyamine levels. For example, in 
cancer cells, higher polyamine levels increased the transcription of SAT1 
expression by binding to the 5’ polyamine-responsive-element (PRE) in the 
SAT1 gene, thus promoting to the catabolism of polyamines. These dynamic 
changes, together with the biosynthesis pathway, guarantees a carefully 
regulated narrow range of cellular polyamine levels. 
 
Figure 1-13 Schematic of the polyamine metabolism pathways Arginine can be 
turned into ornithine (by arginase) or serves as the precursor for NO (catalysed by NOS) 
in cells. Ornithine is then transformed into putrescine by the rate-limiting enzyme ODC. 
Spermidine and spermine are subsequently synthesised by receiving an aminopropyl from 
the decarboxylation of SAM. For the catabolism pathway, spermine and spermidine are 
interconverted to their precursors first by SAT1 mediated acetylation and then oxidisation 
by PAO. Uniquely, spermine can be directly oxidised by SMO to form spermidine. NOS, 
nitric oxide synthase; ARG1, arginase1; ODC, ornithine decarboxylase; DC-SAM, 
decarboxylated S-adenosyl-L-methionine; AMD1, Adenosylmethionine Decarboxylase 1; 
SRM, spermidine synthase; SMS, spermine synthase; SAT1, spermidine/spermine 


































Figure 1-14 Transcriptional regulation of ornithine decarboxylase (ODC) 
(A) The promoter region of the ODC gene contains several regulatory elements, 
including the SP-1 motif, a CAAT site, an LSF site, a cAMP response element 
(CRE), multiple GC- boxes, and a TATA box (TPA binding site). (B) Intron 1 of 
the ODC gene has two CACGTG E-boxes which can bind to Myc. Under 
quiescent conditions, these E-boxes are occupied by the Mnt/Max complex 
resulting in low ODC mRNA expression. However, when cells are proliferating 
(e.g. serum exposure), the Mnt/Max dimer is replaced by the Myc/Max complex, 
thus promoting ODC production. Figure 1-13 B readapted from (Pegg, Anthony 
E. JBC 2006)[172]. 
 
 





Figure 1-15 Antizyme / Antizyme Inhibitor regulation of ODC (A) Post-translational 
regulation of ODC is orchestrated by antizyme and antizyme inhibitor in a polyamine 
dependent manner. When polyamine levels are high, a unique ribosomal frameshifting 
event (B) is triggered to promote the production of the full-length functional antizyme. 
Conversely, when cellular polyamine levels drop, the expression of antizyme inhibitor 
is induced and ODC is liberated from the ODC-antizyme heterodimer, thus preserving 
its protein expression.  
1.3.4 Polyamine transport 
  In addition to the biosynthesis/catalysis pathways, cellular polyamine levels 
are also tightly regulated by an energy-consuming, high-affinity and saturable 
polyamine transport system [190]. Although well described in simple life forms 
such as yeast and trypanosomatids [191], the molecules involved and 
mechanistic details of mammalian polyamine transport systems remain 
enigmatic. Over the past few decades, by using in silico identification combined 
with screening substrates of interests, polyamine transport activities were 
assigned to several members of the solute carrier (SLC) and ATP-binding 
cassette superfamily (Table 1-6). These membrane transporters are not 
primarily responsible for translocating polyamines. Instead, many of them also 
transport other basic amino acids which are structurally similar to polyamines 
[190]. Most recently, ATP13A2, a P5B-ATPase was uncovered as a spermine 
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homology shared by ATP13A2-5, this finding suggests the potential 
involvement of other P5B-ATPases in mammalian polyamine transport [148].     
 
1.3.4.1 General characteristics of mammalian polyamine transporters 
  Though the mechanism is not fully understood, mammalian polyamine 
transporters seem to share some general characteristics which were elegantly 
summarised by Poulin and co-workers [190]. Contrary to the initial finding that 
polyamine transport is Na+-dependent [192], subsequent evidence indicated 
that polyamine uptake is suppressed by high concentrations of monovalent 
cations (Na+, Li+), as a complete replacement of these cations with non- 
(sucrose) promoted putrescine uptake [193, 194]. Based on this property, 
polyamine transporters can potentially be classified into two groups: (a) 
Diamine transporters (e.g. putrescine) that are monocation-sensitive or (b) 
higher polyamine transporters (e.g. spermidine/spermine) that are less 
sensitive to these monocations [190]. Contrary to the inhibitory effect of Na+, 
polyamine transporters seem to favour the binding of divalent metals, such as 
Mn2+, Ca2+, Mg2+, Co2+, to their exofacial portion for translocating polyamines, 
though the underlying mechanism is still unclear [193, 195]. Similar to other 
cation transporters, mammalian polyamine transport systems were also shown 
to be membrane potential dependent as seen in SLC22A1 and SLC22A3 [196]. 
In addition, pH is another parameter that affects polyamine transport in 
mammalian cells. It was demonstrated in L1210 mouse leukaemia cells that 
putrescine uptake was optimal at pH 7.2-8.0 while suppressed between 6.0-7.0. 
Spermidine transport, however, prefers mildly acidic conditions (pH 6.8-7.7) 
[193]. In addition to pH, polyamine transport is also affected by osmolality. It 
has been demonstrated that hypo-osmotic conditions increase putrescine 
uptake more efficiently than spermidine or spermine in L1210 mouse leukaemia 
cells [197] [198]. The presence of the carboxyl side group in the polyamine 
transporters was also shown to be essential for polyamine uptake as chemical 




inhibition of the carboxyl group by N-ethylmaleimide suppressed polyamine 
uptake in CHO cells [199].  
Table 1-6 Summary of mammalian polyamine transporters 
Transporter Tissue distribution Substrate Reference 
OCT1 
(encoded by SLC22A1) 
Widely expressed 
High in liver 
Spd/Spm/Agmatine [196, 200, 201] 
OCT2 
(encoded by SLC22A2) 





(encoded by SLC22A3) 




(encoded by SLC47A1) 
High in kidney Agmatine [200] 
DAX 

















(encoded by ABCB1) 













1.3.4.2 Hypothetical models for mammalian polyamine transport  
  Although a unified theory of how polyamines translocate across mammalian 
cells is not yet available, several hypothetical models have been proposed to 
explain this biological enigma. As illustrated in Figure 1-16, the first model was 
a two-step process described by Soulet et al. [207]. By using Spd-C2-BODIPY, 
they demonstrated in CHO cells that polyamines were first imported through a 




plasma membrane channel and subsequently sequestered into vesicles via a 
vesicular transporter. The vesicles sequestering polyamines mainly colocalised 
with acidic cellular compartments (lysosomes, late endosomes and 
multivesicular bodies), with inhibition of the vacuolar ATPase (V-ATPase) 
repressed by polyamine accumulation. This suggests that the V-ATPase, by 
creating an inward electrochemical H+ gradient, sustains a H+/polyamine 
exchange mediated by the vesicular transporter. Moreover, a relatively slower 
efflux pathway was also proposed in the same study, potentially through 
another vesicular channel, though they did not exclude the possibility of reverse 
transport through the same vesicular transporter. No transporters were 
specified in this model. 
 
Figure 1-16 Schematic of the “two-step” polyamine transport model In CHO cells, 
polyamines enter cells via a plasma membrane channel and are subsequently 
sequestered into acidic vesicles through an unknown vesicular transporter. This 
process is facilitated by the H+ gradient created by the V-ATPase in these vesicles. A 
vesicular exporter may exist for polyamine efflux into the cytosol. However, it is also 
possible that the same vesicular transporter may export the polyamine in reverse. 
  A second model which mainly applies to spermine uptake was proposed by 
Beltings M and colleagues [208]. In this model, spermine import was mediated 




by binding to the heparan sulfate (HS) chains of glypican-1 on the plasma 
membrane of CHO cells. Spermines were then internalised through the 
endocytic pathway. When reaching the late endosome, NO produced via the 
nitrosylation of glucosamine groups in glypican-1 by NO synthase 2 (NOS2), in 
the presence of copper, liberated spermine by the cleavage of spermine-HS 
binding. A detailed mechanism for the release of spermines from endosomes 
was not proposed in this model (Figure 1-17).  
 
Figure 1-17 Glypican-1 mediated spermine uptake in CHO cells In CHO cells, 
spermine first binds to the heparan sulfate side chains of glypican-1 and is then 
internalised via endocytosis. Spermine is transported through the endocytic pathway, 
and when they reach the late endosome, spermine-HS binding is cleaved by NO 
(produced by NOS2) via a Cu2+ dependent process. This frees spermine from 
glypican-1, although the mechanism of spermine efflux was not discussed. 
  Based on the second of these models, a caveolin-mediated polyamine 
endocytosis mechanism was described by Gerner and colleagues [209]. In this 
model, polyamines first bind to an unspecified polyamine binding protein in the 
caveolin-1 rich region on the cell surface and are internalised through the 
caveolar endocytosis (Figure 1-18). Increased putrescine uptake was observed 
in human colorectal carcinoma cells with caveolin-1 knockdown and tissues 




(small intestine, colon and liver) from caveolin-1 knockout mice. This was 
interpreted as an increase in caveolar endocytosis with caveolin-1 deficiency 
increased both the frequency and number of internalised caveolae. However, it 
is noteworthy that the caveolin-1-dependent regulation of caveola formation 
may differ between cells, as caveolae were absent in the pulmonary 
endothelium of caveolin-1-/- mice [210]. Therefore, further validation is required 
in the pulmonary circulation system. Similar to the glypican-1 model, NO 
produced by NOS2 was proposed to dissociate polyamines from the polyamine 
binding protein. This was supported by the observation that the NOS2 knockout 
abolished putrescine import in mouse tissues. Again, this model does not 
address the pathway for polyamine release from the vesicle into the cytoplasm. 
Instead, SLC3A2 was proposed as a cell surface putrescine exporter (Figure 
1-18).  
 
Figure 1-18 Caveolin-mediated polyamine endocytosis For entering cells, 
polyamines (PA), notably putrescine bind to the cell surface PA binding protein in the 
caveolin-1 rich region and internalise via caveolar endocytosis. NO released by NOS2 
liberates polyamines from their binding proteins in endosomes. However, no vesicular 
efflux pathway for polyamines were proposed, although SLC3A2 was described as a 
cell surface exporter of putrescine 




1.3.4.3 Regulation of the mammalian polyamine transport  
  It is well established that increased polyamine levels contribute to the hyper-
proliferative phenotype of cancer cells. Considering that many of the growth 
factors and cytokines are upregulated in cancer cells or tumour tissues, it is not 
entirely surprising that these factors may promote polyamine transport in 
cancer. For example, both oestrogen and insulin were demonstrated to 
promote polyamine transport in human breast cancer cells [211], while IL-3 and 
IL-4 were shown to stimulate spermidine uptake [212]. Intriguing, it has also 
been reported that polyamine transport activities can be inhibited by antizyme. 
In rat hepatoma cells (Hz7), which exhibit high expression of antizyme in 
response to dexamethasone, J L Mitchell and colleagues demonstrated an 
inhibitory effect of antizyme on cellular spermidine uptake and ODC activities. 
However, the detailed mechanism was not determined in this study [213]. 
Whether antizyme directly binds to the cellular polyamine transporter to 
mediate this inhibitory effect or if it indirectly affects the endocytosis pathway 
remains elusive. 
1.3.5 Biological functions of polyamine 
  Polyamines are small aliphatic polycations involve in multiple cellular 
processes. Owing to their highly-charged property, polyamines tend to bind to 
anionic molecules, such as DNA, RNA and phospholipids [214] and hence 
perform their biological functions.  
1.3.5.1 Nucleotides structural and conformation 
  The binding of polyamines to DNA involves the ionic interaction between the 
amine groups in polyamines and the DNA phosphate groups. This interaction 
stabilises the DNA structure, protecting it from environmental insults (e.g. 
radiation) and can also facilitate DNA condensation [215]. Polyamines are also 
essential modulators for chromatin remodelling via the regulation of histone 
acetylation. In the skin of the k6/ODC transgenic mouse, ODC overexpression 
was reported to induce the activities of histone acetyltransferase and 




deacetylase [216]. In addition to DNA, polyamines also bind to RNA such that 
up to 80% of cellular polyamines are associated with RNA [217]. Polyamines, 
by interacting with nucleotide bases, can also stabilise tRNA structure (with the 
affinity decreasing in order from spermine to putrescine) [218]. 
1.3.5.2 Gene expression regulation 
  It is well established that polyamines play important role in the transcriptional 
regulation of gene expression. By interacting with the polyamine-responsive 
element (PRE) in the promoter region of SAT1 to induce expression, 
polyamines can trigger the polyamine catabolic pathway [219]. Moreover, 
polyamines also promote gene expression indirectly via transcriptional 
induction of transcription factors. For example, in rat kidney epithelial cells, 
spermidine stimulated the expression of c-Myc, whereas c-jun and c-fos were 
more sensitive to putrescine supplementation. The activation of these 
transcription factors, in turn, upregulated a set of downstream cell growth-
related genes [220]. Polyamines also participate in the modulation of signal 
transduction by either directly stimulating protein kinase activities [221] or via 
promoting the expression of these protein kinases [222]. Putrescine and 
spermidine can also facilitate the phosphorylation mediated by tyrosine kinases, 
indicating an important role of polyamines in cell proliferation [222]. 
1.3.5.3 Protein synthesis 
  The association of polyamines with the regulation of protein synthesis was 
primarily investigated based on their RNA binding property. Indeed, in rat liver 
cell-free systems, these small polycations can either directly stimulate or 
decreased the optimal Mg2+ concentration for protein synthesis [223, 224]. As 
described above, cellular polyamine levels regulate antizyme translation via a 
ribosomal frameshifting event, thus regulating the rate of ODC degradation. A 
unique regulation comes from spermidine, as it serves as the aminobutyl group 
donor for the generation of hypusine, an amino acid only found in eukaryote, 
and essential for the activation of eukaryotic initiation factor 5A (eIF5A) [186]. 




This is achieved via a two-step catalytic reaction. Firstly, an aminobutyl moiety 
from spermidine is transferred to the lys50 residue in eIF5A by deoxyhypusine 
synthase (DHS) to form the eIF5A deoxyhypusine. Deoxyhypusine hydroxylase 
(DOHH) then mediates the hydroxylation of deoxyhypusine eIF5A, resulting in 
hypusinated eIF5A. Hypusinated eIF5A is essential for the ribosomal 
translation of the polyproline region in mRNA as the hypusine residue stabilises 
and orients the peptidyl-tRNA to read through these regions [225].  
1.3.5.4 Proliferation and cell cycle progression 
  Polyamines have been well recognised as essential mediators of cell growth. 
Increased polyamine levels were observed in hyperproliferative tumour cells 
[226], regenerative tissues [227] and in response to growth stimuli [171]. 
Accumulated evidence also points to a pro-proliferative effect of polyamine 
supplementation in different cell types [228]. Conversely, polyamine depletion 
by DFMO was shown to induce cytostasis in rat hepatoma cells while 
putrescine and spermidine administration restored cell growth [229]. Similar 
findings were also observed in tumour cells, where combined inhibition of 
polyamine synthesis and transport effectively restricted neuroblastoma cell 
growth [230]. One possible explanation for the regulation of cell proliferation by 
polyamines is their ability to mediate cell cycle progression (Figure 1-19). Both 
polyamine related enzymes and cellular polyamine content seem to fluctuate 
during the cell cycle. Biphasic upregulation of ODC activities at the G1/S and 
S/G2 transitions was reported in both human dermal fibroblast and CHO cells 
[231]. A corresponding biphasic increase of all three types of polyamines was 
demonstrated by Heby et al. in CHO cells [232]. However, also in CHO cells, 
Fredlund, J. et al. [233] described that putrescine and spermine mainly 
increased during the S/G2 and G1/S phases respectively, while spermidine 
exhibited a consistent increase throughout the cell cycle (Figure 1-19). Several 
lines of evidence have pointed to the involvement of cyclins in the regulation of 
the cell cycle by polyamines. Polyamine depletion, depending on the treatment, 




can result in cell cycle arrest in either the G1, S or G2/M phases via the 
regulation of cyclin expression [234]. For example, DFMO treatment of human 
melanoma cells induced the expression of p21, which inhibited cyclin-
dependent kinases and led to cell cycle arrest in G1 [235]. Reduced expression 
of cyclin D1 was observed after the resulting cellular polyamine decrease, 
whereas an elevation of putrescine levels was associated with cyclin D1 
upregulation [228]. Additionally, decreased cyclin E levels were attributed to 
reduced spermidine and spermine levels while cyclin A inhibition was induced 
by polyamine depletion via the inhibition of DNA synthesis [228].  
 
Figure 1-19 ODC and polyamine contents during cell cycle This figure summarises 
data from CHO cells. ODC expression fluctuates during the cell cycle with two 
expression peaks observed in the G1/S and S/G2 transition phase. Interestingly the 
translation of ODC is achieved through either cap-dependent or IRES-dependent 
mechanisms depending on the phase of the cell cycle. Corresponding to the fluctuation 
of ODC expression, putrescine level peaks at S/G2 phase whereas spermine doubling 
occurs in G1 and S phase. In contrast, spermidine levels increase over the course of 
the cell cycle. Readapted from Wallace, Heather M. Biochemical Journal 2003 [234] 





  Compared to the relatively clear association of polyamines with cell growth, 
the regulation of cellular apoptosis by polyamines is complex, and cell 
type/context-dependent.  
Anti-apoptotic role of polyamines: Polyamines have previously been 
reported to inhibit cell apoptosis. Reduced polyamine levels were associated 
with the apoptosis induced by heat-shock and γ-irradiation in rat thymocytes 
[236]. Decreased spermine levels sensitise both human and murine cells to 
TNF-induced cell apoptosis [237]. In addition, epidermal growth factor (EGF) 
induces apoptosis of breast cancer cells via the reduction of polyamine levels. 
This apoptotic phenotype was restored by supplementation with putrescine and 
spermidine, but not spermine [238]. 
Pro-apoptotic role of polyamines: In opposition to their reported anti-
apoptotic effects, polyamines have also been demonstrated as inducers of 
apoptosis. Spermidine, through the activation of caspases, can induce 
apoptosis in rat cardiomyocytes (H9c2 cells) [239]. ODC activation, as a result 
of c-Myc overexpression, promoted 32D.3 murine myeloid cell apoptosis, 
though the cellular polyamine levels were not measured in this study [240]. 
Putrescine accumulation was shown to induce apoptosis in DH23A cells by 
affecting protein synthesis via the inhibition of hypusinated eIF5A formation 
[241]. H2O2 and amino-aldehydes resulting from the oxidation of spermidine 
and spermine oxidation are also inducers of cell apoptosis. In physiological 
conditions, these toxic products are removed by peroxisomal catalase [170] 
and aldehyde dehydrogenases [242] respectively. However, when an excess 
of polyamines accumulates, overproduction of H2O2 and aldehyde can lead to 
cytotoxicity [243].   




1.3.5.6 Cell Junction regulation 
  Intercellular junctions, notably tight junctions and adherens junctions are 
indispensable in maintaining epithelial integrity. It has been demonstrated that 
polyamines are involved in the regulation of cell junctions in epithelial cells. 
  E-cadherin is a transmembrane adhesion molecule which, by binding to actin 
filaments, forms strong cell-cell adhesion between epithelial cells. In IEC-6 cells, 
polyamines were shown to regulate E-cadherin via the activation of c-Myc in a 
Ca2+ dependent manner. Increased polyamines induced both E-cadherin 
mRNA and protein expression while polyamine depletion by DFMO suppressed 
E-cadherin expression. Polyamine depletion substantially decreased the 
promoter activities of E-cadherin and increased the paracellular permeability of 
epithelial monolayers [244]. Moreover, polyamines were also implicated in the 
regulation of tight junctions. Polyamines deprivation impaired intestinal 
epithelial barrier function by affecting the synthesis and stability of occludin and 
transcriptionally downregulating ZO1/2 and claudin expression [245] (Figure 1-
20). Taken together, these findings suggest an important role for polyamines in 
the maintenance of epithelial cell-cell junctions.  
     
Figure 1-20 Polyamine depletion affects epithelial cell-cell junctions Under 
physiological conditions, epithelial cells are tightly sealed by the tight junctions and 
adherens junctions to maintain epithelial monolayer integrity. Polyamine depletion by 




DFMO suppresses the expression of several adhesion molecules and leads to the 
disruption of epithelial integrity.  
1.3.6 Polyamines and disease 
1.3.6.1 Polyamines and cancer 
  Owing to their essential roles in cell growth, polyamines have been 
intensively studied in cancer biology for more than 50 years. The first link 
between polyamines and cancer was reported in 1968, with elevated ODC 
activity observed in rat tumour tissues [227]. Further studies showing increased 
levels of polyamines in urine samples of cancer patients strengthened this 
theory [246]. However, the first biochemical evidence of a direct interplay 
between polyamines and oncogenes was revealed by the demonstration of 
ODC as the downstream target of the Myc in cancer cells [247]. Since then, this 
dysregulated Myc-ODC-polyamine axis was confirmed in several different 
cancer types, including lung cancer, breast cancer, leukaemia and colon 
cancers [248-250]. In addition to ODC, the Myc oncogene also transactivates 
eIF5A in multiple cancers. This, together with the increased spermidine from 
ODC upregulation, results in the overproduction of hypusinated-eIF5A and 
increased tumour cell proliferation [251]. Upregulation of other polyamine 
synthesis enzymes has also been described in cancer. In prostate cancer, 
mTORC1 was shown to increase AdoMetDC expression by phosphorylating 
and stabilising the AdoMetDC proenzyme, which consequently increased the 
levels of polyamines [252]. Apart from the biosynthesis pathway, reduced 
polyamine catabolism is another important mechanism contributing to the 
elevation of polyamines in cancer. K-Ras was shown to suppress SAT1 
activation by interfering with PPARγ signalling. This resulted in a persistent 
elevation of the polyamine content in human colon cancer cells and hence 
promoted cell proliferation [253]. Moreover, as reported recently, SAT1 
expression can be induced by the potent tumour suppressor gene p53. By using 
a mouse embryonic fibroblast system, Ou, Y. et al. has shown that p53-




mediated ferroptosis is partly via the activation of SAT1 [254]. In summary, 
cancer cells or tissues are generally characterised by increased polyamine 
content. This can be achieved via the activation of biosynthesis enzymes or the 
downregulation of catabolism enzymes.  
 
1.3.6.2 Polyamines and PAH 
  PAH is a neoplastic growth disorder mainly affecting the small arteries in the 
lung. PAH has been frequently compared with cancer owing to the pathogenic 
similarity shared by these two diseases. Later than the discovery in cancer, a 
link between pulmonary hypertension and polyamine dysregulation was first 
demonstrated in 1984 when elevated polyamine levels were reported in lung 
tissues from rats exposed to monocrotaline (MCT) or chronic hypoxia [255, 256]. 
Intriguingly, these two rat PH models seemed to favour different mechanisms 
for their polyamine augmentation. Hyperactive de novo polyamine biosynthesis 
was mainly observed in MCT treated rats as reflected by the increased activities 
of both ODC and AMD. By targeting this polyamine biosynthesis with DFMO, 
the irreversible inhibitor of ODC, the elevated mPAP in this model was 
significantly attenuated. This suggests that MCT-induced PAH, at least in part, 
is driven by aberrant polyamine biosynthesis [255]. Conversely, chronic 
hypoxia repressed lung ODC activity, and hypoxic rats showed no response to 
the DFMO intervention [255]. This suggests a different mechanism, such as 
increased polyamine transport, may account for the elevation of polyamines in 
hypoxic rat lungs [255]. Indeed, a later study revealed increased putrescine 
uptake in rat lung explants under hypoxic conditions [256]. This theory was 
further supported by the observation that [14C]-spermidine accumulated in the 
intimal and media layers of pulmonary arteries from hypoxic rats [257]. 
However, no polyamine transporters were identified in these studies. Taken 
together, these findings shed light for the involvement of polyamine 
dysregulation in the pathogenesis of PAH but suggest differences between 




inflammation-dependent disease progression (MCT) compared to that 
mediated by hypoxic vasoconstriction. 
  Recently, owing to the advances in Multi-Omics techniques, more evidence 
suggesting polyamine dysregulation in PAH has been uncovered. A 
metabolomics study using human lung samples revealed increased levels of 
ornithine and putrescine in PAH patients compared with healthy subjects [258]. 
Plasma metabolomics profiling also demonstrated increased levels of 
polyamine metabolites in idiopathic or heritable PAH patients, with N-acetyl-
putrescine being prognostic independent of the established prognostic markers 
[259]. Moreover, a study of the human lung transcriptome also identified that 
expression of ODC, the rate-limiting enzyme for polyamine biosynthesis, is 
negatively correlated to the mean pulmonary arterial pressure (mPAP) of PAH 
patients [260].    
 
1.3.6.3 Polyamines and other diseases  
  Disease-associated genetic mutations were first linked to the polyamine 
pathway in 2003, with the discovery of a mutation in SMS, the gene encoding 
spermine synthase. This causes a rare X-linked recessive condition termed 
Snyder-Robinson, manifested with mental retardation as a result of spermine 
deficiency [261].  
  In addition to genetic disorders, polyamines have also been associated with 
neurodegenerative diseases. For example, reduced putrescine levels were 
identified in red blood cells from Parkinson’s disease patients, while spermidine 
and spermine levels were elevated [262]. A metabolomics study of serum 
markers also revealed the prognostic value of polyamine alteration for 
predicting disease progression in Parkinson’s disease [263]. Similarly, 
dysregulated polyamine levels were also reported in brain samples from 
Alzheimer’s patients [264]. However most of these studies are observational 
and lack any detailed mechanism for the dysregulation of polyamine 




metabolism in the disease pathogenesis. Recently, ATP13A2, a P5B-ATPase 
in which germ-line mutations had been implicated in Kufor-Recab syndrome, 
was comprehensively characterised as a late endo/lysosomal spermine 
exporter responsible for the releasing of spermine into the cytoplasm [148]. This 
provides mechanistic details on how defective lysosomal polyamine export may 
contribute to the pathogenesis of neurodegenerative diseases.  
 
1.4 Hypothesis 
  The focus of this thesis is to investigate the biological functions of ATP13A3 
in the pulmonary vasculature and to uncover the underlying mechanism of how 
mutations in ATP13A3 contribute to the pathogenesis of PAH. 
  ATP13A3 is widely expressed across tissues with a relatively high expression 
observed in systemic vessels and lung tissues. Consequently, I hypothesised 
that ATP13A3 is also expressed in pulmonary vascular cells and is important 
for the regulation of vascular cell function. As a putative cation transporter, 
limited lines of evidence have suggested a link between ATP13A3 and 
polyamines, a group of versatile polycations essential for cell function. 
Therefore, I hypothesised that ATP13A3 is likely to function as a polyamine 
transporter in pulmonary vascular cells, with the substrate specificity to be 
determined. Cellular polyamine levels are homeostatically maintained within a 
narrow range to maintain normal biological processes. As a result, ATP13A3 
dysfunction may affect the behaviour of pulmonary vascular cells, such as 
altering proliferation and apoptosis, via the disruption of polyamine 
homeostasis. 
  As mentioned earlier, rare variants in ATP13A3 have been identified in PAH 
cohorts with an overrepresentation of protein-truncating variants and 
enrichment of missense mutations in the cytosolic functional region. The 
truncating mutations suggest a potential loss-of-function, which I predicted 
might affect polyamine transport mediated by ATP13A3. Therefore, I 




hypothesised that genetic defects in ATP13A3 could contribute to PAH 
pathogenesis by disruption of the polyamine homeostasis.  
 
1.5 Thesis Aims  
  To address this hypothesis, the aims of this thesis are summarised as follows: 
1. To assess the impacts of ATP13A3 loss-of-function in pulmonary vascular 
cells.  
2. To investigate the roles of ATP13A3 in cellular polyamine homeostasis and 
determine the transport preference among different type of polyamines in 
human pulmonary vascular endothelial cells. 
3. To perform a functional assessment on PAH associated ATP13A3 variants 
4. To further validate the pathogenic effects of ATP13A3 variants in BOECs 
isolated from a PAH patient (ATP13A3-LK726X) and a genetic mouse model 




















 Methods and Materials  
 
2.1 CELL CULTURE PROTOCOLS 
  All cells were cultured and maintained in humidified incubators with an 
atmosphere of room air supplemented with 5% CO2. All cells were routinely 
tested for mycoplasma contamination and were only used for experiments if 
negative. For cell passaging, cells were trypsinised with 0.25% trypsin (Sigma-
Aldrich) and quenched with full growth media. The resulting cell suspension 
was then transferred into 50mL centrifuge tubes (Star Lab) before centrifuged 
at 400g for 5 minutes. For daily maintenance, cells were seeded into T75 
culture flask at a variety of densities per different cell types. 
Table 2-1 Cell seeding density in different formats 
Format Cell seeding density 
96-well plate 10,000-15,000 cells/well 
24-well plate 30,000 cells/well 
6-well plate 
siRNA transfection 150,000 cells/well 




Polyamine measurement 300,000 cells/well 
6cm dish 300,000 cells/well 








2.1.1 Cell culture of human pulmonary artery endothelial cells (hPAECs) 
  hPAECs were purchased from Lonza. Cells were grown in Endothelial Basal 
Medium (EBM-2) (Promocell) with the addition of Endothelial Growth Medium 
BulletkitTM (5 ng/ml hEGF, 0.2 μg/ml hydrocortisone, 0.5 ng/ml VEGF, 10 ng/ml 
h-FGFB, 20 ng/ml R3-IGF-1, 1 μg/ml ascorbic acid, 22.5 μg/ml heparin and 2% 
FCS) Promocell) and 1% A.A (EGM-2). For experiments, hPAECs were used 
between passage 4 to 7.  
 
2.1.2 Cell culture of blood outgrowth endothelial cells (BOECs) 
  BOECs were isolated from 40-80ml of blood, as previously described [265]. 
For experiments involving BOEC generation, all blood donors provided 
informed consent under human study 07/H0306/134 (Cambridgeshire 3 
Research Ethics Committee). BOEC lines listed below (Table 2-2) were used 
for experiments. 
Table 2-2 Demographic information for Blood outgrowth endothelial cells 
used in these studies 
All lines were grown in EBM-2 supplemented with 5 ng/ml hEGF, 0.2 μg/ml 
hydrocortisone, 0.5 ng/ml VEGF, 10 ng/ml h-FGFB, 20 ng/ml R3-IGF-1, 1 μg/ml 
ascorbic acid (Promocell), 10%(v/v) Foetal Bovine Serum (FBS) and 1% A.A 
Cell line ATP13A3 
mutation 
Gender Age Clinical details 
C1 - female 45 Healthy subjects 
C2 - male 20 Healthy subjects 
C4 - male 30 Healthy subjects 
C7 - male 41 Healthy subjects 
C26 - female 25 Healthy subjects 
C35 - male 33 Healthy subjects 
OC0CQE LK726X male 46 PAH Patient 




and omission of heparin. Cells were maintained in T75 flasks and passaged 
when confluent. All cells were used for experiments at passage 4-7. 
2.1.3 Cell culture of human pulmonary artery smooth muscle cells 
(hPASMCs) 
  Human pulmonary artery smooth muscle cells (hPASMCs) were isolated by 
explant culture from peripheral segments of pulmonary arteries obtained from 
patients undergoing lung transplantation following the protocol described 
previously [266]. Ethical approval of the hPASMCs isolation was obtained 
through the Papworth and Addenbrooke’s Hospital Trust Ethical Committees. 
The hPASMC lines used for the experiment were listed below.  
Table 2-3 Demographic information for human pulmonary artery smooth 
muscle cells used in these studies 
Cell line Gender age 
78MP Male 68 
79MP male 69 
103MP Male 52 
All hPASMCs were maintained in Dulbecco’s Modified Eagle Medium (DMEM, 
Invitrogen) with 4.5 g/L glucose (Gibco) supplemented with 10%(v/v) Heat 
inactivated FBS and 1% A.A. Cells were used between passage 4 to 8.    
 
2.1.4 Culture of the Human microvascular endothelial cell-1(HMEC-1) line 
  The immortalised (SV40-transformed) human microvascular endothelial cell-
1(HMEC-1) line was purchased from ATCC [267]. HMEC-1 were grown in 
MCDB 131 medium (without glutamine) (Thermo Fisher Scientific) 
supplemented with 1 μg/ml Hydrocortisone (Sigma), 10mM Glutamine (Sigma), 
10ng/ml Epidermal Growth Factor (EGF) (R&D systems), 10%(v/v) FBS and 1% 
A.A (HMEC1 full growth media). Cells were passaged twice a week to prevent 
over confluence. 




2.2 NUCLEOTIDES DELIVERY PROTOCOLS 
2.2.1 Transfection of small interfering RNA (siRNA)  
  Cells were seeded at different densities as described in Table 2-1 the day 
before siRNA transfection. Cells were preincubated in Opti-MEM-I reduced 
serum media (Invitrogen) for 2h before transfection. To prepare the lipoplexes, 
DharmaFect1 (Dharmacon, GE) was first added to Opti-MEM1(v/v 1 in 49) and 
incubated at room temperature for 5 minutes. Then, siRNA was diluted to a final 
concentration of 50nM in the tubes containing the DharmaFECT1/Opti-MEM 
pre-mixes and incubated for 20 minutes at room temperature to allow lipoplexes 
to form. During this time, appropriate volumes of fresh OptiMEM were added to 
the wells. The siRNA/DharmaFECT1 complex was added into each well at a 
1:5 dilution such that the final siRNA concentration was 10nM. (i.e. for a 6-well 
plate, 400 μl of siRNA/DharmaFECT1 complex was added into 1.6ml OptiMEM 
in the well).  The cells were incubated with the siRNA/DharmaFECT1 for 4h at 
37℃ before the transfection media were replaced with full growth media. Cells 
were kept in growth media for 24h before further treatment. Knockdown 
efficiency was confirmed by mRNA expression or immunoblotting. To establish 
if the level of knockdown was retained in proliferation experiments, RNA was 
collected on day 0 and day 6. The siRNAs used for experiments were: oligos 
targeting ATP13A3 from Sigma-Aldrich (#1, SASI_Hs02_00356805; #2, 
SASI_Hs02_00356806 and ON-TARGETplus non-targeting Control Pool (siCP) 
from GE Dharmacon.  
 
2.2.2 Transient plasmid DNA transfection  
  The pcDNA6.2 expression plasmid encoding full-length wild type or missense 
mutant ATP13A3 with N-terminal GFP tag was kindly donated by Prof. Peter 
Vangheluwe from KU LEUVEN (Leuven, Belgium) as listed below (Table 2-4). 
Prior to transfection, HMEC-1 cells were seeded at a density of 2.5x105 
cells/well into a 6-well plate and allowed to adhere overnight. The following 




morning, cells were incubated in Opti-MEM-I reduced serum media (Invitrogen) 
for 2 hours before proceeding with transfection. To complete the transfection, 
0.5-3 μg of plasmid DNA was delivered into cells using Lipofectamine LTX with 
Plus reagent (Thermo Fisher Scientific). Briefly, following 3-hour Opti-MEM 
incubation, 9 μl /reaction of Lipofectamine® LTX Reagent was diluted in 200 μl 
/reaction of Opti-MEM in a 15ml Falcon tube (Star Lab) labelled as Tube A. The 
required amount of plasmid DNA was diluted in a separate 15ml Falcon tube 
(Tube B) with 200 μl of Opti-MEM supplemented with 2.5 μl /reaction PLUS 
reagent before mixing thoroughly with the Lipofectamine® LTX reagent and 
incubated at room temperature for 5 minutes. The resulting lipoplexes were 
then added onto cells and incubated at 37°C for 4 hours before being returned 
to HMEC-1 full growth media. Twenty-four hours post-transfection, cells were 
trypsinised and reseeded into collagen-coated 4-chambered Nunc™ Lab-
Tek™ II Chamber Slides™ (Thermo Fisher Scientific) or directly lysed for 
protein or RNA extraction. 
















2.2.3 Lentiviral transduction 
  Lentiviral vectors were kindly produced by Dr. Van Den Haute from Leuven 
Viral Vector Core facility (Leuven, Belgium). Briefly, Lentiviral vectors were 
generated by transfecting HEK293T cells with three plasmids: 
1. A homemade transfer plasmid (pCHMWS-ires-puro) containing wild type or 
mutant ATP13A3 coding sequencing as well as the cis-acting regulatory 
sequences 
2. A packaging plasmid (8.91) encoding viral structural and replicative proteins 
3. An envelope plasmid (VSV-G) which enables pseudotyping the glycoprotein 
of the Vesicular Stomatitis Virus, resulting in increased stability of the lentiviral 
vectors. The resulting lentiviral vectors were further concentrated and 
quantified with a p24 antigen ELISA.  
  Upon receiving the viral particles, lentiviral titer was assessed by real-time 
PCR based assay [268, 269] in hPAECs. Briefly, 75000/well of hPAECs were 
seeded into a 24-well plate followed by the transduction with Lentivirus media. 
An extra well of hPAECs with the lentiviral transduction was included for the 
normalisation of transduction copy numbers. Cells were harvested 72h post-
transduction and genomic DNA was extracted as described in section 2.5.1. 
The resulting genomic DNA was then PCR amplified targeting ATP13A3 and 
the lentiviral packaging cassette (GAG) with the following primers (ATP13A3-
Forward-TGTTCGCCAGTTCCCATTTT, ATP13A3-Reverse- 
TTCATGTAGGCGTCCA 
TTTTCCT, GAG-Forward- AAAGCGAAAGGGAAACCAGA, GAG-Reverse- 
AATTTTTGGCGTACTCACCAGTC). In the meantime, standard curves for 
ATP13A3 and GAG gene copy number (Figure 2-1) were generated by 
amplifying the lentiviral plasmid DNA with known concentration (102 to 1010 
copies/reaction). Standard curves were then used for calculating lentiviral copy 
number in hPAECs. 
 




  The lentiviral titer (TU/ml) was calculated according to the following equations 
[269]: 
Lentiviral titer = (Cell number x Lentiviral copy number/cell) / volume of 
Lentivirus media 
Lentiviral copy number/cell = (GAG copy number of hPAECtransduced / ATP13A3 
copy number of hPAECcontrol) x 2 
hPAECtransduced: hPAECs transduced with lentiviral particles 
hPAECcontrol: hPAECs without the transduction of lentiviral particles 
 
  Wild type and mutant ATP13A3 lentiviral vectors displayed similar lentiviral 
titers (Table 2-5). When transduced at MOI=5, these lentiviral vectors showed 
optimal overexpression of ATP13A3 without compromising the expression of 
other P5 ATPases.  
 
  For experiment involving lentiviral transduction, hPAECs were seeded into 6-
well plates at a density of 200,000 cell/well and allowed for attaching overnight. 
The following day, cells were transduced with the lentiviral vectors diluted in 
EGM-2. hPAECs were left in EGM-2 media containing the lentiviral particles for 
72 hours for the optimal transduction. Cells were then used for the following 
















Figure 2-1 Standard curves of ATP13A3 and GAG gene copy number 
Real-time PCR Ct values of (A) ATP13A3 and (B) GAG amplified was plotted 
against the log value of the lentiviral plasmid DNA copies number. Linear 
regression analysis was performed to generate the standard curve equation of 
calculating the lentiviral copy number of hPAECs. 
Table 2-5 Titers of wild type/mutant ATP13A3 lentiviral vectors 
Plasmid Name Lentiviral titers 
pCHMWS-Hs ATP13A3 WT-ires-puro 2.39 x 107 TU/ml 
pCHMWS-Hs ATP13A3 D498N-ires-puro 2.01 x 107 TU/ml 
pCHMWS-Hs ATP13A3 L675V-ires-puro 1.74 x 107 TU/ml 
pCHMWS-Hs ATP13A3 M850I-ires-puro 2.28 x 107 TU/ml 
pCHMWS-Hs ATP13A3 V855M-ires-puro 2.81 x 107 TU/ml 
pCHMWS-Hs ATP13A3 R858H-ires-puro 2.33 x 107 TU/ml 
pCHMWS-Hs ATP13A3 L956P-ires-puro 1.62 x 107 TU/ml 
 
 
y = -1.588ln(x) + 42.204
R² = 0.9959
y = -1.715ln(x) + 45.229
R² = 0.9954
A B




2.3 CELL FUNCTIONAL ASSAYS 
2.3.1 Cell proliferation assay 
  Cells were seeded in 24-well plates at a density of 30,000/well and left to 
adhere overnight. Transfection of siATP13A3, siCP or DharmaFECT1 reagent 
alone was performed in the following day and cells were returned to full growth 
media afterwards.   
  For assessment of BOEC proliferation, cells were serum-starved with EBM-
2 containing 0.1%(v/v) standard grade FBS (EBM2/0.1% FBS) for 8 hours, 
followed by culturing in EBM-2 media supplemented with 5%(v/v) FBS (EBM-
2/5% FBS) with or without the addition of 30ng/ml VEGF165(R&D Systems), 
5ng/ml BMP9 (R&D Systems) for four days. Treatments were replenished every 
48 hours.  
  For assessment of hPAEC proliferation, cells were quiesced in EBM-2/0.1% 
FBS for 8 hours before treating with 30ng/ml VEGF165(R&D Systems), 5ng/ml 
BMP9(R&D Systems) in EBM-2 media containing 2%(v/v) for six days. 
Treatments were replenished every 48 hours.  
  For assessment of hPASMC proliferation, cells were serum-restricted in 
DMEM containing 0.1%(v/v) FBS and A/A overnight, followed by treatment with 
either 1ng/ml PDGF or 10ng/ml PDGF (R&D Systems) in DMEM with 1%(v/v) 
FBS and A/A. In parallel, cells were treated with 5ng/ml TGFβ or 5ng/ml BMP9 
(R&D Systems) in DMEM containing 5%(v/v) FBS and A/A for 6 days. 
Treatments were replenished every 48 hours. At day 6, all cells were trypsinised 
with 150 μl /well 0.5% trypsin (Sigma-Aldrich) and quenched with 60 μl /well of 
the relevant growth media, followed by 90 μl /well of trypan blue (0.4%, Sigma-
Aldrich). All 300 μl of cell suspension was transferred into a newly labelled 
Eppendorf tube, and cells were counted using a haemocytometer. 
 
 




2.3.2 Annexin V/PI Flow Cytometry Apoptosis assay 
  Annexin V has a high affinity for phosphatidylserine. Cells, while undergoing 
early apoptosis, expose this phospholipid from the cytoplasmic surface to the 
outer leaflet of the cell membrane, inducing binding of annexin V. PI on the 
other hand only enters dead cells that have become permeable and therefore 
distinguishes early apoptotic cells from cells in late apoptosis or necrosis. 
BOECs were plated at 150,000/well into 6-well plates and transfected with 
siATP13A3, siCP or DharmaFECT1 reagent alone. Three extra wells of cells 
were seeded in a 6-well plate for unstained and compensation controls and 
maintained in BOEC media. Cells were then serum-starved in EBM-2/0.1% 
FBS for 8 hours before treating with EBM-2 containing either 1%FBS or 5%FBS 
for another 24 hours. For assessing the response to anti-apoptogens, cells 
were treated with or without 30ng/ml VEGF165 (R&D Systems) or 5ng/ml BMP9 
(R&D Systems) in EBM-2/0.1% FBS for 24 hours. Cells were then trypsinised 
with 1ml/well 0.25% trypsin and quenched with 1ml/well BOEC media. The 
entire cell suspension was transferred into 15mL centrifuge tubes (Star Lab) 
prefilled with 3ml PBS, followed by centrifugation at 350g for 5minutes. Cells 
were washed with 1ml PBS and centrifuged at 350g for 5 minutes again. Cells 
were then resuspended with 100 μl 1x Annexin V binding buffer from FITC 
Annexin V Apoptosis Detection Kit I (BD Biosciences) and transferred into flow 
tubes (Fisher Scientific). For each condition, dual-staining was undertaken by 
adding 5 μl FITC conjugated Annexin V (BD Biosciences) and 5 μl propidium 
iodide (PI) (BD Biosciences) followed by incubation at room temperature for 15 
minutes. For single staining compensation controls, either 5 μl FITC Annexin V 
or 5 μl PI was added into non-transfected cells and incubated for 15minutes. A 
further 400 μl 1x Annexin V binding buffer (BD Biosciences) was added to each 
tube. All samples were then analysed on a BD Accuri™ C6 Plus flow cytometer 
(BD Biosciences). FITC-Annexin V and PI fluorescence signal were collected 
in the FL-1 channel and FL-3 channel respectively. FlowJo (vX, Treestar) 
software was used for fluorophore compensation and data analysis. 




2.3.3 Caspase-Glo 3/7 assay 
  Caspase activity is another indicator for cell apoptosis, as this is the 
executioner caspase that directly promotes chromatin condensation, cell lysis 
and DNA fragmentation.  
  To assess the caspase activities, cells were seeded at a density of 
150,000/well into 6-well plates and transfected with siATP13A3(Sigma-Aldrich), 
siCP (GE Dharmacon) or DharmaFECT1(GE Dharmacon) alone. For each 
condition, cells were trypsinised from 6-well plates, reseeded in triplicates into 
a 96-well plate at a density of 15,000-20,000/well and left to adhere overnight. 
Cells were quiesced in EBM-2/0.1% FBS for 24h before treating with or without 
30ng/ml VEGF165(R&D Systems) or 5ng/ml BMP9(R&D Systems) in EBM-
2/0.1%FBS for 16 hours. For measuring caspase-3/7 activities, 100 μl 
Caspase-Glo® 3/7 Reagent (G8091 Promega) as added into each well, then 
incubated and mixed on a plate shaker in the dark for 15 minutes at room 
temperature. The entire 200 μl from each well was transferred into the 
corresponding well of a white-walled 96-well plate and luminescence was read 
in a GloMax® luminometer (Promega). 
2.3.4 Endothelial permeability assay 
  This assay measures the transit of horseradish peroxidase (HRP) across 
endothelial monolayers seeded in transwell inserts. hPAECs subjected to 
siRNA transfection were trypsinised and reseeded into Corning® Transwell® 
chambers polyester membrane cell culture inserts (0.4 μm pore size, Corning) 
at a density of 50,000 cells/insert and allowed to attach for 30 minutes before 
adding 1ml of EGM2 supplemented with 2% FBS (Promocell) to the lower 24-
well plate chamber. Following overnight incubation at 37°C, hPAECs were 
serum-starved for 6 hours by replacing the media in the inserts with 200 μl, and 
the bottom chambers with 1ml of EBM2/0.1% FBS. Following serum-starvation, 
media was then replaced with 2% FBS supplemented EBM2 with or without the 
addition of 1U/ml Thrombin (Sigma) and incubated for an hour at 37°C. In the 




meantime, 0.05 M Phosphate Citrate Buffer was prepared by dissolving one 
capsule of Phosphate-Citrate buffer with Sodium Perborate (Sigma) into 100ml 
of PBS. The o-Phenylenediamine dihydrochloride (OPD) developing solution 
was then made up by adding one OPD (Sigma) tablet into 50ml Phosphate-
Citrate buffer. Prior to the assessment, media in the inserts was replaced with 
100 μl of EBM2 supplemented with 2% FBS containing 25nM HRP(Sigma) with 
or without the addition of 1U/ml Thrombin. 3 x 15 μl medium from the bottom 
chambers were collected into a new 96-well plate at the following time points: 
0min, 15min, 30min, 1hour, 1.5 hours and 2 hours. 150 μl /well of OPD buffer 
was then added into the 96-well plate and then read at 490nm on the plate 
reader over 10 to 20 minutes. 
 
2.4 ANIMAL MODEL OF ATP13A3 DEFICIENCY 
2.4.1 Atp13a3 P452Lfs mice model 
  C57BL/6N genetic modified mice harbouring a PAH associated frameshift 
mutation(P452fls) in Atp13a3 were created using a CRISPR-Cas9 genetic 
editing system by MRC-Harwell institutes. Mice were subsequently maintained 
on a C57BL/6N background. 
 
2.4.1.1 Cardiopulmonary phenotyping in Atp13a3 P452fls mice 
  Cardiopulmonary phenotyping of these animals by echocardiography and 
catheterisation was undertaken by Dr Ekaterina Legchenko (Morrell laboratory). 
Atp13a3 P452fls wild type, heterozygous and homozygous mice at 3-month 
and 6-month old were anesthetised with inhaled isoflurane for hemodynamic 
measurement. Mice were weighed and recorded before performing the right 
heart catheterisation using a Millar SPR-869 pressure-volume catheter system 
to measure the right ventricular systolic pressure (RVSP). Mice were sacrificed 
following measurement. The blood was collected through inferior vena cava 
followed by 30 minutes clotting at room temperature before centrifuging at 




3000g for 10 minutes. Serum was collected into a new 1.5ml tube and stored 
in -80°C. Right ventricular hypertrophy was assessed using Fulton index. To 
achieve this, the mouse circulation system was flushed with 10ml of saline 
supplemented with heparin using a syringe. Whole heart tissues were collected 
before dissecting the right ventricle free wall (RV) out from left ventricle and 
septum (LV+S) and weighed respectively. The right ventricular hypertrophy 
was revealed using the ratio of RV/LV+S (Fulton index). The resulting heart 
tissues were transferred into cryo-vials and frozen in liquid nitrogen for protein 
and RNA extraction. 
 
2.4.1.2 Tissue collection 
Lung tissues: Following hemodynamic measurements by catheterisation 
under terminal anaesthesia, the right main bronchus was tied off with suture to 
prevent exposure to formalin. The gravity perfusion apparatus comprised a 22-
gauge flexible cannula (0.9x25mm BD Venflon) connected via polypropylene 
tubing to a 5ml syringe placed with the base at a height of 6.5cm above the 
bench was inserted. The cannula and tubing were-pre-filled with 10% neutral-
buffered formalin and the syringe was filled to the 3ml mark. The tubing was 
sealed with an artery clamp to prevent flow. The trachea was exposed and a 
partial incision was made, followed by insertion of the 22-gauge cannula, which 
was tied into place with suture. The clamp was released and the left lung lobes 
were fixed and inflated with 10% neutral-buffered formalin for 10 minutes. The 
left lobe was then excised and placed into 10% neutral-buffered formalin pots 
prior to tissue processing and paraffin wax embedding. The whole right lung 
lobes were excised, placed in cryovials and frozen in liquid nitrogen for RNA 
and protein extraction. 
 
Liver and kidney: The mouse liver and kidney were also collected. Briefly, both 
kidneys were dissected with left kidney fixed in 10% neutral-buffered formalin 




for histology assessment and right kidney snap-frozen in a cryovial in liquid 
nitrogen for later protein and RNA extraction. For mouse liver collection, the left 
lobe was snap frozen in a cryovial while the rest of the tissue was fixed in 
neutral-buffered formalin. 
 
2.4.1.3 Atp13a3-P452Lfs mouse genotyping protocol 
Mouse Genomic DNA extraction 
  Mouse genomic DNA was isolated from ear notches by digestion overnight 
with 350 μl of digestion buffer (50mM Tris-HCl, pH 8.0; 5mM EDTA, pH 8.0; 
100mM NaCl; 1% sodium dodecyl sulfate (SDS)) supplemented with 9 μl of 
proteinase K (Biolab) in 1.5ml tubes at 50°C. Following digestion, 100 μl of 4.5M 
Sodium perchlorate (Thermo Fisher Scientific) was added and mixed by 
inversion before adding 600 μl /sample chloroform and further mixing. The 
homogenate was then centrifuged at 4000g for 1 minute at room temperature. 
The resulting ~300 μl of the upper aqueous phase was transferred into a new 
tube followed by adding 600 μl of ice-cold 100% ethanol. Samples were mixed 
thoroughly by inversion and centrifuged at 12,000g for 5 minutes at 4°C. After 
discarding the supernatants, pellets were washed with 1ml of 70% ice-cold 
ethanol and centrifuged at 12,000g for 5 minutes at 4°C. The supernatants were 
removed again, and pellets were left air dry for 5 minutes before resuspending 
in 100 μl of nuclease-free water.  
Genotype determined by the polymerase chain reaction and restriction 
enzyme digestion 
  As described above, the Atp13a3-P452Lfs mutation was edited into the 
mouse genome using the CRISPR-Cas9 system. The introduction of the 
P452Lfs mutation as well as the addition of silent mutations for preventing Cas9 
protein from the “re-cut”, created an additional BseRI restriction enzyme 
digestion site which was therefore used for mouse genotyping.   




To achieve this, a DNA fragment was amplified from mouse genomic DNA 
using the following primers: 
Atp13a3-P452Lfs-F: 5’-AGCCTAGGGCCTCAAACATTA -3’ 
Atp13a3-P452Lfs-R: 5’-AACAAACCGACCTTGTCAAAGC -3’ 
20 μl PCR reactions were set up as described below. 
5x GoTaq® Buffer 4 μl 
MgCl2 1.2 μl 
10mM dNTP 0.4 μl 
Forward/Reverse Primer mix 1.2 μl 
Nuclease-free water 11.8 μl 
GoTaq® polymerase 0.12 μl 
Genomic DNA 2 μl 
Reactions were then run using the following program: 
Step Temp. Time 
Initial denaturation 95°C 2 minutes 
30 cycles 
Denature 95°C 30 seconds 
Anneal 64°C 30 seconds 
Extend 68°C 1 minute 
The resulting amplicon covering the P452Lfs region was then digested using 
the following reactions with BseRI (NEB) to determine mouse genotypes. 
PCR product 5 μl 
Cutsmart 2.5 μl 
Nuclease free water 16.5 μl 
BseRI 1 μl 
The digestion reactions were performed at 37°C for an hour and inactivated at 
80°C for 20 minutes. Following digestion, 2 μl of the reaction was used for 
electrophoresis in a 1.5% Agarose gel at 100V for 45 minutes before imaging. 




Samples presented with digested bands were then sent out for Sanger 
sequencing (Genewiz) for genotype confirmation.   
 
2.4.2 Monocrotaline (MCT) Rat model 
  Monocrotaline (MCT) is a pyrrolizidine alkaloid used for the establishment of 
pulmonary hypertension in rats. Once injected, the monocrotaline is 
dehydrogenated by rat liver into monocrotaline pyrrole, which is toxic. MCT 
induces pulmonary vascular injury through an inflammatory response [270]. 
This model was generated by Dr Elisabet Ferrer. Briefly, Male Sprague Dawley 
rats (~200 to 250 g, Charles River, Margate, UK) were randomised into two 
groups. Injections of saline were given to control rats as vehicle control. Rats 
in the experimental PAH group were given 40 mg/kg of MCT, which induces a 
progressive PAH phenotype over a 21-day period. To assess the disease 
progression of the MCT rat model, hemodynamic phenotyping was performed 
at week 0, week1, week 2and week 4. At each of the time point, rats were 
anaesthetised with inhaled isoflurane and right and left ventricular function were 
assessed using a Millar SPR-869 pressure-volume catheter. Hearts were 
dissected, and the weights of the right ventricle and left ventricle plus septum 
were recorded. Lung tissues were flushed before harvesting and snap-frozen 
in cryovials for downstream molecular analyses. 
 
2.4.3 Sugen 5416/hypoxia rat model 
  Sugen 5416 is a semi-specific tyrosine kinase inhibitor that inhibits both 
vascular endothelial growth factor receptor 2 (VEGFR2) and VEGFR1. The 
combination of a weekly injection of Sugen 5416 followed by 3 weeks exposure 
to hypoxia causes rats to develop a progressively worsening pulmonary 
hypertensive phenotype when subsequently maintained in normoxia [270]. 
This model was generated by Dr Lu Long and Dr Xudong Yang. Briefly, Male 
Sprague Dawley rats (~150 to 200 g, Charles River) were randomised into four 




groups. For the control group, rats were kept in normoxic conditions (21% O2) 
for eight weeks; for the hypoxia (Hx) group, rats were maintained in 10% O2 in 
normobaric chambers for three weeks. For the Sugen-Hypoxia model (SuHx) a 
single intraperitoneal -injection of Sugen (SU-5416, 20 mg/kg, Tocris, Bristol, 
UK) in the vehicle (0.5% carboxyl methylcellulose sodium, 0.4% polysorbate 80, 
0.9% benzyl alcohol, all Sigma) was administered to each rat. After Sugen 
injection, rats were transferred to normobaric hypoxic chambers and 
maintained in hypoxia for three weeks, followed by maintenance for a further 5 
weeks in normoxia over which time they develop progressive pulmonary 
hypertension. For the hypoxia+normoxia group, rats were maintained in 
hypoxia for three weeks, followed by five weeks of normoxia. At week 8, rats 
were assessed for cardiopulmonary phenotype and sacrificed for tissue 
collection as described above. 
 
2.5 Molecular Biology Techniques 
2.5.1 Cell genomic DNA extraction 
  Cell total genomic DNA was isolated using the DNeasy Blood & Tissue Kit 
(Qiagen). To achieve this, cells grown in 6-well plates were harvested and 
resuspended in 200 μl PBS supplemented with 20 μl of proteinase K (600 
mAU/ml, Qiagen). 200 μl of lysis buffer AL (Qiagen) was then added and 
thoroughly mixed, followed by incubation at 56°C for 10 minutes. Following this 
incubation, 200 μl ethanol was added and well mixed before transferring into a 
DNeasy Mini spin column (Qiagen) and centrifuged at 6000g for 1 minute. After 
discarding the flow-through, 500 μl of washing buffer AW1(Qiagen) was added 
onto the column and centrifuged again at 6000g for 1 minute. The column was 
then washed again with 500 μl of buffer AW2 (Qiagen) and centrifuged at 6000g 
for 3 minutes to remove washing buffer completely. The column was then 
transferred into a new 1.5ml tube (Star Lab) and 200 μl of nuclease-free water 
was added before spinning down at 6000g for one minute for eluting DNA. The 




final genomic DNA yield was determined by NanoDrop™ Lite 
Spectrophotometer (Thermo Fisher Scientifics). 
2.5.2 Plasmid DNA preparation 
2.5.2.1 Minipreparation of plasmid DNA 
  Small scale plasmid DNA was isolated using the GenElute™ Plasmid 
Miniprep Kit (Sigma). Following overnight culture, 5ml of recombinant E. coli 
was pelleted at 12000g for one minute and resuspended in 200 μl of 
resuspension buffer (Sigma). Lysis buffer (200 μl, Sigma) was then added, 
followed by mixing by gentle inversion 6-8 times. To precipitate cell debris, 
proteins, lipids and chromosomal DNA, 350 μl of neutralisation solution (Sigma) 
was added and the tube mixed by inversion 4-6 times before centrifuging at 
12000g for 10 minutes. The aqueous phase was then carefully transferred into 
a GenElute Miniprep Binding Column (Sigma) and centrifuged at 12000g for 
one minute and the flow-through discarded. The column was then washed by 
adding 750 μl wash solution (Sigma) and centrifuged at 12000g for one minute. 
An additional two minutes centrifugation at 12000g was performed to remove 
excess ethanol. The column was then transferred into a new 1.5ml tube (Star 
Lab) and DNA was eluted with 50 μl of nuclease-free water by centrifuging at 
12000g for one minute. The final DNA yield was assessed using a NanoDrop™ 
Lite Spectrophotometer (Thermo Fisher Scientifics). 
2.5.2.2 Purification of DNA fragments from PCR reactions 
  DNA fragments from PCR reactions intended for Sanger sequencing or 
plasmid ligation were purified using the Invisorb® Fragment CleanUp kit 
(Stratec Molecular). To purify the DNA fragments, 250 μl or 500 μl binding 
buffer was added to 50 μl or reaction volume greater than 50 μl of PCR 
reactions. The resulting mixture was vortexed briefly before loading onto a spin 
filter column and incubated for 1 minute at room temperature. The column was 
then centrifuged at 12000g for four minutes and the flow-through discarded. 
The column was then transferred into a new 1.5ml tube, and 20-40 μl of elution 




buffer (stratec molecular) was added and incubated for at least one minute at 
room temperature before being centrifuged at 12000g for one minute. The final 
DNA concentration was assessed using a NanoDrop™ Lite Spectrophotometer 
(Thermo Fisher Scientifics). 
2.5.2.3 DNA fragment extraction from an agarose gel slice 
  Following agarose gel electrophoresis, DNA fragments at the intended size 
were rapidly excised from the agarose gel with a razor blade under UV light 
exposure and extracted using the Invisorb® Fragment CleanUp kit (Stratec 
Molecular). The resulting gel slices were then weighted and split into several 
reactions if they exceeded 300mg per slice. 0.5-1ml of Gel solubiliser S was 
used to dissolve gel slices at 50°C for 10 minutes. Binding Enhancer solution 
(250-500 μl) was then added with and the mix briefly vortexed before loading 
800 μl onto a spin filter column and centrifuging at 11000g for two minutes. For 
volume higher than 800 μl, the residual volume was loaded and centrifuged 
again. The column was then washed with 500 μl of wash buffer, centrifuged at 
11000g for one minute. After discarding the filtrate, the column was spun for an 
additional two minutes at 11000g before adding 20 μl elution buffer and 
incubating for five minutes at room temperature. To elute the DNA, the column 
was centrifuged at 11000g for one minute, and DNA concentration was 
















2.5.3 RNA extraction from cells/tissues 
2.5.3.1 Cell RNA extraction 
  For RNA analysis, cells were seeded in 6-well plates at a density of 
1.5×10^5/well and grown overnight in growth medium prior to transfection or 
exposure to treatments. Total RNA was extracted using RNeasy Mini Kit buffers 
(Qiagen, West Sussex, UK) and Silica Membrane Mini Spin Columns 
(EconoSpin). Briefly, cells were harvested and lysed in wells by scraping with 
350 μl /well buffer RLT containing 0.1% (v/v) B-mercaptoethanol. The cell lysate 
was transferred into labelled RNase/DNase-free tubes and mixed with 350 μl 
/tube 70% (w/v) ethanol thoroughly. The entire 700 μl was then transferred into 
a mini-column (EconoSpin) and centrifuged at 8000g for one minute. The flow-
through was discarded, and the columns washed with 350 μl /column RW1 
buffer followed by centrifugation at 8000g for one minute. The flow-through was 
discarded, and 80 μl DNAse mix, comprising 70 μl RDD buffer (Qiagen) and 10 
μl RNase-free DNase (Qiagen) was carefully added into the central filter of each 
mini-column for genomic DNA elimination. The columns were incubated for 15 
minutes at room temperature and washed again with 350 μl /column RW1 
buffer, centrifuging at 8000g for one minute. The flow-through was discarded, 
and the columns washed twice with 500μM/column RPE buffer, with 
centrifugation at 8000g for one minute followed by discarding the waste. The 
columns were then centrifuged for an additional two minutes at 8000g. The 
mini-columns were then transferred into the newly labelled RNase/DNase-free 
tubes. RNA samples were eluted by adding 30 μl RNase-free water into the 
central filter and incubating for two minutes at room temperature. The columns 
were centrifuged at 8000g for one minute and the RNA concentration measured 
using a NanoDrop Lite Spectrophotometer (Thermo Fisher Scientific). RNA 
samples were stored at -20°C and used as required. 





2.5.3.2 Tissue RNA extraction 
  RNA from mouse lung tissues were extracted using QIAzol Lysis Reagent 
(Qiagen). To achieve this, one lobe of the mouse lung tissue was excised on 
dry ice and transferred into a sterile 2ml tube (Star Lab) containing a stainless-
steel bead (Qiagen) that had been prechilled on dry ice. 1ml/tube of QIAzol 
Lysis Reagent (Qiagen) was then added. The tubes were transferred 
immediately into the prechilled TissueLyser racks and balanced before 
homogenising at 25Hz for 5 minutes. Tissues were then checked to confirm 
they were fully homogenised. An additional 5-minute homogenisation at 25Hz 
was applied if residual tissue chunks presented. Following homogenisation, 
tubes were transferred onto ice. In the meantime, 5PRIME Phase Lock Gel 
tubes (Quantabio) used for separating RNA from protein and lipid were 
prepared by centrifuging at 1500g for 30 seconds. The tissue homogenate was 
then warmed to room temperature, added into the corresponding Phase Lock 
Gel tube (Quantabio) and incubated for five minutes. 200 μl /sample of 
chloroform was then added, followed by vigorous shaking for 30 seconds to 
generate an emulsion. The samples were then centrifuged at 12000g for 10 
minutes at 4°C. The aqueous layer containing the RNA was carefully 
transferred into a fresh 1.5ml tube (Star Lab) before adding 250 μl isopropanol 
(Sigma) and incubation at -70°C for 30 minutes. The samples were pelleted at 
12000g for 10 minutes at 4°C followed by washing with 1ml 75% (v/v) ethanol 
(Sigma) and centrifuged at 7500g for 5 minutes at 4°C. After discarding the 
supernatant, tubes were left upside down to air dry for 10-15 minutes. RNA 
pellets were then dissolved in 100 μl /sample of nuclease-free water and 
concentration was measured using a NanoDrop Lite Spectrophotometer 
(Thermo Fisher Scientific). 1 μl of RNA samples were then electrophorised onto 
a 1% agarose gel. Only samples with distinct 28S/18S RNA bands were kept 
and stored at -20°C for future experiments. 





2.5.3.3 cDNA synthesis  
  Equal amounts of RNA (500-1000ng) extracted as described above were 
added into labelled MicroAmp® Reaction Tubes (Applied Biosystems) and 
diluted with DEPC-treated Water (Invitrogen) to a final volume of 14.2 μl per 
tube. 5.8 μl /sample RT master mix (comprising 2 μl 10x RT buffer, 0.8 μl 
100mM 25X dNTP, 2 μl 10x RT Random Primers and 1 μl MultiScribeTM) 
Reverse Transcriptase from a High Capacity Reverse Transcriptase kit 
(Applied Biosystems) was prepared and added to each RNA sample tube 
accordingly. Single-stranded cDNA synthesis was performed on a Veriti® 96-
Well Thermal Cycler (Applied Biosystems). Samples were initially incubated at 
25°C for 10 minutes, followed by reverse transcription at 37°C for 120 minutes. 
The reaction was terminated at 85°C for 5 minutes and kept at 4°C before 
sample collection. cDNA samples were stored at -20°C and used as required. 
2.5.3.4 Quantitative Reverse Transcriptase-PCR 
  cDNA (2 μl) together with 1.8 μl associated premixed primer sets (final 
concentration in mix = 200nM), 5 μl 2X SYBR Green JumpStart Taq ReadyMix 
(Sigma-Aldrich), 0.2 μl ROX reference dye (Invitrogen) and 1 μl DEPC-treated 
water were added into a well of a MicroAmp® Optical 384-Well Reaction Plate 
(Applied Biosystems), making a 10 μl /well reaction. Amplifications were 
performed on a QuantStudio 6 Flex Real-Time PCR System (Applied 
Biosystems). Reactions were initiated with a 2-minute pre-incubation at 95℃, 
followed by 50 amplification cycles of 30-second denaturation at 95℃, 30 
seconds annealing at 55℃ and 30-seconds extension at 72℃. Melt curve 
analysis was performed to rule out nonspecific amplification, and no-template 
controls were included. Primers for human genes were designed using Primer-
BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/), and primer efficiency 
confirmed to be between 90-110% before use. The relative expression levels 
of all target genes were calculated using the 2^-(△△Ct) method by normalizing 




to the stably expressed housekeeping genes. Differences in gene expression 
are presented as the fold change relative to control. Relative expression of 
target genes in different cell lines or mouse tissues was determined as 2^-
(CTtarget mean-CT3HK). CT3HK is calculated as the arithmetic mean of the CT value 
of B2M, ACTB and HPRT. 
Table 2-6 Primer sequences for human genes analysed using qPCR 
Gene 
name 
Forward 5’ - 3’ Reverse 5’ - 3’ 
Human genes 
ATP13A1 AGTACGCCCATTGTGAAACT TTGAACATCTGTAGCGTGGT 
ATP13A2 AGCTCCTCAGTTTCATCCGT TTCCAACGGAAGAGCAGCAA 
ATP13A3 GAAAATAGGCACAGGATCAG ATTTTACACTATGGTGGGTG 
ATP13A4 ACCCTAAGCTGGTGCCTTTC TGGCCAGGCTGAGAAGAATG 
ATP13A5 ATTGATGGAAGCTGCGTGGT TCTGGGGCAATGGTGTCTTT 







CCNB1 CTGCTGGGTGTAGGTCCTTG TGCCATGTTGATCTTCGCCT 
CCND1 TGTCCTACTACCGCCTCACA CTTGGGGTCCATGTTCTGCT 









ARG1 TGGGGAAGACACCAGAAGAA AGTCCGAAACAAGCCAAGGT 
ARG2 ACTGCCCAGACCTTTGTGTT TGATGAAGTGGTAAGGGGTGT
G 
ODC1 ATATTGGCGGTGGCTTTCCT TGCAAGCGTGAAAGCTGATG 
AMD1 CTAGATGTCGATGCTGGGGG CACAGCAAGAGTGGCAGAGA 
SRM ACCAAGTGTTACAAGCCCCA ACACGTGTTTGGTGAGTGAG 
SMS TGGCAGGACCATGGCTATTT TGAAGGTCCAGCAACACCAA 
SMOX TGGCCCTGTAGCTTTTCTTTT AGGCACTTACAATAACAAGGCA
G 




SLC3A2 ACCAGAAGGATGATGTCGCT TCCAGAATGACACGGATGCT 




















Table 2-7 Primer sequences for mouse/rat genes analysed using qPCR 
Gene Forward 5’ - 3’ Reverse 5’ - 3’ 
Mouse genes 
Atp13a3 TGAAGCTTCCGTGGCATCTC GCACGACCTTCCCTGATA AGG 
Odc1 ACTGTGCAAGCAAGACTGAA ACTTTGCCTTTGGATGTGCT 
Amd1 TCACGAAAATAGCCGGGAAA TAGCGAACAACCAACAACCA 
Srm TGCGAGATTGATGAGGATGT ACGTCAAAGGCATCTTGGTT 
Sms ACGTCAAAGGCATCTTGGTT TTCCTTAAGAGGCAGCCAAA 
Smox TCACTGCCAAATGTGTTCCT TACCCAGCCTGGAGAAAAAGAAA 











Oaz3 AGAAGATGCTGCCTTGTTGT AAGCTGGCTGTGGTCTTTTT 
Azin1 TGTGGTCCAGAAATGCCAAA TGGCAACTGATATGCCACAA 
B2m GTATACTCACGCCACCCACC TGGGGGTGAATTCAGTGTGAG 




Hprt CTTCCTCCTCAGACCGCTTT ATCGCTAATCACGACGCTGG 
Actb GGGAAATCGTGCGTGACAT GTGATGACCTGGCCGTCAG 
 
2.6 Immunoblotting 
2.6.1 Whole-Cell Protein extraction 
  For protein extraction, 300,000 cells were plated in 6-cm dishes prior to 
experiments. Following the experiment procedure (e.g. transfection, 
transduction), cells were snap-frozen on an ethanol-dry ice bath and lysed in 
SDS-lysis buffer (125mM Tris (pH 7.4), 2% SDS, 10% glycerol) containing the 
EDTA-free protease inhibitor cocktail (Roche). The cell lysates were collected 
and sonicated for 10 seconds with a 10-micrometre amplitude on ice using a 
probe sonicator. 
2.6.2 Tissue protein extraction 
  One lobe of mouse lung tissue was excised on dry ice and transferred into a 
sterile 2ml tube (Star Lab) containing a stainless-steel bead (Qiagen). 1ml/tube 
of SDS Lysis buffer (125mM Tris (pH 7.4), 2% SDS, 10% glycerol) containing 
EDTA-free protease inhibitor cocktail (Roche) was then added. The tubes were 
transferred immediately into the prechilled TissueLyser racks, balanced before 
homogenising at 25Hz for 5 minutes. Tissues were then checked if well 
homogenised. An additional 5-minute homogenisation at 25Hz was applied if 
residual tissue chunks presented. The resulting tissue homogenate was then 
sonicated before assaying for concentration using a modified Lowry assay as 
described below. 
2.6.3 Lowry assay 
  A modified Lowry assay (Bio-Rad DC Assay, Bio-Rad) was performed for 
assessing protein concentration. A standard curve was constructed using BSA 
(20 μl /well) with the concentration ranging between 0 to 1mg/ml. A volume of 
2 μl /well of cell lysate was pipetted in duplicate into a 96-well plate. To each 
well, 25 μl of A(S) reagent (comprising 20 μl of reagent S(Bio-Rad) in every 1ml 




of reagent A(Bio-Rad)), was added into each well followed by 200 μl /well 
reagent B(Bio-Rad) and left to develop for 15 minutes. The absorbance of the 
samples and standards plate was read on a plate reader at 595nm, and protein 
concentration was calculated by linear regression in Graphpad Prism. 
2.6.4 Protein separation by Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
  Cell lysates(30-45 μg) were denatured at 99°C for 6 minutes with the addition 
of 5x Sample loading buffer. Samples were then rested on ice for two minutes 
before loading onto a 10% SDS-PAGE gels. All gels were freshly made using 
the recipe listed below. Following loading, cell lysates were separated by 
electrophoresis at 120V in stacking gel for 15 minutes before running at 150V 
in resolving gel for 60 to 90 minutes. 6 μl PageRuler™ Plus Prestained Protein 
Ladder (#26619 Thermo Fisher Scientific) was run in a separate lane for 
estimation of protein mass. Proteins were then transferred onto polyvinylidene 
fluoride membranes (GE Healthcare) by semi-dry blotting at 90mA for 120 
minutes. Membranes were then blocked for an hour with either 5% (w/v) 
BSA(Sigma-Aldrich) or 5%(w/v) non-fat milk in TBST buffer (0.05% Tween-20 
in TBS) before overnight incubation with primary antibodies as listed below. In 
the following morning, membranes were washed three times with TBST (0.05% 
Tween-20) for 10 minutes before incubating with corresponding secondary 
antibodies for an hour at room temperature. Membranes were again washed 
three times with TBST (0.05% Tween-20) for 10 minutes before rinsed with 
PBS to clear residual TBST before developing. For protein detection, 1.5ml/blot 
enhanced chemi-luminescence reagent mixture(A+B) (GE Bioscience) were 
added onto the membrane and developed for 20 minutes with X-ray film (GE 
healthcare) in the darkroom. For assessing loading controls, all blots were re-
probed with mouse monoclonal anti-α-tubulin antibody (1:5000, T9026 clone 
DM1A, Sigma-Aldrich) for 30 minutes at room temperature followed by anti-
mouse horseradish peroxidase antibody (1:5000, P0447, Dako) for 30 minutes 




at room temperature. All blots were developed for 0.5 to 1 minute for visualising 
proteins. 
Table 2-8 PAGE gel recipe 
 10% Resolving Gel 4% Stacking Gel 
PROTOGEL 5ml 1ml 
Gel buffer 3.9ml 1.95ml 
dH2O 5.94ml 4.47ml 
10%APS 150 μl 75 μl 
TEMED 15 μl 7.5 μl 
PROTOGEL (Bio-Rad): 30% acrylamide, 0.8% Bisacrylamide 
Resolving gel buffer (Bio-Rad): 1.5 M Tris.HCl, 0.384% SDS; pH 8.8 
Stacking buffer (Bio-Rad): 0.5 M Tris.HCl, 0.4% SDS; pH 6.8 
APS (Sigma-Aldrich): Ammonium persulfate 
TEMED (Sigma-Aldrich): N,N,N’,N’,-Tetramethylethylenediamine 
Table 2-9 Antibodies utility in cell immunostaining 































2.7.1 Slide coating 
  4-chambered Nunc™ Lab-Tek™ II Chamber Slides™ (Thermo Fisher 
Scientific) were pre-coated with 500 μl /chamber Type I Rat Tail Collagen (Type 
I Rat Tail Collagen 1:100 v/v diluted with 0.02N acetic acid, BD Biosciences) 
for 90 minutes before washing three times with PBS. Slides were then left in 
the tissue culture hood to dry and kept in the fridge before use.   
2.7.2 Immunostaining 
  Following 48-hour transient siRNA or plasmid DNA transfection, Cells were 
then trypsinised and reseeded into collagen-coated 4-chambered slides and 
left to adhere overnight. On the following day, cells were washed with PBS and 
fixed in 4% (v/v) Paraformaldehyde solution (Sigma) at room temperature for 
10 minutes before being permeabilised with 0.05%(v/v) Saponin in 0.5% BSA 
for a further 20 minutes. For blocking nonspecific binding, cells were incubated 
in 0.5% BSA/PBS for an hour. The plastic chambers were then removed from 
the slides, followed by overnight incubation with the intended primary 
antibodies listed below (Table 2-10). In the following morning, cells were 
washed three times with PBS before incubation with the corresponding 
fluorescent antibodies at room temperature for an hour, as shown below. Cells 
were then briefly washed twice with PBS before mounting with mount medium 
containing DAPI (Vector Laboratories) and kept in the dark at 4°C before 












Table 2-10 Antibodies utility in cell immunostaining 


















































































1:100 rabbit Alexa 
Fluor®488 
1:100 













2.8 Polyamine measurement by Liquid chromatography-mass 
spectrometry 
2.8.1 Aqueous metabolites extraction 
Adherent cells 
  To extract aqueous metabolites, cells were seeded at a density of 
300,000cells/well into 6-well plates. Following the intended experiments, cells 
were then washed twice with phosphate-free buffer (162mM ammonium 
acetate 7.4) before being lysed with 350 μl 4:1 methanol: water. Cells were 
harvested from the plates with a cell scraper and carefully transferred into 
corresponding 2ml flat-bottom screw cap tubes. The resulting cell lysate was 
sonicated for 5 minutes in a water bath sonicator. An additional 5-minute 
sonication was applied if obvious cell debris was still present. The cell 
homogenate was then centrifuged at 21000g for 10 minutes at room 
temperature to pellet residual debris, and the supernatant was carefully 
transferred into new tubes. The resulting cell aqueous metabolites were then 
lyophilised using a centrifugal evaporator (Savant, Thermo Scientific) overnight 
and stored at -20 ⁰C prior to further preparation and analysis. For internal 
normalisation, the pellets remaining from the previous step were further lysed 
with SDS lysis buffer as described previously and assessed for protein 
concentration using Lowry assay.  
Mouse lung tissues 
  Mouse lung tissues were homogenised in the TissueLyser II (Qiagen) 
followed by extraction in 4:1 methanol: water as described previously. To 
achieve this, one lobe of the mouse lung tissue was excised on dry ice and 
weighed before being transferred into a sterile 2ml tube (Star Lab) containing 
with a stainless-steel bead (Qiagen). All tubes were rested on dry ice prior to 




lysing in 1ml/tube of 4:1 methanol: water. The tubes were transferred 
immediately into the prechilled TissueLyser racks, balanced before 
homogenising at 25Hz for 5 minutes. Tissues were then checked if well 
homogenised. An additional 5 to 10 minutes homogenisation at 25Hz was 
applied if residual tissue chunks still presented. The resulting lung homogenate 
was sonicated for one minute before centrifuged at 21200g for ten minutes at 
room temperature. Following centrifugation, the top aqueous layer was 
transferred into a fresh tube while the organic bottom layer was collected into a 
separate tube followed by a second extraction using 1ml 4:1 methanol: water. 
The resulting aqueous layer was combined and dried, as described previously. 
The residual pellets were lysed with SDS lysis buffer as described previously, 
and protein concentration was assessed using Lowry assay.  
Targeted analysis of the metabolites was then performed by Dr. James West 
(Kaser Lab) using a Quantiva triple stage quadrupole mass spectrometer 
coupled to a Vanquish Horizon (all analytical instrument combinations supplied 
by Thermo Fisher Scientific). The resultant data were acquired, processed and 
integrated using Xcalibur (Version 3.0, Thermo Fisher Scientific) and 
Compound Discoverer (Version 2.1, Thermo Fisher Scientific). 
 
2.9 Human induced pluripotent stem cell 
2.9.1 Cell culture 
  Human induced pluripotent stem cells (iPSCs) were maintained in 6-well 
plates coated with gelatine to aid the attachment. To prepare the plates, 
1.5ml/well of 0.2% (w/v) porcine gelatine (Sigma) solution in cell culture grade 
water (Hyclone) was added. After one-hour incubation at room temperature, 
the solution was replaced with DMEM supplemented with 10% FBS and 
incubated for at least 2 hours in the incubator before use. Prior to laying down 
cells, plates were washed once with PBS and replenished with respective 
growth media. 




  For feeder-dependent human induced pluripotent stem cells (hiPSCs), cells 
were grown on top of a 25% confluent irradiated mouse embryonic fibroblast 
(iMEF) cell layer in feeder-dependent hiPSCs media as described in the 
Appendix while feeder-free hiPSCs were cultured in BK media. For feeder-free 
H9 human embryonic stem cells (hESCs), cells were grown in CDM-BSA 
supplemented with activin A (10mg/ml) and FGF-2(12ng/ml) [271]. 
2.9.2 Generation of ATP13A3-R858H induced pluripotent stem cell lines 
2.9.2.1 CRISPR-Cas9 genetic editing overview 
  The Clustered Regularly Interspaced Short Palindromic Repeat 
(CRISPR)/CRISPR association protein 9 (Cas9) genetic editing system[272] 
was used to introduce a PAH associated ATP13A3 missense mutation (R858H) 
into the C2 iPSC line generated from BOECs from a wild-type individual without 
any previous history of PAH.  
 
Figure 2-2 Strategy overview of introducing ATP13A3-R858H mutation using the 
CRISPR-Cas9 system. 
The completion of the CRISPR-Cas9 directed genetic editing (ATP13A3-R858H) 
involves two steps: 1. To Introduce a double-strand break at the desired editing region 




















strand break introduced by CRISPR-Cas9 complex is then repaired by the homology-
directed repair (HDR) pathway with the direction of a repairing template bearing the 
R858H mutation. 
2.9.2.2 Design of the CRISPR-Cas9 guide RNA 
  The CRISPR-Cas9 system is consist of two components: a guide RNA 
(gRNA) and a CRISPR endonuclease. A gRNA is a ~20bp nucleotide sequence 
shares the homology with the target genomic region. Following the binding of 
gRNA to the DNA target, a 3-bp protospacer adjacent motif (PAM) immediately 
downstream of the 3’ end of the target region senses the signal for Cas9 
endonuclease which then introduces a double stream break (DSB). CRISPR-
Cas9 guide RNAs using in this study were designed using the online platform, 
benchling ( www.benchling.com ), based on the algorithm considering the 
target efficiency and off-target possibility. gRNA primers used for CRISPR 
Nuclease vector cloning were listed below (Table 2-11) 
Table 2-11 Primers used for CRISPR-Cas9 cloning 

































Side direct mutagenesis (SDM) primer 











2.9.2.3 Generation of the ATP13A3-R858H CRISPR-Cas9 nuclease vector 
  To create the CRISPR-Cas9 complex targeting for ATP13A3-R858H editing,  
double-stranded oligonucleotides with the sequences listed in Table 2-11 were 
cloned into the GeneArt® CRISPR Nuclease Vector (A21174, Life technologies) 
(Figure 2-3) per the manufacturer’s protocol. In Brief, 5 μl of each 
Forward/Reverse strand oligonucleotide at 200μM were reannealed in a 20 μl 
reaction containing 2 μl of annealing buffer and 8 μl of DNase/RNase-free water. 
The reaction was left at room temperature for 30 minutes before diluted 100-
fold twice to make the 5nM working solution for ligation. 2 μl of Linearised 
GeneArt® CRISPR Nuclease Vector was ligated to 2 μl of 5nM double-stranded 
oligonucleotide solution at room temperature for 2 hours before proceeding to 
transformation. One Shot® TOP10 chemically competent E. coli was used for 
transformation, adding 3 μl of the ligation reaction to a vial of E.Coli. Tubes 
were left on ice for 30 minutes before heat-shock for 30 seconds at 42°C. 250 
μl of S.O.C medium was added, followed by shaking on a Thermomixer for an 
hour at 500rpm. 50 μl of the transformation reaction was spread evenly on a 
prewarm LB agar plate containing 100 μg/ml ampicillin and incubated at 37°C 
overnight. Colonies were picked in the following day and cultured in 5ml of LB 
broth containing the appropriate antibiotics overnight. Plasmid DNA was then 
purified and stored at -20 ⁰C prior use. The GeneArt® CRISPR Nuclease Vector 
contains an orange fluorescent protein (OFP) to enable FACs enrichment of 
cleaved cell population and assessment of cleavage efficiency. 





Figure 2-3 Schematic of GeneArt® CRISPR Nuclease Vector. 
The GeneArt® CRISPR Nuclease Vector is a 9219bp plasmid constructed with 
the targeting CRISPR RNA (crRNA), a trans-activating crRNA (tracrRNA) as 
well as the Cas9 nuclease expression cassette. Double-strand oligonucleotides 
encoding the desired target CRISPR RNA (without PAM sequence) were 
cloned into the 3’ downstream overhang of U6 promotor, ensuring the 
expression of Cas9 nuclease. The vector also contains an orange fluorescent 
protein (OFP) cassette, which following transfection, enables cell population 
enrichment with Fluorescence-activated cell sorting (FACs). The image was 











2.9.2.4 Generation of the ATP13A3-R858H repairing template 
  The double-strand break introduced by CRISPR-Cas9 complex is repaired 
through either non-homologous end joining (NHEJ) or homology-directed repair 
(HDR). The NHEJ is an active but error-prone repairing pathway whereas the 
HDR is less efficient by has a high-fidelity. To introduce a precise modification 
in ATP13A3, a repair template containing the desired mutation was designed 
and delivered together with the CRISPR-Cas9 nuclease vector to maximise the 
utilisation of HDR for gene editing. To introduce the ATP13A3-R858H(G>A) 
mutation into the wild type C2 iPSC line, using AccuPrime™ Pfx DNA 
Polymerase kit (Invitrogen) as described below. 
2.9.2.4.1 Cloning of LHA and RHA into pCR™-BluntII-TOPO® plasmid 
vectors 
  Two ~1kb DNA fragments namely Left homology arm (LHA), and right 
homology arm (RHA) were first cloned from the C2 genomic DNA and then 
subcloned into pCR™-BluntII-TOPO® plasmid vectors respectively using the 
Zero Blunt® TOPO® PCR Cloning Kit (Life technologies) as shown below. 
Reagent Volume 
LHA/RHA PCR product 3 μl 
Salt solution 1 μl 
Nuclease free water 1 μl 
pCR™-BluntII-TOPO® 1 μl 
The cloning reaction was mixed and incubated at room temperature for an hour 
before proceeding to transform One Shot® TOP10 chemically competent cells. 
2.9.2.4.2 Site direct mutagenesis in LHA-TOPO vector 
  As illustrated in Figure 2-2, the R858H mutation, together with three silent 
mutations aiming to prevent CRISPR re-cutting was introduced into the LHA 
using QuickChange II Site-Directed Mutagenesis (SDM) kit (Agilent 
Technologies). The pair of SDM primers were designed following the 
manufacturer’s protocol.  




Briefly, the criteria assigned were that the primer length should fall between 25 
and 45 bases, with a melting temperature (Tm) of ≥78°C. The intended 
mutations should occupy the middle of the primers, leaving 10-15bp of correct 
sequence at each side. PCR reaction was set up as below:   
10x buffer 5 μl 
LHA-TOPO vector 50ng 
SDM Forward primer 125ng (1.26 μl) 
SDM Reverse primer 125ng (1.26 μl) 
dNTP 1 
Nuclease free water 36.48 
Pfu ultra 1 
Reactions were further amplified as follow: 
95°C 30 seconds 1 cycle 
95°C 30 seconds  
18 cycles 55°C 1 minute 
68°C 5 minutes 
  Following the mutagenesis PCR reaction, 1 μl of Dpn I restriction enzyme 
was added into the reaction and incubated for an hour at 37°C to digest parental 
methylated and hemi-methylated DNA. 1 μl of Dpn I treated reaction was then 
used for the transformation of 50 μl of XL-1 Blue cells. The cells were incubated 
on ice for 30 minutes before heat shocked for 45 seconds at 42°C. 500 μl of 
SOC medium was added and shaken in a Thermomixer at 500rpm for an hour 
at 37°C. 250 μl of transformation reaction was spread evenly onto two LB agar 
plates with 100 μg/ml Kanamycin followed by overnight incubation at 37°C. 
Plasmid DNA was prepared in the following day with the success of 
mutagenesis confirmed by Sanger sequencing (Genewiz) for the engineered 
LHA-TOPO vector. 




2.9.2.4.3 Construction of RHA-LNDA vector 
  To complete the targeting repairing template, the two engineered DNA 
fragments, LHA and RHA in pCR™-BluntII-TOPO® were cloned into the Lox 
neo-DTA (A)(LNDA) plasmid backbone which contains a phosphoglycerate 
kinase promoter-driven neomycin resistance (PGK-NEO) positive selection 
cassette and an MC-1DTA (diphtheria toxin A) negative selection cassette as 
illustrated in Figure 2-2. LNDA vector was first linearised with SmaI (NEB) while 
the RHA fragment was cut out with the same restriction enzyme from the RHA-
TOPO vector following the reaction listed below. 
RHA-TOPO vector/LNDA 5 μg (11.5 μl /5 μl) 
Cutsmart 5 μl 
Nuclease free water 32 μl /38.5 μl 
SmaI 1.5 μl 
  Both reactions were performed at 25°C for two hours for digestion and at 
65°C for another 20 minutes to inactive the enzyme. 1.11 μl of Calf intestinal 
alkaline phosphatase (CIAP) (Promega) was added into the reaction and 
incubated for 10 minutes at 37°C, followed by inactivation for 2 minutes at 80°C 
to prevent the recircularization and re-ligation of RHA-TOPO vector and 
linearised LNDA vector. 
  Following the digestion step, RHA-TOPO reaction was loaded onto a 1.5% 
Agarose gel (low melting point) and ran for one hour before image by the Gel 
doc imaging machine. A band present at 1kb was excised under UV light and 
purified using the Invisorb® Fragment CleanUp kit (stratec molecular). RHA 
fragments purified from the previous step was ligated to the linearised LNDA 
vectors using the T4 DNA ligase Kit follow the manufacturer’s protocol. ligation 
reaction was transformed using One Shot® TOP10 chemically competent E. 
Coli cells. The success of constructing the RHA-LNDA vector was confirmed 
by Sanger sequencing (Genewiz). 




In comparison to the RHA fragments, the LHA fragments with the target 
mutation were cloned out by double digestion with NheI and AvrII restriction as 
described below (Table 2-11). 
  Briefly, 5 μg of LHA-TOPO vector was digested with NheI as listed above for 
an hour at 37°C followed by the inactivation of the enzyme at 65°C for 20 
minutes. The linearised vector was then digested by adding 1.5 μl AvrII into the 
reaction and incubated for another hour at 37°C. In the meantime, The RHA-
LNDA vector was linearised using the same restriction enzymes (Table 2-17). 
Both products were purified using the Invisorb® Fragment CleanUp kit (stratec 
molecular).   
RHA-LNDA vector/ 
LHA-TOPO vector 
5 μg (5 μl)/ 
5 μg (10 μl) 
Cutsmart 5 μl 
Nuclease free water 37 μl / 33.5 μl 
NheI 1.5 μl 
AvrII 1.5 μl 
  To complete the construction of the final repairing template, the purified LHA 
fragments were ligated to the linearised RHA-LNDA vector in the reaction 
described below.  
5x Ligase buffer 4 μl 
Vector DNA 60 fmol 
Insert DNA 180 fmol 
T4 Ligase 1 μl 
  The ligation reaction was performed at 25 °C for 20 hours. 2 μl of the reaction 
was used for the transformation of One Shot® TOP10 chemically competent 
cells. The success of the construction of the LHA-RHA-LNDA vector was 
confirmed by Sanger sequencing (Genewiz). 




2.9.3 Cell electroporation 
  Feeder-dependent C2 wild type iPSCs were removed from iMEF feeder cells 
and cultured in BK media as a feeder-free condition for a week before 
electroporated. 5 μg of the R858H targeting construct was linearised with 1.5 μl 
of NheI restriction enzyme digestion overnight followed by the purification of the 
linearised vector using Invisorb® Fragment CleanUp kit (stratec molecular). 
3 μg of the linearised R858H targeting construct together with 2 μg of CRISPR 
vector was co-transfected into C2 wild type iPSCs using the Human Stem Cell 
Nucleofector Kit 1(Lonza). To achieve this, feeder-free C2 iPSCs growing in 6-
well plates at ~70% confluence was washed twice with 1.5ml/well PBS before 
dissociation with 0.5ml/well of 1xTrypLE Select (Thermo Fisher Scientific) 
supplemented with 2 mM EDTA (Thermo Fisher Scientific) at 37°C for 5 
minutes. 1ml/well of BK media was then added to the cell suspension to 
neutralise the TrypLE Select. Cell numbers were counted in the cell suspension 
before transferring 8x105 cells into a 1.5ml Eppendorf tube and centrifuged at 
150 x g for 3 minutes at room temperature. After discarding the supernatant, 
the cell pellet was gently resuspended with 100 μl of Nucleofector® Solution 
(Lonza). 3 μg of the linearised R858H targeting construct together with 2 μg of 
CRISPR vector were added into cell suspension before transferred into a 
cuvette. The cuvette was then inserted into the Amaxa Nucleofector machine 
(Lonza) and cells were electroporated with Program B-016 before being 
transferred back into a 24-well plate prefilled with 500 μl of prewarmed BK 
media. As a positive control, a separate set of C2 iPSCs were transfected with 
μg of pmaxGFP vector (Lonza) using the same electroporation protocol. To 
check the transfection efficiency, cell fluorescent imaging for assessing OFP 
expression was performed on a Leica DMI3000 B manual inverted microscope 
24 hours post-transfection. 




2.9.4 Fluorescence-activated cell sorting (FACs) enrichment of CRISPR 
targeted cells. 
  24-hour post-transfection, cells in 24-well plates were washed with 500 μl 
/well of PBS once and dissociated with 250 μl /well of 1xTrypLE Select (Thermo 
Fisher Scientific) supplemented with 2 mM EDTA (Thermo Fisher Scientific) at 
37°C for 5 minutes before neutralizing with 0.5ml/well of BK media. The cell 
suspension was then transferred into a 5ml Falcon™ Round-Bottom 
Polystyrene Tubes (fisher scientific) and pelleted at 300g for 5 minutes at room 
temperature. The resulting cell pellet was then resuspended gently in 1ml of BK 
media before loaded onto the BD FACSAriaTM Fusion (BD) cell sorter. A 
separate set of C2 iPSCs without CRISPR transfection was harvested 
following the same protocol and run on the cell sorter for negative cell 
gating prior to the CRISPR cell enrichment. Forward Scatter Width (FSC-
W) against Forward Scatter-Area (FSC-A) parameters were used for 
gating out cell debris and doublets. 561 582/15-A channel against 633 
660/20-A channel was used for OFP positive cell gating. Following the 
negative cell gating, the CRISPR targeted cell suspension was run at 10 
000 events/second on the platform, and single positive cell drops were 
collected into a 5ml Falcon™ FACs Tubes (fisher scientific) prefilled with 1ml 
BK media. After sorting, the enriched cell suspension was centrifuged at 300g 
for 5 minutes at room temperature. The cell pellet was resuspended in 1 ml of 
BK medium before transferred into a 10cm Corning® culture dish for iPSCs 
colony formation. 
2.9.5 Genomic cleavage detection 
  The cleavage efficiency of the CRISPR-Cas9 system was assessed using 
the GeneArt® Genomic Cleavage Detection Kit (Thermo Fisher Scientific).  
48-hour post-transfection, CRISPR targeted cells, as well as pmaxGFP control 
cells, were harvested from the 24-well plated and the resulting cell suspension 




centrifuged at 200g for 5 minutes at 4°C. Cells were then lysed in 50 μl of Cell 
lysis buffer supplemented with 2 μl of Protein Degrader provided from the kit. 
The lysing process was performed in the thermal cycler following the program 
listed below. 
68°C 15 minutes 
95°C 10 minutes 
4°C Hold 
  Following lysing, the resulting genomic DNA from the targeted cells were 
used for PCR amplifying the region where the CRISPR had introduced a 
double-strand break using the primers listed in table 2-11. The reaction volume 
is described as followed. 
Component CRISPR-iPSCs pmaxGFP-iPSCs 
Cell lysate 2 μl - 
10uM F/R primer mix 1 μl - 
Control Template & 
primers 
- 1 μl 
AmpliTaq Gold® 360 
Master Mix 
25 μl 25 μl 
Nuclease free water 22 μl 24 μl 
 
The PCR reactions were run following the program below. 
Enzyme 
activation 
95°C 10 minutes 1x 
Denature 95°C 30 seconds  
40x anneal 55°C 30 seconds 
Extend 72°C 30 seconds 
Final extension 72°C 7 minutes 1x 
Hold 4°C Hold 1x 
 




  The introduction of the double-strand breaks by the CRISPR-Cas9 system 
also created genomic insertions and/or deletions(indels) via the action of the 
NHEJ cellular repair mechanism. Therefore, the PCR amplicons from the 
previous step were denatured and reannealed to create mismatches which can 
be cleaved by Detection enzyme from the kit, resulting in two distinct bands 
after electrophoresis. To achieve this, 2 μl of PCR product together with 1 μl of 
10X Detection Reaction Buffer and 6 μl of water were mixed thoroughly in a 
PCR tube and amplified using the program described below.  
95°C 5 minutes - 
95°C-85°C - –2°C/sec 
85°C-25°C - –2°C/sec 
4°C - hold 
  1μl of detection enzyme from the kit was added to the mismatched product 
and incubated at 37°C for an hour before electrophoresis on a 2% agarose gel 
for an hour at 90V and imaging on a Geldoc imaging platform. The cleavage 
efficiency was calculated following the equation listed below: 
Cleavage Efficiency = 1– [(1–fraction cleaved) ½] 
Fraction Cleaved = sum of cleaved band intensities / (sum of the cleaved and 
parental band intensities) 
2.9.6 ATP13A3-R858H genotyping 
  After FACs enrichment, the targeted C2 iPSCs were grown from individual 
single cells to reach individual cell colonies in 10cm dishes for two weeks. At 
day 14, cell colonies were hand-picked using 200μl pipette tips under a 
microscope and carefully transferred into 0.5ml sterile tubes prefilled with 60μl 
of 1xTrypLE Select (Thermo Fisher Scientific) supplemented with 2 mM EDTA 
(Thermo Fisher Scientific) to disperse the colonies before seeding into a 96-
well plate prefilled with 150μl of BK media. Cells were grown to confluence and 
split 1 to 2 into a new 96-well plate with the remaining half of the cell suspension 
used for genomic DNA isolation. To assess the successful introduction of 




R858H ATP13A3 mutation, a pair of genotyping primers (Table 2-11), were 
used to amplify the LHA with the intended R858H mutation using the cell 
genomic DNA. 2μl of the resulting PCR product was used for positive genotype 
screening using NdeI restriction enzyme digestion as the introduction of R858H 
mutation will create a de novo Ndel cutting site in the amplicons. The positive 
PCR samples with two distinct bands were then purified using the Invisorb® 
Fragment CleanUp kit (stratec molecular) and submitted for Sanger sequencing 
to confirm the genotype. 
 
2.9.7 Generation of iPSC-derived vascular cell-like cells 
2.9.7.1 Generation of iPSC-derived endothelial cells(iPSC-ECs) 
iPSCs-EC differentiation protocol 
  iPSCs-ECs derived from the R858H targeted as well as the C2 wild type 
iPSCs were generated using a 10-day differentiation protocol as described 
previously [273]. On day 0, 6 colonies/line were collected from the feeder-
dependent iPSC lines and dispersed slightly in 1ml of 25% media (Appendix) 
before being seeded into a 0.2% gelatin-coated T25 flask (star lab) prefilled 
with 4ml of 25% medium. Following overnight attachment, the medium was 
aspirated and replaced with 5ml/flask of CDM-PVA supplemented with 20ng/ml 
FGF2, 10μM LY294002 (Sigma) and 10ng/ml BMP4 (Thermo Fisher Scientific). 
Cells were differentiated into the mesoderm phase with this conditioned media 
for 4 days. On day 5, the medium was replaced with 5ml/flask of CDM-PVA 
supplemented with 5ng/ml FGF2, 20ng/ml human VEGFA165, 10ng/ml BMP4, 
10μM SB 431542 and 5μM DAPT to differentiate cells towards the endothelial 
cell phase. On day 6 and day 7, cells were fed in E+ media supplemented with 
5ng/ml FGF2, 20ng/ml human VEGFA165, 10ng/ml BMP4, 10μM SB 431542 
and 5μM DAPT. On day 8 and day 9, cells were changed into E+ media 
supplemented with 5ng/ml FGF2, 20ng/ml human VEGFA165, 10ng/ml BMP4 
and ROCK inhibitor (0.1%v/v) to prevent cell apoptosis. On day 10, the iPSC-




derived endothelial cell population was isolated using the Magnetic-activated 
cell sorting (MACS) system. 
 
Magnetic-activated cell sorting (MACS) enrichment of iPSC-ECs 
  Following the endothelial cell differentiation process, cells were first dual-
labelled with two endothelial-specific markers CD144 (CD144 MiroBeads, 
human, Miltenyi Biotec) and CD31 (CD31 MicroBead Kit human, Miltenyi Biotec) 
before isolation using the OctoMACS™ Separator (Miltenyi Biotec). 
iPSCs from the T25 flask were washed twice with 3ml of PBS before 
dissociation with 1.5ml of 2xTrypLE Select (Thermo Fisher Scientific) 
supplemented with 2 mM EDTA (Thermo Fisher Scientific) at 37°C for 5 
minutes. The detached cell suspension was then passed through a 50 μm cell 
filter before neutralization with 3ml of E+ media supplemented with 2 mM EDTA 
(E+ + EDTA media). The resulting cell suspension was then pelleted at 300g for 
5 minutes followed by resuspending in 60μl of E+ + EDTA media. 20μl of FcR 
blocking Reagent (CD31 MicroBead Kit human, Miltenyi Biotec) together with 
20μl of CD31 Microbeads and 20μl of CD144 MicroBeads were added into the 
cell suspension followed by brief vortex and incubation at 4°C for 15 minutes. 
Following incubation, 1ml of E+ + EDTA media was added to wash off excess 
microbeads and then centrifuged at 300g for 5 minutes. During the 
centrifugation step, the MS columns (Miltenyi Biotec) used for EC isolation were 
attached to the OctoMACS™ Separator with a 15ml Falcon tube (Starlab) 
prepared underneath each column for cell collection. The columns were then 
rinsed and equilibrated with 0.5ml of E+ media before EC sorting. Following 
centrifugation of the cells, the resulting pellet was resuspended in 0.5ml of E+ 
media and added straight away to the MS columns. After the cell suspension, 
had flowed through, columns were then washed three times with 0.5ml of E+ 
media, resulting in a total of 2ml EC-negative cell suspension in the collection 
tube. Following washing, the MS columns were transferred into a new 15ml 
Falcon tube for EC-positive cells collection. 1ml warm E+ FGM media was 




added into the columns, and the iPSC-ECs immediately flushed out by firmly 
pushing the plunger into the column. Both the EC-negative and EC-positive cell 
suspensions were counted for calculation of the differentiation efficiency. iPSC-
ECs were then seeded in tissue culture plates per the yield. iPSC-ECs were 
maintained for a maximum of 2 weeks in E+ FGM media when endothelial 
marker staining, the cell apoptosis assay and mRNA/protein extraction were 
performed.  
 
2.9.7.2 Generation of iPSC-derived smooth muscle cells (iPSC-SMCs) 
  To generate iPSC-SMCs, R858H targeted as well as the C2 wild type iPSCs 
underwent a 17-day differentiation protocol as described previously [273]. 
On day 0, 6 colonies/line were collected from the feeder-dependent iPSCs lines 
and dispersed slightly in 1ml of 25% media before seeding into a 0.2% gelatin-
coated T25 flask (star lab) prefilled with 4ml of 25% media. To start smooth 
muscle cell differentiation, iPSCs were cultured in 5ml/flask of CDM-PVA 
supplemented with 20ng/ml FGF2, 10μM LY294002 (Sigma) and 10ng/ml 
BMP4 (Thermo Fisher Scientific) for 36 hours to induce early mesoderm 
differentiation. Subsequently, cells were cultured in 5ml/flask of CDM-PVA + 
FGF-2 (20 ng/ml) and BMP4 (50 ng/ml) for a further 3.5 days to induce late 
plate mesoderm formation. On day 5, cells were trypsinised and reseeded into 
new T25 flasks at a density of 5x105 cell/flask to avoid over-confluence. Cells 
were cultured in CDM-PVA supplemented with PDGF-BB (10 ng/ml, Thermo 
Fisher Scientific), TGF-b1 (2 ng/ml, Thermo Fisher Scientific) and BMP4 (50 
ng/ml) for a further 12 days to differentiate into Smooth muscle cells. iPSC-
SMCs were then matured for another seven days in DMEM supplemented with 
10%FBS. 
 




 Results I-ATP13A3 and vascular cells 
3.1 Introduction 
  Pulmonary Arterial Hypertension (PAH) is characterised by vascular 
remodelling caused by dysfunctional vascular cells. The disease pathogenesis 
is believed to be initiated by the disruption of endothelial functions [274, 275]. 
Teichert-Kuliszewska et al. [48] showed that BMPR2 loss-of-function 
predisposes PAECs to apoptosis. An in vivo study also revealed that 
endothelial specific knockout of Bmpr2 predisposed mice to PAH [276]. 
SU5416, a tyrosine kinase inhibitor, inhibits vascular endothelial growth factor 
receptors (VEGFR1 [277], VEGFR2 [278]) and in combination with hypoxia, 
induces endothelial injury in the rat pulmonary vasculature causing a 
progressive pulmonary vascular remodelling [45, 279]. Hyperproliferative and 
apoptosis-resistant pulmonary artery smooth muscle cells have been well 
documented as another important component contributing to vascular 
remodelling in PAH [40, 274, 275].  
  A recent whole genome sequencing study of a PAH cohort, led by the Morrell 
laboratory, revealed 11 ultra-rare heterozygous mutations in the gene encoding 
ATP13A3, a P5-type ATPase [27]. P-type ATPases are a group of membrane 
transporters which, by forming phosphorylated intermediates via ATP 
hydrolysis, translocate cations across cell membranes [110, 280]. Phylogenetic 
analysis has revealed five subgroups of this superfamily, namely P1-P5 
ATPases [141, 280]. Among these, the P5-ATPases remain the least studied 
group with no known substrate specificity and ATP13A3 represents a P5B-
ATPase of unknown cellular function.  
  Data from GTEX platform (https://www.gtexportal.org/home/) reveals 
ATP13A3 as widely expressed across human tissues. Interestingly, apart from 
the thyroid gland, a relatively high level of ATP13A3 is observed in systemic 
arteries tissues and lung tissues (Chapter 1 Introduction). Single-cell RNAseq 
using lung tissues from healthy subjects [154] further indicates abundant 




ATP13A3 expression in pulmonary macrophages, dendritic cells and vascular 
endothelial cells (Chapter I Introduction). These suggest a potential link of 
ATP13A3 to the functions of the pulmonary vasculature. Here in this chapter, I 
will assess the expression of ATP13A3 and other P5-ATPases in pulmonary 
vascular cells and investigate the impacts of ATP13A3 deficiency to cell 
functions. 
3.1 Results 
3.1.1 ATP13A3 is highly expressed in pulmonary vascular cells.   
  I first assessed the mRNA expression of ATP13A1-5 by qPCR in human 
pulmonary artery endothelial cells (hPAECs), human pulmonary artery smooth 
muscle cells (hPASMCs) and blood outgrowth endothelial cells (BOECs). As 
illustrated in Figure 3-1, ATP13A3 was expressed in all three types of cells with 
highest levels observed in hPAECs, slightly lower levels in hPASMCs and 
lowest levels in BOECs. hPAECs also showed the highest ATP13A1 and 
ATP12A2 mRNA expression, though the levels were only 15% of the ATP13A3 
expression. Unlike ATP13A1-ATP13A3, ATP13A4 and ATP13A5 were barely 
expressed in these cell types (data not shown).  
3.1.1 Validation of ATP13A3 siRNA knockdown efficiency in different cell 
types  
  ATP13A3 loss of function is thought to participate in in the pathobiology of 
PAH [27]. To characterise this in human vascular cells, two siRNA 
oligonucleotides targeting different regions of the human ATP13A3 mRNA were 
tested for their knockdown efficiency in both hPASMCs and BOECs. Forty-eight 
hours post-transfection, cells were harvested and assessed for ATP13A3 
mRNA expression by qPCR. In comparison with siRNA control pool, hPASMCs 
transfected with siATP13A3#1 exhibited an average of 80% reduced ATP13A3 
expression while the mean knockdown efficiency of siATP13A3#2 was only 40% 
(Figure3-2). Similarly, siATP13A3#1 transfection in BOECs also yielded a 
higher knockdown efficiency (~85%) than siATP13A3#2 transfection (~50%) 




(Figure3-3). Therefore, siATP13A3#1 was chosen for further experiments. In 
addition, to assess the specificity of siATP13A3 #1, mRNA expression of other 
P5-ATPases was also examined in BOECs. As shown in Figure 3-4, 
siATP13A3#1 yielded an average of ~90% knockdown of ATP13A3 without 
affecting the expression of ATP13A1 and ATP13A2. Basal expression of 
ATP13A4, ATP13A5 were undetectable and were therefore not included in the 
panel. 
 
Figure 3-1 P5-ATPase family gene expression in vascular cell types  
Relative expression of ATP13A1-3 in hPAECs, hPASMCs and BOECs were 
assessed by qPCR (n=4). Data are presented as fold-change normalised to the 
arithmetic mean of the Ct values of three different housekeeping (3HK) genes 
B2M, ACTB, HPRT. One-way ANOVA with Tukey’s post hoc test was used for 
multiple comparisons among the mRNA expression of P5-ATPases in different 












































Figure 3-2 siATP13A3 knockdown efficiency in human pulmonary artery smooth 
muscle cells.  
hPASMCs (78MP, 79MP, 103MP) were transfected with 10nM ATP13A3 siRNA (#1, 
#2) and assessed for knockdown efficiency 48-hour post-transfection. ATP13A3 
mRNA was presented as fold-change relative to B2M and further normalised to DH. 
One-way ANOVA with Tukey’s post hoc test for multiple comparisons was used for 
data analysis **P<0.01, ***P<0.001 compared with siCP. 
 
Figure 3-3 siATP13A3 knockdown efficiency in blood outgrowth endothelial  
BOECs (C4, C7, C26) were transfected with ATP13A3 siRNA (#1, #2) and assessed 
knockdown efficiency 48-hour post-transfection. ATP13A3 mRNA was presented as 
fold-change relative to B2M and further normalised to DH. One-way ANOVA with 
Tukey’s post hoc test for multiple comparisons was used for data analysis *P<0.05, 















































































Figure 3-4 ATP13A3 depletion in BOECs did not alter mRNA expression 
of other P5-ATPases  
mRNA expression of (A) ATP13A3, (B) ATP13A1, and (C) ATP13A2 in BOECs 
transfected with DharmaFECT1 (DH1) alone, siATP13A3 or non-targeting 
siRNA control (siCP) (n=3). Data are presented as fold-change relative to B2M 
and further normalised to DH1. Mean ± SEM was shown and data were 
analysed using a One-way ANOVA with Tukey’s post hoc test for multiple 











3.1.2 Characterising the impact of ATP13A3 loss-of-function in cell 
proliferation 
3.1.1.1 ATP13A3 deficiency impaired the proliferation of pulmonary artery 
smooth muscle cells.  
  Having shown that ATP13A3 is expressed in hPASMCs, I then questioned 
whether manipulating ATP13A3 expression could alter hPASMC proliferation. 
As shown in Figure 3-5, ATP13A3 silencing in hPASMC restrained cell 
proliferation both in 1% FBS or 5% FBS DMEM (Figure 3-5 A). The efficiency 
of siATP13A3 knock-down was confirmed at the mRNA level both at day 0 
(81.70% ± 0.63% reduction) and day 6 (67.50% ± 2.28% reduction) (Fig3-5 B). 
The proliferation of hPASMC is induced by cytokines such as PDGF [281] and 
inhibited by TGFβ [282] and BMP6 [61, 62], with responses to these ligands 
thought to be dysregulated in PAH [283]. Therefore, I assessed hPASMC 
proliferation in response to these cytokines after siATP13A3 transfection. In 
general, the proliferation of hPASMCs transfected with or without ATP13A3 
siRNA was enhanced to a similar extent by 10ng/ml PDGF (2.49 versus 2.28-
fold change, siATP13A3 and siCP) (Figure 3-5 C). On the other hand, 10ng/ml 
TGFβ suppressed the proliferation of siATP13A3 transfected hPASMCs by 
22.1% and siCP transfected cells by 25.4%. BMP6 also showed a similar 
degree of growth suppression in siATP13A3 (15.6%) and siCP (12.2%) 











3.1.2.1 ATP13A3 knockdown impaired human endothelial cell 
proliferation  
  Endothelial dysfunction is a key feature in the pathogenesis of PAH [274, 
275]. Therefore, I first sought to examine whether ATP13A3 deficiency affected 
the proliferation of human pulmonary artery endothelial cells (hPAECs). Again, 
the siATP13A3 knockdown efficiency was confirmed at both day 0 and day 6 
with an average of ~90% and ~65% mRNA reduction respectively (Figure 3-6 
B). Similar to hPASMCs, siATP13A3 significantly reduced hPAEC proliferation 
by approximately 20% comparing to cells transfected with non-targeting siRNA 
control (siCP). (Figure 3-6 A). To further characterise the impact of ATP13A3 
deficiency on proliferation in the context of cytokine supplementation, 
transfected hPAECs were cultured with the addition of either 30ng/ml VEGF-A 
or 5ng/ml BMP9. VEGFA-165, an isoform of vascular endothelial growth factor, 
is an angiogenic endothelial mitogen [284]. BMP9 is a potent vascular 
quiescence factor crucial for maintaining endothelial homeostasis [285]. 
Although BMP9 was shown to promote angiogenesis in cancer cells [286], it 
has been demonstrated that BMP9 exerted anti-angiogenic effect and 
suppressed the proliferation of PAECs [39]. Interestingly, hPAECs transfected 
with siATP13A3 were less responsive to VEGF-A when compared to the siCP 
group (Figure3-6 A). Consistent with our previous finding, BMP9 treatment 
slightly reduced basal hPAEC proliferation and siATP13A3 transfection further 
decreased cell number. Similar findings were also observed in blood outgrowth 
endothelial cells (BOECs) transfected with siATP13A3 (Figure 3-7). ATP13A3-
deficient BOECs restrained cell proliferation with or without the addition of 
30ng/ml VEGF-A or 5ng/ml BMP9, further indicating an important role of 
ATP13A3 in maintaining cell growth. 





Figure 3-5 ATP13A3 knockdown impaired the proliferation of pulmonary 
smooth muscle cells 
(A) Cell number of transfected hPASMCs following 6-day incubation in DMEM 
containing either 1%FBS or 5%FBS (n=3) (B-C) The proliferation of post-
transfected hPASMCs treated with or without the addition of (B) 10ng/ml PDGF, 
(C)10ng/ml TGFβ or (C) 50ng/ml BMP6 in 1% FBS over a 6-day period (n=4). 
(D) Relative expression of ATP13A3 mRNA normalised to DH1 group at both 
day0 and day6 (n=3). Data are presented as mean ± SEM. One-way ANOVA 
with Tukey’s post hoc test for multiple comparisons was used for data analysis 
among DH1, siATP13A3, and siCP under different treatments. *P<0.05 and 
***P<0.001 compared with siCP. 
A B
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Figure 3-6 ATP13A3 deficiency impaired pulmonary artery endothelial cell 
proliferation 
(a) Proliferation of transfected hPAECs following 6-day incubation in EBM2 
media supplied with 2%FBS alone, or with the addition of 30ng/ml VEGF-A or 
5ng/ml BMP9 (n=3) (b) Relative expression of ATP13A3 mRNA normalised to 
DH1 group at both day 0 and day 6 (n=3). Data are presented as fold change 
normalised to DH1 at different time points (mean ± SEM). One-way ANOVA 
with Tukey’s post hoc test for multiple comparisons was used for data analysis. 




















































Figure 3-7 ATP13A3 knock-down impairs blood outgrowth endothelial cell 
proliferation 
(a) Proliferation of transfected BOECs followed 6-day incubation in EBM2 
containing 0.1%FBS alone, or with the addition of 30ng/ml VEGF-A or 5ng/ml 
BMP9 (n=3 biological replicates) (b) Relative expression of ATP13A3 mRNA 
normalised to DH1 group at both day 0 and day 6 (n=3 biological replicates). 
Data are presented as mean ± SEM. One-way ANOVA with Tukey’s post hoc 
test for multiple comparisons was used for data analysis. *P<0.05 and 
**P<0.001 compared with siCP. 
A
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3.1.2.2 ATP13A3 deficiency attenuated CCNE1, CCNA1, CCNB1 
expression in endothelial cells. 
  Cyclins are proteins involve in the regulation of the cell cycle progression. 
With the observation that ATP13A3 deficiency restrains BOECs proliferation, I 
then questioned whether this effect was related to changes in the expression 
of cyclins. To test this hypothesis, 48-hour post-transfection cells were 
synchronised in EBM-2 containing 0.1% FBS for 28 hours before treating with 
or without 30ng/ml VEGF-A or 5ng/ml BMP9 for an additional 12 hours. 
Intriguingly, although CCND1 mRNA expression was increased by 
approximately 48% with the addition of VEGF-A, it was downregulated by 40% 
with 5ng/ml BMP9, indicating a potential role of BMP9 in suppressing G1 phase 
progressing (Figure 3-8). CCNE, though not regulated with the addition of either 
VEGF-A or BMP9, was significantly reduced by siATP13A3 transfection (Figure 
3-8 A) when compared to siCP. Similarly, both CCNA1 and CCNB1 were also 
negatively regulated by siATP13A3 (Figure 3-8 A) regardless of VEGF-A or 
BMP9 treatment. CCND1, on the other hand, was not altered by ATP13A3 
deficiency (Figure 3-8 A). Collectively, these data suggest a potential 













Figure 3-8 ATP13A3 knockdown attenuated CCNE1, CCNA1, CCNB1 expression 
in BOECs. (a) Relative expression of CCND1, CCNE1, CCNA1 and CCNB1 in transfected 
BOECs cultured with or without the addition of 30ng/ml VEGF-A or 5ng/ml BMP9 for 12 
hours. Data were presented as fold-change relative to B2M and further normalised to DH1 
in 0.1% FBS (n=4) (b) Knockdown efficiency of siATP13A3 in BOECs incubated with or 
without 30ng/ml VEGF-A or 5ng/ml BMP9. Mean ± SEM was shown. One-way ANOVA 
with Tukey’s post hoc test for multiple comparisons was used for data analysis. *P<0.05 
and **P<0.01 compared with siCP.  
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3.1.3 Characterising the impact of ATP13A3 deficiency in endothelial cell 
apoptosis 
3.1.3.1 Loss of ATP13A3 induced blood outgrowth endothelial cells 
apoptosis at low serum levels. 
  As ATP13A3 knockdown reduced BOECs cell numbers at day 6, I questioned 
whether this observation is due to increased apoptosis induced by loss of 
ATP13A3. Both annexin V/propidium iodide (PI) staining and caspase-3 activity 
were used to evaluate cell apoptosis. Quantified by flow cytometry, early 
apoptotic cells were defined as the annexin V+/PI- cell population. As assessed 
by Annexin V/PI staining, ATP13A3 deficiency in BOECs, when grown in EBM-
2 containing 0.1% FBS, led to a more pro-apoptotic response (16.8% ± 3.3% 
in siATP13A3 versus 11.5% ± 3.4% in DH1 and 10.9% ± 2.9% in siCP) whereas, 
in 5% FBS, loss of ATP13A3 did not induce apoptosis (figure 3-9 A, B).  
  These findings were also confirmed by assaying for caspase activity using 
the Caspase-Glo® 3/7 Assay, which utilises a luminogenic substrate that is 
cleaved by caspase-3. The luminescent signal, representing caspase-3 activity, 
was significantly increased in BOECs transfected with siATP13A3 under 0.1% 
FBS (Figure 3-9 C). VEGF inhibits endothelial cell apoptosis both through the 
PI3K-Akt pathway [287] and by inducing Bcl-2 expression [288]. BMP9 has also 
been demonstrated by our group to inhibit endothelial cell apoptosis [39]. 
Therefore, I examined whether the apoptosis induced by ATP13A3 deficiency 
under low serum levels can be restored by VEGF and BMP9. With the addition 
of 30ng/ml VEGF-A, BOECs transfected with siATP13A3 showed a decreased 
percentage of AV+/PI- cell population (7.9% ± 2.3% versus 16% ± 1%, VEGF-
A versus 0.1%, P＜0.01). Although BMP9 prevents endothelial cell apoptosis 
via a different mechanism, still at a concentration of 5ng/ml, it reduced the 
AV+/PI- population in siATP13A3 transfected cells by around 10% (Figure 3-10 
A, B). Again, the Caspase-Glo® 3/7 Assay showed a similar result, with both 




VEGF-A and BMP9 reducing apoptosis in siATP13A3 transfected BOECs 
(Figure 3-10 C).   
 
Figure 3-9 Loss of ATP13A3 induced BOECs apoptosis at a lower serum 
level 
(A) Following transfection, BOECs were treated for 24 hours in 0.1%FBS or 
5%FBS (n=4) before assessing for cell apoptosis by Annexin-V (AV) and 
propidium iodide (PI) staining. (B) Quantification of early apoptosis (defined as 
Annexin V+/PI-). (C) Assessment of caspase-3 activity with Caspase-Glo® 3/7 
assay. Data are presented as Mean ± SEM. One-way ANOVA with Tukey’s 
post hoc test for multiple comparisons was used for data analysis. *P<0.05, 
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Figure 3-10 Apoptosis induced by loss of ATP13A3 could be rescued by VEGF 
and BMP9 
(A) Following transfection, BOECs were treated for 24 hours in 0.1%FBS or 
5%FBS with or without the addition of 30ng/ml VEGF-A or 5ng/ml BMP9 (n=4) 
before assessing for cell apoptosis by Annexin-V (AV) and propidium iodide (PI) 
staining. (B) Quantification of early apoptosis (defined as Annexin V+/PI-). (C) 
Assessment of caspase-3 activity with Caspase-Glo® 3/7 assay. Data are 
presented as Mean ± SEM. One-way ANOVA with Tukey’s post hoc test for 
multiple comparisons was used for data analysis. *P<0.05, **P<0.01, 

































3.1.3.2 ATP13A3 deficiency induced apoptosis in human pulmonary 
artery endothelial cells at low serum level. 
  Having demonstrated that loss of ATP13A3 in BOECs led to enhanced 
apoptosis in low serum, I then questioned if hPAECs behave in a similar way 
to BOECs. As expected, loss of ATP13A3, led to increased activation of 
caspase-3 in hPAECs as detected by Caspase-Glo® 3/7 Assay. Again, this 
effect could be restored with the addition of either VEGF-A or BMP9 (Figure 3-
11). 
 
Figure 3-11 ATP13A3 deficiency induced apoptosis in human pulmonary 
artery endothelial cells  
Cellular caspase activity was assessed by the Caspase-Glo® 3/7 assay 
(Promega). hPAECs were treated for 24 hours in 0.1%FBS with or without the 
addition of 30ng/ml VEGF-A or 5ng/ml BMP9 (n=3). Data are presented as 
Mean ± SEM. One-way ANOVA with Tukey’s post hoc test for multiple 
comparisons was used for data analysis among DH1, siATP13A3, siCP 
transfected cells in 0.1% FBS, *P<0.05 compared with siCP, and among 
siATP13A3 transfected cells treated with or without VEGF and BMP9. *P<0.05 
and **P<0.01 compared with siATP13A3 in 0.1% FBS. 
Figure 9
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3.1.4 Characterising the impact of ATP13A3 deficiency on endothelial cell 
permeability 
  The pulmonary artery endothelium represents a barrier crucial for 
maintaining vascular homeostasis. The disruption of endothelial integrity has 
been recognised as an important contributor to PAH pathogenesis, promoting 
the vascular remodelling and disease development [39, 289-291]. As described 
in the previous section, ATP13A3 deficiency led to reduced endothelial cell 
proliferation and increased apoptosis under low-serum condition. Therefore, I 
sought to assess if this also affect the integrity of hPAECs monolayer. To 
ensure that we were assessing intact monolayers, hPAECs were initially plated 
at different densities in transwell chambers and stained with a VE-Cadherin 
antibody to assess the optimised number for confluent cell monolayer formation. 
As presented in Figure 3-12, when plated at 0.5 x 105 / chamber, hPAECs 
formed a clear and integral monolayer as revealed by the formation of adherens 
junctions (VE-cadherin) across the endothelial cells. hPAECs plated both at 1.0 
x 105, and 1.5x105/chamber presented uneven staining for cellular junctions 
and cell clumps at several regions, suggesting overloading of the transwell 
membrane (Figure 3-12). Therefore, cells were plated at 0.5 x 105/ chamber for 
all further permeability assays. 
3.1.4.1 Validation of endothelial permeability assay 
  Inflammatory factors (e.g. TNFα) [39, 292] or thrombogenic mediators (e.g. 
thrombin) [293, 294] have been reported to increased endothelial permeability. 
Therefore, after seeding into the transwell chambers, hPAECs were treated 
with either TNFα or Thrombin at a range of concentrations to assess their ability 
to induce increased endothelial permeability. As shown in Figure 3-13, hPAECs 
incubated with 1U/ml thrombin displayed a significantly higher permeability at 
60 minutes when compared to cells without treatment. This effect was 
continuously exaggerated by exposure to 1U/ml thrombin until the end of the 2-
hour time point. However, when incubated with 10U/ml thrombin, the 




permeability of hPAEC monolayers was not significantly increased compared 
to the hPAECs treated with 1U/ml thrombin (Figure 3-13). On the contrary, 
TNFα treatment did not induce overt leakage in hPAECs, even at the highest 
dose (1ng/ml) (Figure 3-13). 
 
Figure 3-12 VE-Cadherin staining of human pulmonary artery endothelial cells 
(hPAECs) seeded in transwell chambers Representative images of cellular 
adherens junction (VE-Cadherin, magenta) staining of hPAECs seeded in transwell 
chambers (10X). Nuclei were stained with DAPI (blue). Cell clumps (white arrow) were 
















    
Figure 3-13 Thrombin induces increased permeability of hPAECs.  
hPAECs were treated with or without (A) thrombin (1U/ml or 10U/ml) or (B) TNFα 
(0.1ng/ml, 0.3ng/ml, 1ng/ml) over a 2-hour period. 15μl of the medium was collected 
three times from the bottom wells at the indicated time points followed by the detection 
of horseradish peroxidase (HRP) activity. Raw absorbance was presented (n=3 
technical repeats), and One-way ANOVA with Tukey’s post hoc test for multiple 
comparisons was used for analysing data at each time point. *P<0.05 and ***P<0.001 
compared with the basal condition. 
 
3.1.4.2 ATP13A3 deficiency increased hPAECs permeability in the present 
of thrombin 
  To assess the impact of ATP13A3 deficiency on endothelial permeability, 
endogenous ATP13A3 expression was knocked down by siRNA transfection. 
Following 6-hour serum-starvation in 0.1% FBS EBM2, transfected hPAECs 
were cultured in EBM2 supplemented with 2% FBS and assessed for 
endothelial permeability. As illustrated in Figure 3-14, ATP13A3 deficient cells 
exhibited similar monolayer permeability compared to cells transfected with 
siCP or without transfection. Intriguingly, after 30 minutes of exposure to 1U/ml 
thrombin, siATP13A3 started to enhance hPAECs permeability compared to 
DH1 or siCP, and the difference continue to exaggerate and peaked at the 2-































































































































































important role of ATP13A3 in maintaining endothelial integrity, especially under 
the exposure to pathogenic insults.  
 
Figure 3-14 ATP13A3 deficiency alone did not induce leakage in hPAECs (A) 
Transfected hPAECs were cultured in EBM2 supplemented with 2% FBS in the 
transwell chambers. 15μl of the medium was collected three times from the bottom 
wells at the indicated time points followed by the detection of horseradish peroxidase 
(HRP) activity. Raw absorbance values are presented (n=4). One-way ANOVA with 
Tukey’s post hoc test for multiple comparisons was used for analysing data at each 









Figure 3-15 ATP13A3 deficiency in combination with Thrombin triggered 
hPAEC leakage (A) Transfected hPAECs were culture in transwell chambers in the 
EBM2 supplemented with 2% FBS with the addition of 1U/ml Thrombin. 15μl of the 
medium was collected three times from the bottom wells at the indicated time points 
followed by the detection of horseradish peroxidase (HRP) activity. Raw absorbance 
values are presented (n=4). (B) Breakdown of the Raw absorbance at the 2-hour time 
point. One-way ANOVA with Tukey’s post hoc test for multiple comparisons was used 
for analysing data at each time point. *P<0.05 when compared siATP13A3 to siCP.  
A
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  In this Chapter, I have investigated the expression pattern of ATP13A3 in 
different vascular cells and assessed the impacts of ATP13A3 deficiency on 
vascular cell functions.  
  Comparison of the mRNA levels of different P5-ATPases in hPAECs, 
hPASMCs and BOECs revealed ATP13A3 as the highest expressed P5-
ATPase gene. This observation indicated a potential role of ATP13A3 in 
pulmonary vascular physiology, especially in the endothelial cell as hPAECs 
displayed a higher level of ATP13A3 than the other two cell types. Based on 
these data, I moved on to assess the impacts of ATP13A3 deficiency on 
vascular cell functions.  
  The pathology of pulmonary arterial hypertension is characterised by hyper-
proliferative and anti-apoptotic pulmonary vascular cells that lead to 
progressive vascular occlusion and elevated blood pressure[40, 274, 275]. 
However, the underlying primary cellular defect is thought to reside in the 
endothelium.  Evidence both in vivo [44, 45] and in vitro [39, 48] suggests that 
endothelial cell apoptosis may contribute to disease initiation by reducing the 
integrity of the pulmonary artery endothelium. Here, I have shown that 
ATP13A3 deficiency (achieved by siATP13A3 transfection) reduces cell 
proliferation in both hPAECs and BOECs. Loss of ATP13A3 probably affects 
cell cycle progression as ATP13A3 deficiency down-regulates the mRNA 
expression of CCNE, CCNA and CCNB. Loss of ATP13A3, at a low serum level 
(0.1%FBS), increased the Annexin V+/PI- cell population and promoted 
caspase-3 activity in both hPAECs and BOECs, indicating a protective role of 
ATP13A3 in cell viability under conditions of stress. These observations initiate 
the idea that ATP13A3 is involved in endothelial homeostasis. However, the 
underlying mechanism is still unclear. It is likely the phenotypic changes led by 
ATP13A3 deficiency is independent of or not directly regulated by the VEGF or 
BMP signalling, though other pathways such as TGFβ or inflammatory 
signalling should be examined for the regulation of ATP13A3 in vascular cells. 




In addition, although snapshot (48-hour post-transfection) qPCR data 
suggested that ATP13A3 deficiency affect cyclins expression, further 
investigations are still needed to reveal its role on the full cell cycle progression. 
Increased endothelial permeability has also been implicated in the pathobiology 
of PAH. Endothelial cells with BMPR2 deficiency displayed increased 
permeability [39] and altered leukocyte translocation across the vascular 
wall[289]. Intriguingly, loss of ATP13A3 in hPAECs showed exacerbation of 
endothelial leakage in the presence of thrombin stimulation, indicating an 
important role of ATP13A3 in maintaining endothelial integrity. 
  Depletion of ATP13A3 in PASMCs, opposite to the expectation, presented a 
hypo-proliferative rather than a hyper-proliferative phenotype. However, 
PASMCs with depleted ATP13A3 showed a similar response to a pro-
proliferative mitogen (PDGF) and an anti-proliferative factor (TGFβ), implicating 
the reduction in proliferation caused by ATP13A3 loss of function in PASMCs 
is likely to be independent of these two pathways. 
  In summary, ATP13A3 loss of function impairs the cellular function of 
pulmonary vascular cells, yet the mechanism underlying these observations 
remains unclear. ATP13A3 and its orthologs have been implicated as putative 
polyamine transporters in pancreatic cancer cells [147] and C.elegans (CATP-
5)[139]. Polyamines are a group of aliphatic cations ubiquitous exist in nature 
and participate in a broad spectrum of the cellular processes, including 
proliferation, apoptosis [104, 295]. Together with the above observations in 
vascular cells, I hypothesised that ATP13A3 loss of function is likely to cause 
cellular dysfunction by affecting cellular polyamine homeostasis. The evidence 
of ATP13A3 functioning as a polyamine transporter in maintaining endothelial 
cell polyamine homeostasis will be described in the next chapter. 
 




 Results II-ATP13A3 and Polyamine 
Homeostasis 
4.1 Introduction 
  P-type ATPases are transmembrane proteins, by forming phosphorylated 
intermediates, transport substrates across cellular membranes [110, 280]. 
While ATP13A3, a P5B-ATPase, is widely existing in eukaryotes, the biological 
functions of this putative transporter are still elusive. CATP-5, an orthologue of 
ATP13A3 in C.elegans, was demonstrated to translocate polyamine across the 
apical membrane of the intestinal cells [139]. Additionally, a study in cancer 
biology revealed a correlation between ATP13A3 level and polyamine uptake 
in pancreatic cancer cells [147]. However, no study to date has directly 
addressed whether ATP13A3 is involved in polyamine transport and nor a 
transport substrate is proposed.   
  Polyamines are highly charged polycations widely exist in nature. Putrescine, 
spermidine and spermine are the three main types of polyamine found in 
mammalian cells. These highly charged molecules are essential in many 
cellular processes, including cell growth, apoptosis, transcription and 
translation regulation, as well as stress responses [104, 171, 191, 296-298]. 
Cellular polyamine levels are tightly governed by the coordination between the 
polyamine biosynthesis/catabolism pathways and the transport system. As 
shown in Figure 4-16, polyamine biosynthesis is initiated by the rate-limiting 
enzyme ornithine decarboxylase (ODC), which converts ornithine into 
putrescine. ODC levels are highly regulated by polyamine concentrations, as 
described in the paragraph below. The higher polyamines, namely spermidine 
and spermine, are generated by spermidine synthase (SRM) or spermine 
synthase (SMS) through the addition of aminopropyl groups to their precursors 
(putrescine and spermidine respectively). Decarboxylated S-




adenosylmethionine produced by S-adenosylmethionine decarboxylase (AMD) 
serves as aminopropyl groups donor for these reactions.  
As the critical polyamine biosynthesis enzyme, ODC is dynamically regulated 
at multiple levels [172]. Increased ODC mRNA was seen in response to tumour 
promotors and hormones in a cell-context dependent manner [174, 299]. For 
example, activation of c-Myc results in the overexpression of ODC in cancer 
cells [122, 300]. Moreover, translational regulation of ODC alternates between 
the cap-dependent and internal ribosome entry site (IRES)-dependent 
mechanisms [301, 302], with the latter happens mainly during G2/M phase 
[302]. Upon translation, ODC protein is rapidly turned over via the antizyme-
mediated degradation. Antizyme 1 (OAZ1), which non-covalently binds to ODC 
monomers, directs it to 26S proteasome for degradation [179]. This process is 
independent of ubiquitination but dynamically regulated by intracellular 
polyamine levels. Elevated polyamines trigger a unique ribosomal frameshifting 
event [179, 183], resulting in the translation of full-length antizymes. Polyamine 
depletion, however, represses this frameshifting event and hence preserved 
ODC expression via reducing antizyme production [185].  Antizyme inhibitor 
(AZIN), a protein structurally homologous to ODC but lacking the 
decarboxylase activity, also participates in ODC regulation by liberating it from 
the ODC-antizyme complex, thus prevents it from degradation [186-188].  
  As shown in Figure 4-16, to maintain homeostasis, polyamines can also be 
interconverted back into their precursors via the catabolic pathway. Spermine 
and spermidine are first acetylated by spermidine/spermine acetyltransferase 
(SSAT) to form N1-acetylspermine or N1-acetylspermidine. These metabolites 
are then oxidised back to spermidine or putrescine respectively by the 
polyamine oxidase (PAO). Spermine can also be interconverted directly into 
spermidine by spermine oxidase (SMOX). These oxidative reactions result in 
toxic metabolites (H2O2 and amino aldehyde), which under physiological 
conditions can be resolved by peroxisomal catalase [170] and aldehyde 




dehydrogenases [303]. However, when polyamines accumulation happens, the 
resultant H2O2 overproduction may cause cytotoxicity [243].   
The polyamine transport systems (PTS) is another essential pathway for 
regulating intracellular polyamine levels. Although well described in simple life 
forms such as E. coli and trypanosomatids [304, 305], the PTSs in mammalian 
cells remains elusive. Previous studies have demonstrated polyamine transport 
activities in members of the solute carrier (SLC) and ATP-binding cassette 
superfamily [190, 206] (Summarised in Chapter 1, Table 1), though these 
transporters are primarily responsible for translocating amino acid. Most 
recently, ATP13A2, a P5B-ATPase was uncovered as a spermine exporter 
resided in the endo/lysosomal compartment. Considering the high homology 
shared by ATP13A2-5, this may suggest the potential involvement of other 
P5B-ATPases in transporting polyamines [148].  
  As molecules essential for many cellular processes, polyamine, when 
dysregulated, can cause diseases, such as cancer [171], neurodegenerative 
diseases [262-264]. Similarly, aberrant polyamine contents were also reported 
in PAH. For example, increased polyamine accumulation has been 
demonstrated in the lungs of monocrotaline (MCT)- and hypoxia- treated rats. 
These changes tracked closely the hemodynamic elevation and right 
ventricular remodelling in both models [255, 256]. Intriguingly, the two models 
seemed to favour different mechanisms for their polyamine augmentation. MCT 
treatment significantly induced the upregulation of de novo polyamine 
biosynthesis [255] while hypoxia promoted polyamine accumulation in rat lungs 
via increased transport [256]. These findings shed lights for the involvement of 
polyamine dysregulation in PAH pathogenesis, but suggest differences 
between inflammation-dependent disease progression (MCT) compared to that 
mediated by hypoxic vasoconstriction. In addition, a human lung metabolomics 
study revealed ornithine and putrescine upregulation in PAH patients [258]. 
Plasma metabolomics profiling also demonstrated increased polyamine 
metabolites in idiopathic or heritable PAH patients, with N-acetyl-putrescine (in 




relation to bilirubin) being prognostic independent of other established 
prognostic markers [259]. Taken together, these suggest a link between 
polyamine dysregulation and PAH pathogenesis.   
  As described in the previous chapter, ATP13A3 deficiency leads to 
endothelial dysfunction. To further expand these findings, in this chapter, I will 
describe explore the link between ATP13A3 and polyamine homeostasis in 




4.2.1 Cellular localisation of ATP13A3 
  To understand the biological functions of ATP13A3 in human vascular cells, 
I first sought to characterise its cellular localisation. As a putative 
transmembrane transporter, I initially hypothesised that ATP13A3 might be 
expressed on the plasma membrane of pulmonary vascular cells.   
 
4.2.1.1 Validation of the anti-ATP13A3 antibody in endothelial cells 
  To address the hypothesis, I first sought to test the specificity of the anti-
ATP13A3 antibody (Sigma) in visualising the endogenous ATP13A3 
localisation by transfecting human pulmonary artery endothelial cells with 
siATP13A3 followed by immunofluorescent staining. 90% of ATP13A3 mRNA 
knockdown was achieved in hPAECs at 48-hour post-transfection (Figure 4-
1B). hPAECs transfected with DH1 or siRNA control pool (siCP) displayed 
ATP13A3 fluorescent staining both in the cytoplasm and nuclei, while the 
expression level was significantly reduced in cells transfected with siATP13A3 
(Figure 4-1 A). The reduced fluorescent ATP13A3 signal indicated that the 
antibody was specific and therefore it was used for all the following 
immunostaining.  




4.2.1.2 Endogenous ATP13A3 is localised to the nuclei and perinuclear 
area in endothelial cells 
  I then sought to characterise the localisation of endogenous ATP13A3. To 
achieve this, hPAECs were co-stained with anti-ATP13A3 and anti-VE-
Cadherin antibodies for visualising cell surface. Contrary to my hypothesis, as 
shown in Figure 4-2, little overlap was revealed between endogenous ATP13A3 
and VE-Cadherin. Instead, ATP13A3 mainly presented within the cytoplasm 
(perinuclear) or nuclei, indicating an intrinsic cellular compartments localisation 
of this transmembrane protein (Figure 4-2). 
 
Figure 4-1 Immunostaining of ATP13A3 in transfected hPAECs  
(A) Transfected hPAECs at a density of 50,000 cells/chamber were stained with an 
anti-ATP13A3 antibody (Sigma, 1:200, turquoise). Nuclei were visuaised with DAPI 
(blue). Representative images were taken at 20X magnification using a Leica Sp5 
confocal microscope (Leica microsystem). (B) ATP13A3 mRNA expression was 
presented as fold change relative to B2M expression and normalised to the DH1 (N=3). 
One-way ANOVA with Tukey’s post hoc test for multiple comparisons was used for 

























































Figure 4-2 Endogenous ATP13A3 is mainly localised to the perinuclear region 
and nuclei of hPAECs  
hPAECs were co-stained with anti-ATP13A3 (1:200) and anti-VE-Cadherin (1:200). 
Representative images were taken at (A) 40X (B) 63X magnification using the Leica 
Sp5 confocal microscope platform (Leica microsystem). ATP13A3 (turquoise) signal 
was indicated by the white arrow while the cell plasma membrane was visualised by 











4.2.1.3 Overexpressed ATP13A3 colocalised with endogenous ATP13A3 
in HMEC-1 
  To further characterise the cell compartmentalisation of ATP13A3, GFP-
tagged ATP13A3 (GFP-ATP13A3) was transiently overexpressed in HMEC-1 
cells using hATP13A3-N-EGFP-pcDNA6.2 donated by Prof. Peter Vangheluwe 
(KU Leuven). Before proceeding with cell compartmentalisation 
characterisation, the over-expression pattern of GFP- ATP13A3 was compared 
to the endogenous ATP13A3 staining pattern in HMEC-1. As presented in 
Figure 4-3, the GFP-ATP13A3 signal produced by plasmid overexpression 
(green) presented mainly in the perinuclear region. It also overlaid with the 
endogenous ATP13A3 (red), indicating a good correlation with the localisation 
of transiently overexpressed ATP13A3 (figure 4-3 A). 
 
4.2.1.4 ATP13A3 colocalised with the recycling endosome marker Rab11 
in endothelial cells 
  As described in the last two sections, both endogenous and overexpressed 
ATP13A3 were localised mainly to the perinuclear region of hPAECs or HMEC-
1 cells. These findings suggest distinct compartmentalisation of ATP13A3 in 
endothelial cells. Interestingly, the previous study from Sørensen et al. [141] 
showed that in Hela cells, transiently overexpressed ATP13A3 colocalised with 
the endosomal markers Rab11 and EEA-1. To characterise its cellular 
localisation, GFP-ATP13A3 was transiently overexpressed in HMEC-1 cells 
followed by immunostaining with endo/lysosomal markers. Cells 
overexpressing GFP-ATP13A3 did not present apparent morphological 
abnormalities under the microscope.  
  Similar to the previous study, GFP-ATP13A3 colocalised with the recycling 
endosome marker Rab11 in HMEC-1 cells (Figure 4-4). Any overlap with the 
early endosome marker EEA-1, late endosome marker Rab7 or lysosomal 




marker LAMP1 was minimal (Figure 4-4). These findings suggest a biological 
role of ATP13A3 in the cellular endosomal system. 
 
Figure 4-3 Fluorescent images of HMEC-1 overexpressing hATP13A3-N-EGFP-
pcDNA6.2 
(A) hATP13A3-N-EGFP-pcDNA6.2 was transiently overexpressed for 48 hours in 
HMEC-1 cells followed by staining with the anti-ATP13A3 antibody. Representative 
images were taken at 63X magnification using the Leica Sp5 confocal microscope 
platform (Leica microsystem). GFP-ATP13A3 overexpression is represented by the 
green fluorescent signal, whereas endogenous ATP13A3 staining is indicated by the 
red fluorescent signal. (n=3) (B) ATP13A3 mRNA expression is presented as fold 










































Figure 4-4 ATP13A3 is localised to the recycling endosome in HMEC1 
cells 
hATP13A3-N-EGFP-pcDNA6.2 (1 μg DNA) was transiently overexpressed in HMEC-
1 cells of for 48 hours before being stained with anti-EEA1(1:200), anti-Rab7(1:200), 
anti-Rab11 (1:200) and anti-LAMP1 (1:200). Representative images were taken at 63X 
























































































4.2.1.5 Disease-associated ATP13A3 mutants do not display cellular 
compartmental mislocalisation in HMEC-1 cells. 
  After showing the colocalisation of ATP13A3 with the recycling endosome 
marker Rab11, I then assessed if the PAH-associated ATP13A3 mutations led 
to compartmental mislocalisation in HMEC-1 cells. The hypothesis stemmed 
from the observation by Podhajska et al. [306] that overexpression of the 
Parkinson-related ATP13A2 mutations in human SH-SY5Y neural cells, 
another P5-ATPase from the same family as ATP13A3, displayed 
mislocalisation from the lysosome to the endoplasmic reticulum. To 
characterise the cellular localisation of the PAH associated ATP13A3 mutations, 
five missense heterozygous mutations (L675V, M850I, V855M, R858H, L956P) 
identified from the PAH cohort were transiently over-expressed (plasmids 
donated by Prof. Peter Vangheluwe) in HMEC-1 cells. Cells overexpressing the 
wild-type or mutant GFP-ATP13A3 did not exhibit any overt cell toxicity. Unlike 
ATP13A2 mutants expressed in SH-SY5Y cells, PAH related missense mutants 
expressed in HMEC-1 cells did exhibit a different localisation when compared 
to the wild-type ATP13A3. The different GFP-ATP13A3 mutants still colocalised 
with Rab11 while overlap with other endo/lysosomal markers was minimal 
(Figure 4-5) low. However, in comparison to wild type GFP-ATP13A3, 
overexpression of mutations such as L675V, M850I and V855M led to enlarged 
and condensed vesicles indicating a potential disruption of cell vesicular 













Figure 4-5 Disease-associated ATP13A3 mutants do not display cellular 
mislocalisation in HMEC-1 cells. 
Wild type or disease-associated mutant hATP13A3-N-EGFP-pcDNA6.2 (1 μg DNA) 
were transiently over-expressed in HMEC-1 cells for 48 hours before being stained 
with anti-EEA1(1:200), anti-Rab7(1:200), anti-Rab11 (1:200) and anti-LAMP1 (1:200). 
Representative images were taken at 63X magnification using the Leica Sp5 confocal 
microscope platform (n=4) (Leica microsystem). 




4.2.2 ATP13A3 and polyamine transport 
4.2.2.1 ATP13A3 deficiency reduced the cellular polyamine content in 
human pulmonary artery endothelial cells (hPAECs) 
  ATP13A3 has previously been implicated in polyamine transport. To assess 
its link with polyamine homeostasis in vascular cells, the cellular polyamine 
contents were measured by liquid chromatography-mass spectrometry (LC-MS) 
in hPAECs with or without ATP13A3 deficiency. siATP13A3 yielded an average 
of 90% reduction of ATP13A3 mRNA in hPAECs (Figure 4-6 D). Notably, when 
compared to cells transfected with siCP, siATP13A3 transfected hPAECs 
showed approximately 35% lower cellular putrescine levels (Figure 4-6 A). 
Spermidine and spermine, were less affected by ATP13A3 deficiency in 
hPAECs, with an average reduction of 20% and 18% respectively (Figure 4-6 
B, C). Consistent with my previous findings (Chapter 3), the mRNA expression 
of other P5-ATPases was not altered by siATP13A3 in hPAECs (Figure 4-7). 
These findings suggest that ATP13A3 is likely to play an essential role in 
maintaining the polyamine homeostasis in endothelial cells, with a bias towards 
putrescine.   
 
4.2.2.2 ATP13A3 loss of function reduces the putrescine uptake capacity 
  To assess the polyamine uptake capacity, transfected hPAECs were 
incubated with or without the addition of 1mM putrescine, 10μM spermidine, or 
10μM spermine overnight and measured for cellular polyamine contents. As 
shown in Figure 4-8, consistent with the previous findings, ATP13A3 deficiency 
reduced the basal level of putrescine, spermidine and spermine in hPAECs. 
Interestingly, unlike ATP13A2, which favours a higher transport selectivity to 
spermine, ATP13A3 showed a higher preference to putrescine, manifesting by 
a sharp decrease of putrescine uptake in ATP13A3-deficient hPAECs. 
Spermidine and spermine were less affected (Figure 4-8 B, C). Taken together, 
these findings reinforce the hypothesis that ATP13A3 is involved in polyamine 




homeostasis, as achieved by favouring a higher transport preference for 




Figure 4-6 ATP13A3 deficiency reduces the cellular polyamine levels in 
hPAECs 
Cellular Putrescine (A), Spermidine (B), or Spermine (C) contents of hPAECs 
transfected with DharmaFECT1(DH1) alone, siATP13A3 or non-targeting 
siRNA control (siCP) were assessed by Liquid chromatography-mass 
spectrometry (LC-MS) forty-eight hours post-transfection (N=3).  Data are 
presented as the polyamine peak area ratio relative to sample protein 
concentration, and further normalised to DH1. Mann–Whitney U test was 
applied for data analysis. *P<0.05 compared with siCP. PUT: putrescine; SPD: 
spermidine; SPM: spermine (D) mRNA expression of ATP13A3 relative to B2M 



















































Figure 4-7 ATP13A3 depletion did not affect the mRNA expression of 
other P5-ATPases in PAECs 
mRNA expression of (A) ATP13A3, (B) ATP13A1, and (C) ATP13A2 of 
hPAECs transfected with DharmaFECT1 (DH1) alone, siATP13A3 or non-
targeting siRNA control (siCP). Data are presented as the fold-change relative 
to B2M and further normalised to DH1(n=3). Mean ± SEM are shown, and data 
were analysed using a one-way ANOVA with Tukey’s post hoc test for multiple 












Figure 4-8 ATP13A3 deficiency reduces the cellular polyamine content and 
putrescine uptake in hPAECs 
Cellular Putrescine (A), Spermidine (B), or Spermine (C) levels of hPAECs cultured 
overnight in EBM2 containing 2%FBS and supplemented with or without 1mM 
putrescine, 10μM spermidine, or 10μM spermine. Cellular polyamine content was 
measured by Liquid chromatography-mass spectrometry (LC-MS) (N=3). Data are 
presented as polyamine peak area ratio relative to sample protein concentration, and 
further normalised to 0.1% FBS DH1. Mann–Whitney U test was applied for 
comparison between siATP13A3 and siCP in basal or different polyamine 
supplementation group. *P<0.05 compared with siCP. (D) mRNA expression of 


































































































































































































































































































































































































4.2.2.3 PAH associated ATP13A3 missense mutations display impaired 
polyamine uptake capacity in hPAECs 
  I then assessed if PAH-associated mutations affect ATP13A3 mediated 
polyamine uptake. For comparison, wild type (WT), a catalytic-dead mutant 
(D498N) and the PAH associated missense mutations of ATP13A3 (L675V, 
M850I, V855M, R858H, L956P) were transiently overexpressed with lentiviral 
transduction in hPAECs. The overexpression efficiency for each construct was 
comparable, with an approximately three-fold increase of ATP13A3 mRNA 
observed in transduced hPAECs (Figure 4-9 A). hPAECs were further 
incubated with or without 1mM Putrescine overnight before measuring for 
polyamine by LC-MS. In the basal condition (without putrescine 
supplementation), neither wild type nor mutant ATP13A3 altered the cellular 
polyamine content (Figure 4-10 B). However, when supplemented with 
putrescine, WT-ATP13A3 overexpression significantly increased putrescine 
uptake by 2-fold compared to GFP-tagged empty vectors (Figure 4-10 A).  
  ATP13A3 overexpression in hPAECs did not overtly alter ATP13A2 or 
ATP13A1 mRNA (Figure 4-9 B), so the changes I observed strongly suggested 
a specific effect of ATP13A3 on putrescine uptake. The presence of the 
conserved catalytic site (D498) is crucial for this effect as catalytically dead 
mutation (D498N) substantially reduced putrescine uptake compared to wild 
type ATP13A3 (Figure 4-10 A). Interestingly, the PAH-associated mutants, 
L675V, M850I, and V855M significant impaired the putrescine uptake mediated 
by ATP13A3 (42-60%) (Figure 4-10 A) while R858H and L956V exerted a 
milder disruption (20% and 21% respectively) (Figure 4-10 A). Taken together, 
these results provide strong evidence for ATP13A3 as a putrescine transporter 
in endothelial cells and demonstrate impairment of PAH associated mutations 
on ATP13A3 mediated polyamine uptake. 






Figure 4-9 mRNA expression of P5-ATPases in hPAECs transiently 
overexpressing lentiviral-transduced WT and mutant ATP13A3 
mRNA expression of (A) ATP13A3, (B) ATP13A1, and (C) ATP13A2 in hPAECs 
transiently overexpressing lentiviruses encoding wild type (WT), catalytically 
dead mutant (D498N), PAH-associated mutants (L675V, M850I, V855M, 
R858H, L956P) ATP13A3 or GFP-tagged empty vectors (n=3). Data are 














Figure 4-10 Cellular putrescine levels in hPAEC overexpressing lentiviral 
wild type or mutant ATP13A3 
Cellular putrescine in hPAECs transiently overexpressing lentiviruses encoding wild 
type (WT), catalytically dead mutant (D498N), PAH-associated mutants (L675V, M850I, 
V855M, R858H, L956P) ATP13A3 or GFP-tagged empty vectors followed by overnight 
incubation with (A) or without (B) the presence of 1mM Putrescine (N=4).  Data are 
presented as polyamine peak area ratio relative to sample protein concentration, and 
further normalised to GFP-empty vector. Mann–Whitney U test was applied for data 
analysis. *P<0.05 compared with con-GFP. *P<0.05 compared with WT, *P<0.05 









4.2.2.4 Generation of HMEC-1 lines stably expressing short-hairpin RNAs 
targeting ATP13A3  
  Although the disease-associated mutants L675V, M850I, and V855M 
substantially reduces putrescine uptake capacity, the other two mutants 
assessed (R858H and L956P) exerted a milder effect. This could potentially be 
interpreted as a less deleterious phenotype being masked by the endogenous 
ATP13A3 expression. Therefore, to overcome this, I sought to generate an 
HMEC-1 cell line with low basal ATP13A3 expression by stable expressing a 
short-hairpin RNA (shRNA) targeting ATP13A3. In total, four shRNAs (MiR1-4) 
targeting different regions of ATP13A3 were tested for their knockdown 
efficiency (Figure 4-11). In parallel, a control cell line expressing shRNA 
targeting firefly luciferase was generated (HMEC-1-MiR-fluc). All four ATP13A3 
short-hairpin RNAs significantly reduced the ATP13A3 mRNA expression in 
HMEC-1 cells, with MiR-2 yielded the highest knockdown efficiency (~80%) 
(Figure 4-11 A). However, MiR-2 also caused reduction of ATP13A1 (~30%) 
and ATP13A2 (35%) mRNA (Figure 4-11 B, C). In contrast, the HMEC-1 line 
expressing MiR-1, though only exhibiting around 50% reduction of ATP13A3 
mRNA, preserved the expression of ATP13A1 and ATP13A2 mRNA. 
Additionally, unlike MiR2-4 which target the ATP13A3 cDNA region, MiR-1 
targets the 3’ UTR region of ATP13A3 cDNA and is unlikely to affect the 
ATP13A3 overexpression achieved by plasmid or lentiviral transfection. Taken 
together, MiR-1 outweighed other shRNAs and the HMEC-1 line stably 
expressing MiR-1 (HMEC-1-MiR-1) was chosen for further experiments. Of 
note, the HMEC-1-MiRfluc line did not alter expression of ATP13A1-3 (Figure 
4-11 A-C).  
 




4.2.2.5 Overexpression of ATP13A3 in HMEC-1 suppressed ATP13A1 and 
ATP13A2 mRNA expression  
  Having generated the HMEC-1-MiR-1, I then assessed the overexpression 
efficiency of pcDNA6.2-hATP13A3 in these cells. To optimise experimental 
conditions, 0.5 μg -3 μg of plasmid DNA was transfected into HMEC-1-MiR-1 
and assessed for the ATP13A1-3 mRNA. Again, HMEC-1-MiR-1 displayed 50% 
reduction of ATP13A3 mRNA compared to HMEC-1-MiR-fluc (Figure 4-12 A). 
ATP13A3 mRNA showed a dose-dependent increase with the transfection of 
pcDNA6.2-hATP13A3, with 3 μg plasmid DNA displayed the highest 
overexpression level (35-fold change) (Figure 4-12 A). Interestingly, pcDNA6.2-
hATP13A3 transfected at 2 μg and 3 μg amounts substantially suppressed the 
mRNA expression of both ATP13A1 and ATP13A2. 1 μg of pcDNA6.2-
hATP13A3, while yielding a 5-fold ATP13A3 mRNA increase, did not affect the 
expression of other P5 ATPases (Figure 4-12 B, C). Therefore, 1 μg of 
pcDNA6.2-hATP13A3 was used for characterising the putrescine uptake 










Figure 4-11 mRNA expression of P5-ATPases in HMEC-1 stably 
expressing different ATP13A3 shRNAs 
mRNA expression of (A)ATP13A3, (B)ATP13A1, (C)ATP13A2 in control 
HMEC-1 or HMEC-1 stably expressing MiR-1, MiR-2, MiR-3, MiR-4, non-
targeting control (MiR-Fluc) (n=4). Data are presented as fold-change relative 
to B2M and further normalised to control HMEC-1. Mean ± SEM are shown and 
data were analysed using a One-way ANOVA with Tukey’s post hoc test for 































































































































































































































































































































































































































































































































                      
 
Figure 4-12 ATP13A3 mRNA expression of HMEC-1-MiR-1 transiently 
overexpressing pcDNA6.2-hATP13A3 
mRNA expression of (A)ATP13A3, (B)ATP13A1, (C)ATP13A2 in HMEC-1-MiR-
1 transiently transfected with 0.5 μg -3 μg of pcDNA6.2-hATP13A3 or MiR-Fluc 
(n=2). Data are presented as fold change relative to B2M and further 















4.2.2.6 PAH associated missense ATP13A3 mutation display impaired 
polyamine uptake capacity in HMEC-1  
  Having shown that PAH associated mutations displayed impaired putrescine 
uptake capacity, I then assessed if HMEC-1 cells can recapitulate the previous 
findings in hPAECs. To achieve this, 1 μg of wild type or mutant ATP13A3 
(D498N, L675V, M850I, V855M, R858H, L956P) was transiently overexpressed 
in HMEC-1-MiR-1 cells. As shown below, HMEC-1-MiR-1 cells displayed a 50% 
basal reduction of ATP13A3 mRNA compared to HMEC-1-MiR-fluc cells 
(Figure 4-13 A). Overexpression of ATP13A3 mediated by the wild type and 
mutant ATP13A3 plasmid DNA was comparable in HMEC-1 without affecting 
ATP13A1-2 (Figure 4-13 A). Similar to siRNA knockdown in hPAECs, HMEC-
1-MiR-1 also displayed reduced basal putrescine level, though to a lesser 
extent (18%) (Figure 4-13 A). Overexpression of wild type ATP13A3 in HMEC-
1-MiR-1 cells significantly increased their putrescine uptake by 4-fold while the 
D498N mutant displayed a similar uptake capacity to cells without 
overexpression (Figure 4-13 B). Again, PAH-associated mutants showed 
impairment of putrescine uptake in comparison to the wild type, with V855M 
exhibiting the most significant reduction. Though the reduction of putrescine 
uptake caused by R858H and L956P mutants was less prominent than the 
other disease-related mutants, they displayed a more significant reduction in 
uptake by HMEC-1 cells than observed in hPAECs when compared to wild type 
















Figure 4-13 P5-ATPase mRNA expression in HMEC-1-MiR-1 transiently 
overexpressing WT and mutant ATP13A3 
mRNA expression of (A) ATP13A3, (B) ATP13A1, and (C) ATP13A2 in HMEC-
1 MiR-Fluc cells or HMEC-1-MiR-1 cell stransiently overexpressing the 
ATP13A3 wild type (WT), the catalytically dead mutant (D498N) or PAH-
associated mutants (L675V, M850I, V855M, R858H, L956P) n=2. Data are 















Figure 4-14 Cellular putrescine levels of HMEC-1 cells overexpressing 
wild type or mutant ATP13A3 
Cellular Putrescine in HMEC-1-MiR-fluc cells or HMEC-1-MiR-1 cells transiently 
overexpressing ATP13A3 wild type (WT), the catalytically dead mutant (D498N) or 
PAH-associated mutants (L675V, M850I, V855M, R858H, L956P) followed by 
overnight incubation with (A) or without (B) 1mM Putrescine (N=4). Data are presented 
as polyamine peak area ratio relative to sample protein concentration, and further 
normalised to MiR-Fluc. Mann–Whitney U test was applied for data analysis. *P<0.05 
compared with MiR-Fluc. PUT: putrescine 
A
B




4.2.2.7 hPAECs overexpressing PAH-associated ATP13A3 mutations 
showed reduced sensitivity to polyamine accumulation 
  Although polyamines are essential for many cellular processes, it has been 
shown that excessive polyamines accumulation (especially spermidine and 
spermine) can be toxic and lead to apoptosis [106] or oxidative stress [307]. To 
further evaluate the functional impacts of PAH associated mutations, hPAECs 
overexpressing wild-type or mutant ATP13A3 were exposed to 
putrescine(10mM), spermidine(1mM) and spermine(1mM) and assessed for 
cellular caspase activity. In control hPAECs (transduced with GFP-tagged 
empty vector), putrescine did not induce cell toxicity whereas both spermidine 
and spermine overnight incubation caused approximately 50% increase of 
caspase activity (Figure 4-15). Interestingly, wild type ATP13A3 but not the 
D498N mutant sensitised hPAECs to putrescine, causing nearly 60% increase 
in caspase activity when compared to control hPAECs (Figure 4-15 A). The 
magnitude of the increased apoptosis caused by wild type ATP13A3 under 
spermidine (~30%) and spermine (~20%) incubation was less profound than 
putrescine (Figure 4-15 B, C). The caspase activity induced by spermidine was 
~15% lower in hPAECs overexpressing the D498N-ATP13A3 mutant than in 
cells expressing wild type ATP13A3, while the difference under spermine 
incubation was negligible (less than 5%) (Figure 4-15 B, C). Similar to the 
polyamine uptake observations, PAH-associated mutants, namely L675V, 
M850I and V855M, were less sensitive to putrescine toxicity, with the V855M-
ATP13A3 showed the highest tolerance to putrescine. In contrast, the R858H 
and L956P mutants behaved more closely to wild type ATP13A3 (Figure 4-15 
A). Intriguingly, all PAH-associated mutants showed similar sensitivity to 
spermidine or spermine incubation in comparison to wild type ATP13A3 (Figure 
4-15 B, C).  





Figure 4-15 PAH associated mutations presented resistance to 
putrescine-induced apoptosis in hPAECs 
hPAECs were transiently transduced with wild type (WT), catalytically dead 
mutant (D498N), PAH-associated mutants (L675V, M850I, V855M, R858H, 
L956P) ATP13A3 or GFP-tagged empty vectors.  Cells were then cultured 
overnight with or without the presence of (A)10mM Putrescine, (B)1mM 
Spermidine or (C)1mM spermine and assessed for cellular caspase activity 
(N=3). Data are presented as fold change relative to con-GFP cultured in 









4.2.3 ATP13A3 and polyamine metabolism 
4.2.3.1 ATP13A3 depletion in endothelial cells affects polyamine 
metabolic enzymes  
  From the data presented in this result chapter earlier, ATP13A3 may function 
as a polyamine transporter as ATP13A3 deficiency in endothelial cells 
substantially impaired putrescine uptake capacity. Interestingly, endothelial 
cells with reduced ATP13A3 mRNA expression displayed lower basal 
polyamine content (Figure 4-6 A; Figure 4-14 A). This indicates a potential 
regulation of ATP13A3 on polyamine metabolism.  
 
  To test this hypothesis, the mRNA expression of polyamine biosynthesis and 
catabolism enzymes (Figure 4-16) was compared among hPAECs transfected 
with or without siATP13A3. As previously shown, ATP13A3 depletion did not 
affect the expression of other P5-ATPases (Figure 4-7). Strikingly, 48-hour 
post-transfection, siATP13A3 significantly suppressed the expression of the 
polyamine catabolic enzymes in hPAECs. Specifically, spermine oxidase (SMO) 
was reduced by 35%, polyamine oxidase (PAO) by 30% and 
spermidine/spermine acetyltransferase (SSAT) by 52% (Figure 4-16 C). 
Interestingly, the expression of two polyamine biosynthesis enzymes, 
spermidine synthase (SRM) and spermine synthase (SMS) was also 
downregulated by 31% and 30% respectively (Figure 4-16 B). Taken together, 
these findings suggest that ATP13A3 depletion not only reduces polyamine 











Figure 4-16 ATP13A3 deficiency affects the mRNA expression of polyamine 
metabolic pathway enzymes in hPAEC (A) Schematic of cellular polyamine 
metabolism. Arginine from the urea cycle is converted into ornithine by arginase 1. The 
resulting ornithine is then decarboxylated into putrescine by the rate-limiting enzyme 
of polyamine synthesis ornithine decarboxylase (ODC). Spermidine synthase and 
spermine synthase catalyse the transfer of the aminopropyl moiety from S-adenosyl-
methionine to mediate the production of spermidine and spermine respectively. mRNA 
expression of polyamine biosynthesis enzymes (B) and catabolic enzymes (C) of 
hPAECs (n=4). Data are presented as fold-change relative to B2M and further 
normalised to DH1. Mean ± SEM are shown and data were analysed using a One-way 
ANOVA with Tukey’s post hoc test for multiple comparisons. *P<0.05, **P<0.01 




































































































































  A similar effect was recapitulated in BOECs, with mRNA expression of the 
polyamine metabolic enzymes being reduced by siATP13A3. ATP13A3 
depletion in BOECs decreased the expression of both SRM and SMS by 50% 
and 43% respectively (figure 4-17 A). Additionally, the polyamine catabolic 
enzymes, SMO, PAO, and SSAT1 also displayed reduced mRNA expression 
(figure 4-17 B). This is likely to be a specific effect for ATP13A3 as siATP13A3 
transfection did not alter the mRNA expression of other P5-ATPases (Figure 4-
18). Taken together, these findings suggest a potential regulatory role of 
ATP13A3 in cellular polyamine metabolism. 
 
 
Figure 4-17 ATP13A3 deficiency affects the mRNA expression of 
polyamine metabolic pathway enzymes in BOECs 
mRNA expression of different polyamine catabolic enzymes (A) and polyamine 
biosynthesis enzymes (B) in BOECs transfected with DharmaFECT1 (DH1) 
alone, siATP13A3 or non-targeting siRNA control (siCP) (n=4). Data are 
presented as fold-change relative to B2M and further normalised to DH1. Mean 
± SEM are shown and data were analysed using a One-way ANOVA with 











Figure 4-18 ATP13A3 depletion in BOECs does not alter the mRNA 
expression of other P5-ATPases  
mRNA expression of (A) ATP13A3, (B) ATP13A1, and (C) ATP13A2 of BOECs 
transfected with DharmaFECT1 (DH1) alone, siATP13A3 or non-targeting 
siRNA control (siCP) (n=4). Data are presented as fold-change relative to B2M 
and further normalised to DH1. Mean ± SEM are shown and data were 
analysed using a One-way ANOVA with Tukey’s post hoc test for multiple 
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4.2.3.2 ATP13A3 depletion upregulates ornithine decarboxylase (ODC) 
protein expression in endothelial cells 
  Ornithine decarboxylase (ODC) is essential for polyamine biosynthesis, and 
its regulation is heavily reliant on polyamine levels. Increased cellular 
polyamine trigger the proteasomal degradation of ODC mediated by antizyme 
while reduced polyamine levels preserve ODC by suppressing functional 
antizyme expression (Figure 4-19). As ATP13A3 depletion reduces polyamine 
levels in endothelial cells, I then question if ODC may be altered by ATP13A3 
deficiency. Intriguingly, ATP13A3 depletion did not affect ODC mRNA in 
hPAECs (Figure 4-19 B). Instead, ODC protein level was upregulated by 
approximately two-fold, indicating a post-translational regulation of ODC by 
ATP13A3 depletion (Figure 4-20). Similar observations were also found in 
BOECs (Figure 4-19 C; Figure 4-21). Immunostaining of ODC in hPAECs 
further confirmed its upregulation by ATP13A3 deficiency (Figure 4-23). 
 
  As mentioned earlier, ODC degradation is dynamically monitored via the 
regulation of antizyme (Figure 4-19). Since ATP13A3 depletion reduced the 
polyamine content, I then questioned if antizyme (OAZ) participated in ODC 
regulation in this context. Consistent with this hypothesis, OAZ mRNA was 
reduced in both BOECs (42%) and hPAECs (50%) with siATP13A3 transfection 
(Figure 4-20 B, C), suggesting that upregulation of ODC1 protein is potentially 
a consequence of the downregulation of OAZ1 mRNA levels. mRNA level of 
antizyme inhibitor (AZIN), which competes ODC for antizyme, was not altered 
(Figure 4-20 B, C), indicating that ODC upregulation mediated by ATP13A3 
loss is more likely via the downregulation of antizyme. Interestingly, unlike 
endothelial cells, ATP13A3 deficiency did not cause ODC upregulation in 
hPASMCs (Figure 4-22), suggesting a cell-type dependent effect of ATP13A3 
on ODC regulation. 






Figure 4-19 ATP13A3 depletion did not alter ODC1 but reduced OAZ1 at 
transcriptional level 
(A) schematic of ornithine decarboxylase regulation in cells. ODC is highly regulated 
by antizyme through a polyamine dependent manner. Increased cellular polyamine 
levels trigger the production of functional antizyme (OAZ1) by mediating a ribosomal 
frameshift event. The resulting antizyme forms a complex with ODC, mediating 
ubiquitin-independent degradation through the 26S proteasome. When polyamine 
levels drop, the antizyme inhibitor competitively binds to antizyme and therefore 
releases ODC for polyamine biosynthesis. ODC1, OAZ1, AZIN1 mRNA expression in 
BOECs (B) or hPAECs (C) transfected with DH1, siATP13A3 or siCP (n=4). Data are 
presented as fold change relative to B2M and further normalised to DH1. Mean ± SEM 
are shown and data were analysed using a One-way ANOVA with Tukey’s post hoc 



























Figure 4-20 ATP13A3 depletion upregulates ODC1 protein expression in 
human pulmonary artery endothelial cells 
Immunoblotting of (A) ATP13A3 (B) ODC1 in cell lysates harvested from 
hPAECs 48-hours post-transfection of DharmaFECT1(DH1) alone, siATP13A3 
or non-targeting siRNA control (siCP) (N=3). Densitometric analysis of 
ATP13A3 and ODC are presented as fold change relative to α-tubulin and β-
actin respectively and further normalised to DH1. Mean ± SEM are shown and 
data were analysed using a One-way ANOVA with Tukey’s post hoc test for 




















































































Figure 4-21 ATP13A3 depletion upregulates ODC1 protein expression in human 
blood outgrowth endothelial cells  
Immunoblotting of (A) ATP13A3 (B) ODC1 in BOECs 48-hours post-transfection (N=3). 
Densitometry analysis of ATP13A3 and ODC are presented as fold change relative to 
α-tubulin and β-actin respectively and further normalised to DH1. Mean ± SEM are 
shown and data were analysed using a One-way ANOVA with Tukey’s post hoc test 
for multiple comparisons. *P<0.05, ***P<0.001 compared to siCP. 
 
Figure 4-22 ATP13A3 depletion does not alter ODC protein expression in human 
pulmonary artery smooth muscle cells 
Immunoblotting of ODC and βactin in hPASMCs 48-hours post-transfection (N=3). 
Densitometry analysis of ODC are presented as fold change relative to β-actin and 
further normalised to DH1. Mean ± SEM are shown and data were analysed using a 






















































































Figure 4-23 Immunofluorescent staining of ODC in human pulmonary 
artery endothelial cells (hPAECs) 
hPAECs were transfected with DharmaFECT1(DH1) alone, siATP13A3 or non-
targeting siRNA control (siCP) before staining with mouse anti-Ornithine 
Decarboxylase/ODC (abcam 1:100) and rabbit anti-mouse Alexa Fluor®488 
(1:100) Representative images were taken at 20X (N=3). Fluorescent intensity 
was quantified using ImageJ. Data were analysed using a One-way ANOVA 
































4.2.3.3 Ornithine exacerbates apoptosis by promoting putrescine 
accumulation in hPAECs lacking ATP13A3 
  Polyamine biosynthesis is initiated by converting ornithine into putrescine 
with ODC. The induction of ODC has been demonstrated to contribute to the 
apoptosis of CEM T leukaemia cells [308]. Upregulation of ODC was also 
observed in cardiomyocytes under ischemic conditions, leading to an increase 
of apoptosis [309]. It has been shown (Chapter 3) that ATP13A3 deficiency led 
to endothelial cells apoptosis, which was accompanied by ODC overproduction. 
Therefore, I questioned whether ODC is involved in this apoptotic phenotype. 
As shown in Figure 4.24 A, overnight Ornithine incubation did not induce 
apoptosis in hPAECs (DH1 or siCP) with normal ATP13A3 expression levels. 
However, when transfected with siATP13A3, hPAECs displayed a dose-
dependent increase of apoptosis in response to ornithine incubation. To assess 
if this was due to aberrant polyamine homeostasis, the cellular polyamine 
contents of hPAECs incubated with 10mM ornithine were measured by LC-MS. 
As illustrated in Figure 4-23, exogenous ornithine substantially increased (~2 
fold) putrescine content in ATP13A3-deficient cells, whereas hPAECs with 
normal ATP13A3 expression (DH1 and siCP) were less affected (Figure 4-23 
B). Spermidine and spermine, however, remained lower in siATP13A3 
transfected hPAECs without being affected by ornithine incubation. 
Interestingly, DFMO by inhibiting ODC activities only neutralised the apoptosis 
induced by exogenous ornithine but not the basal apoptosis triggered by 













Figure 4-24 Ornithine exacerbates apoptosis by mediating putrescine 
accumulation in hPAECs lacking ATP13A3 
(A) hPAECs transfected with siATP13A3 or non-targeting siRNA control (siCP) 
were incubated with 0.1-10mM of ornithine overnight and assessed for cellular 
caspase activities (N=2). Data are presented as fold changes normalised to 
siCP in 0.1%FBS. hPAECs were incubated overnight with 10mM ornithine and 
assessed for cellular (B) putrescine, (C) spermidine and (D) spermine by LC-
MS (N=1). Data are presented as levels relative to protein concentration and 




























































Figure 4-25 DFMO alleviates ornithine-induced apoptosis in hPAECs 
hPAECs transfected with DharmaFECT1(DH1) alone, siATP13A3 or non-
targeting siRNA control (siCP) were cultured in 0.1%FBS EBM2 with or without 
the presence of 10mM ornithine, 100μM DFMO or in combination overnight. 
Cellular caspase activity was assessed in the following morning as described 
in chapter 2.3.3 (N=2). Data are presented as fold change normalised to DH1 
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4.2.4 Characterisation of a BOEC line derived from a PAH patient with a 
germ-line ATP13A3 mutation  
  ATP13A3 mutations have previously been identified as being associated with 
PAH [27]. As described above, ATP13A3 is likely to function as a polyamine 
transporter in maintaining endothelial cell homeostasis. Polyamine uptake 
analysis in hPAECs has revealed that polyamine transport capacity is impaired 
in ATP13A3 mutants with polyamines. A limitation of my studies up to this point 
is that they were reliant on overexpression and knockdown studies. Therefore, 
to further validate my observations in the context of endogenous ATP13A3 
mutations, a mutant BOEC line was generated from a PAH patient bearing a 
heterozygous frameshift mutation (LK726X, c.2176_2180delTTAAA) in 
ATP13A3. The genotype of ATP13A3LK726X BOECs was confirmed by Sanger 
sequencing (Figure 4-26)   
 
4.2.4.1 ATP13A3-LK726X frameshift mutation is likely to cause nonsense-
mediated mRNA decay (NMD) 
  Nonsense-mediated mRNA decay (NMD) is a cellular surveillance 
mechanism that selectively eliminates genetically defective mRNA with 
premature terminate codon induced by nonsense or frameshift mutations. In 
comparison to wild type BOECs, ATP13A3LK726X BOECs displayed overlapping 
peaks at the mutation site in both genomic DNA (gDNA) and cDNA sequencing 
chromatograms (Figure 4-27), indicating a mismatch of the wild type and 
mutant allele. Interestingly, the ratio of mutant peak height/WT allele peak 
height (~1/5) in the ATP13A3-LK726X cDNA chromatogram was lower than 
that of in the gDNA (~1/2). The difference in peak height ratios suggests the 









Figure 4-26 Genotyping of control and ATP13A3LK726X BOECs  
Sanger sequencing data of the PCR products amplified from the genomic DNA of 
control BOECs (C4, C7, C35) and ATP13A3LK726X BOECs using the strategy described 
in the material and method section. ATP13A3LK726X BOECs showed the heterozygous 
deletion of TTAAA at the mutation site. 
 
Figure 4-27 ATP13A3-LK726X frameshift mutation may induce nonsense-
mediated mRNA decay (NMD) in BOECs  
Sanger sequencing data of the PCR products amplified from the genomic DNA (gDNA) 
and cDNA of control BOECs (C35) and ATP13A3LK726X BOECs using the strategy 
described in the material and methods section. Wild type (WT) and mutant alleles are 
















4.2.4.2 ATP13A3LK726X BOECs showed reduced protein and mRNA 
expression of ATP13A3 
  The frameshift mutation LK726X creates a premature stop codon (TGA 733X) 
in ATP13A3 and was therefore predicted to disrupt its mRNA expression 
through nonsense-mediated decay (NMD) (Figure 4-27). To assess this, three 
control BOECs lines derived from healthy volunteers (Chapter 2) were used for 
comparing ATP13A3 protein and mRNA expression with ATP13A3-LK726X 
BOEC line. Consistent with the hypothesis, mutant BOECs showed 
approximately 60% less ATP13A3 mRNA compared to the control lines, 
suggesting this mutation leads to haploinsufficiency. The ATP13A3 protein 
level in LK726X BOECs was also lower than that in (~1/3) control BOEC lines. 
Comparison of the mRNA expression of other P5-ATPases revealed no 
apparent difference between control and mutant (LK726X) BOECs (Figure 4-
30).  
4.2.4.3 LK726X frameshift mutation impairs polyamine homeostasis in 
BOECs  
  I then questioned if LK726X mutation also impaired ATP13A3 mediated 
polyamine uptake in BOECs. To assess this, mutant (LK726X) and control 
BOECs were cultured with or without the presence of 1mM putrescine, 10μM 
spermidine, or 10μM spermine overnight before measured for cellular 
polyamines. Similar to the findings in ATP13A3-deficient control endothelial 
cells (Figure 4-8), LK726X, by causing ATP13A3 reduction, also significantly 
impaired the putrescine uptake without affecting spermidine and spermine 
levels (Figure 4-29). Interestingly, unlike siATP13A3 which affected basal level 
of all polyamine types, ATP13A3LK726X BOECs only exhibited lower putrescine 
level compared with control BOECs (Figure 4-29). Again, this is likely to be an 
ATP13A3-specific effect, as P5B-ATPases mRNA of ATP13A3LK726X BOECs 
was similar to those of the control lines (Figure 4-30). 





Figure 4-28 ATP13A3LK726X BOECs showed reduced level of protein and 
mRNA expression of ATP13A3  
(A) immunoblotting of ATP13A3 and α-Tubulin in control BOEC lines (C4, C7, 
C35) and ATP13A3-LK726X BOEC line (n=3). (B) Densitometric analysis of 
ATP13A3 are presented as fold change relative to α -Tubulin. Mean ± SEM are 
shown and data were analysed using a One-way ANOVA with Tukey’s post hoc 
test for multiple comparisons. (C)mRNA expression of ATP13A3 are presented 
as fold change relative to B2M expression. Mean ± SEM are shown and data 
were analysed using a One-way ANOVA with Tukey’s post hoc test for multiple 



















































































Figure 4-29 LK726X frameshift mutation impairs polyamine homeostasis 
in BOECs 
Mutant (LK726X) or control BOECs were cultured with or without the addition 
of 1mM putrescine, 10μM spermidine, or 10μM spermine overnight before 
measured for cellular Putrescine (A), Spermidine (B), or (C) Spermine by Liquid 
chromatography-mass spectrometry (LC-MS). (N=3). Data are presented as 
polyamine peak area ratio relative to sample protein concentration, and further 
normalised to C4 control BOECs. One-way ANOVA was used for statistical 
analysis among different BOECs with or without polyamine supplement. 

























































































































































































          
Figure 4-30 ATP13A1, ATP13A2 mRNA expression in control and ATP13A3LK726X 
BOECs  
(A) ATP13A1, (B) ATP13A2 mRNA expression was assessed in control BOECs (C4, 
C7, C35) from healthy subjects and the ATP13A3-LK726X BOEC line (n=4). Data are 
presented as relative expression normalised to B2M expression. Mean ± SEM are 
shown and data were analysed using a One-way ANOVA with Tukey’s post hoc test 
for multiple comparisons. 
           
Figure 4-31 OAZ1, AZIN1 mRNA expression in control and ATP13A3LK726X BOECs 
(A) antizyme (OAZ1) (B) AZIN1 (Antizyme inhibitor) mRNA expression was assessed 
in control BOECs (C4, C7, C35) from healthy subjects and the ATP13A3-LK726X 






























































































4.2.4.4 ATP13A3LK726X BOECs display increased ODC1 mRNA and protein 
expression 
  I demonstrated earlier in this chapter that ATP13A3 deficiency could 
upregulate ODC1 protein in BOECs (Figure 4-21). Since ATP13A3LK726X 
BOECs exhibited impaired ATP13A3 expression, I then questioned if ODC was 
also altered as a result of ATP13A3 reduction in these mutant BOECs. Unlike 
transient ATP13A3 knockdown in BOECs, which post-translationally 
upregulated ODC1 protein expression, ATP13A3LK726X BOECs also showed an 
average of ~50% higher ODC1 mRNA expression than control BOECs (Figure 
4-32 C). ODC1 protein level was also increased by approximately 2-fold (Figure 
4-32 A, B). Different from the observation in siATP13A3 transfected control 
BOECs., antizyme mRNA level was comparable among ATP13A3LK726X 
BOECs and control BOECs (Figure 4-31). Interestingly, higher mRNA 
expression of antizyme inhibitor (AZIN1) was observed in ATP13A3LK726X 
BOECs (Figure 4-31).  
4.2.4.5 ATP13A3LK726X BOECs showed increased expression of polyamine 
biosynthesis enzymes 
  ATP13A3 deficiency (achieved by siRNA transfection) has been 
demonstrated to polyamine related enzymes in endothelial cells (Figure 4-16, 
4-17). To further characterise the LK726X frameshift mutation, mRNA 
expression of these enzymes was assessed in both ATP13A3LK726X and control 
BOECs. Opposite to the expectation, both adenosylmethionine decarboxylase 
(AMD1) and spermidine synthase (SRM) were upregulated by ~ 2-fold in 
ATP13A3LK726X BOECs (Figure 4-33 B, C). spermine synthase (SMS) was ~70% 
higher in LK726X mutant BOECs (Figure 4-33 D). Arginase 1 mRNA 
expression was also slightly elevated (~30%) in LK726X BOECs though the 
expression level of control BOECs was variable (Figure 4-33 A). In comparison, 
expression of polyamine catabolic enzymes, namely spermidine/spermine 
acetyltransferase 1 (SAT1), polyamine oxidase (PAO) and spermine oxidase 




(SMOX) were only marginally different among ATP13A3LK726X and control 
BOECs (Figure 4-34). Taken together, LK726X BOECs displayed in general a 
higher level of biosynthesis enzyme while the expression of the catabolic 
enzyme remained similar to control BOECs.  
 
Figure 4-32 ATP13A3LK726X BOECs displayed increased ODC1 protein and mRNA 
expression levels 
(A) immunoblotting of ODC1, β-actin in control (C4, C7, C35) and ATP13A3LK726X 
BOEC line (n=3). (B) Densitometry analyses of ODC1 are presented as fold changes 
relative to β-actin. Mean ± SEM are shown and data were analysed using a One-way 
ANOVA with Tukey’s post hoc test for multiple comparisons. (C)mRNA expression of 
ODC1 is presented as fold change relative to B2M expression. Mean ± SEM are shown 
and data were analysed using a One-way ANOVA with Tukey’s post hoc test for 
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Figure 4-33 ATP13A3LK726X BOECs display increased mRNA expression of 
polyamine biosynthesis enzymes.  
mRNA expression of polyamine biosynthesis related enzymes (A) Arginase 1 (ARG1) 
(B) Adenosylmethionine decarboxylase (AMD1) (C) Spermidine synthase (SRM) (D) 
spermine synthase (SMS) in control BOEC lines (C4, C7, C35) and ATP13A3-LK726X 
BOEC line (n=2). Data are presented as fold change relative to B2M. Mean ± SEM are 
shown and data were analysed using a One-way ANOVA with Tukey’s post hoc test 




Figure 4-34 ATP13A3LK726X BOECs displayed increased mRNA expression of 
polyamine biosynthesis enzymes  
mRNA expression of polyamine catabolic enzymes (A) Spermidine/spermine 
acetyltransferase1 (SAT1) (B) polyamine oxidase (PAO) (C) Spermine oxidase (SMOX) 
in control BOEC lines (C4, C7, C35) and ATP13A3-LK726X BOEC line (n=2). Data are 
presented as fold changes relative to B2M. Mean ± SEM are shown and data were 
























































































































4.2.4.6 ATP13A3LK726X BOECs displayed higher sensitivity to serum-
deprivation induced apoptosis 
  Having shown that the LK726X frameshift mutation causes ATP13A3 
reduction in BOECs, I then questioned if this predisposes cells to apoptosis. As 
shown in Figure 4-35 A, when grown in EGM2 supplemented with 10% FBS, 
ATP13A3LK726X BOECs displayed similar cellular caspase activity to control 
BOECs. Increased caspase activity was observed in BOECs cultured in EBM2 
supplemented with 5% FBS, with no significant difference among mutant and 
control BOECs (Figure 4-35 B). When further exposed to serum-free condition 
(0.1% FBS EBM2), the caspase activity of ATP13A3LK726X BOECs was 
significantly higher than that of the control BOECs (C35), similar to that 
observed in siATP13A3 transfected BOECs (Figure 4-35 C). 
 
    
Figure 4-35 ATP13A3LK726X BOECs display higher sensitivity to serum-
deprivation induced apoptosis  
Cellular caspase activity of BOECs cultured in (A) 10% EGM2 (B) 5% EBM2 and (C) 
0.1% EBM2 was assessed by Caspase3/7 Glo kit (Promega) (n=3). Data in (A) are 
presented as raw arbitrary units. Data in (B) and (C) are presented as fold changes 
relative to the corresponding caspase activity in (A). Mean ± SEM are shown and data 
were analysed using a One-way ANOVA with Tukey’s post hoc test for multiple 
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  In this result section, I have demonstrated that ATP13A3 functions as a 
polyamine transporter in endothelial cells and reveal functional impairments of 
PAH-associated mutations on ATP13A3 mediated polyamine uptake.  
 
  Similar to the previous findings in Hela cells [141], subcellular localisation 
analysis revealed ATP13A3 as residing in the recycling endosome (Rab11) of 
endothelial cells. Mammalian polyamine transport systems are extremely 
understudied. The endocytic pathway has been proposed as one potential 
route for mediating cellular polyamine trafficking [190]. In line with this theory, 
here I have observed that ATP13A3 deficiency in endothelial cells substantially 
reduced the basal levels of putrescine and the uptake of exogenous putrescine. 
Basal spermidine and spermine contents were also reduced, but to a lesser 
extent in siATP13A3 hPAECs while the uptake capacity remained relatively 
intact. These observations, provide strong evidence for ATP13A3 as a 
polyamine transporter with a higher selectivity towards putrescine than 
spermidine and spermine in endothelial cells. Different to my findings, 
ATP13A3 levels were previously shown correlating to spermidine uptake in 
pancreatic cancer cells [147]. However, the authors did not rule out the 
possibility of spermidine transport activities being affected by other P5-
ATPases. Previously, in silico analysis of P5B-ATPases protein sequences 
revealed a conserved putative substrate-binding region [134], suggesting 
similar transport substrates may be shared. However, the fact that ATP13A2 
mainly transport spermine in neuron cells [148] while ATP13A3 mediates 
putrescine translocation in endothelial cells reveals the complexity of the 
transport activities of P5-ATPases, which may be cell-type dependent.  
 
  In addition to the transport systems, cellular polyamine content is also fine-
tuned by the metabolism pathways. Transient ATP13A3 knockdown 
significantly reduced polyamine content in endothelial cells, predominantly 




affecting putrescine level. As a potential compensatory mechanism, endothelial 
cells activate their polyamine biosynthesis pathway by post-translationally 
upregulating ODC1. This is likely achieved via the downregulation of OAZ1 
mRNA, which preserves ODC expression by suppressing proteasomal 
degradation. Interestingly, increased Odc activity was reported in MCT treated 
rat lung tissues, with DFMO, the irreversible ODC inhibitor, blunted the RVSP 
elevation [255]. This suggests a pathogenic role of ODC elevation in PAH and 
also indicates a possible involvement of ATP13A3 deficiency in PAH 
pathogenesis. Other biosynthesis enzymes such as spermidine synthase (SRM) 
and spermine synthase (SMS) mRNA were also reduced by ATP13A3 
deficiency, possibly in compensation for the precursor (putrescine) loss. This 
also partially explains the basal reduction of spermidine and spermine by 
ATP13A3 reduction in hPAECs.  
 
  Polyamines are essential for cell growth. Elevated polyamine level sustains 
hyperproliferation in cancer cells [104, 171] while depletion of the polyamine 
pool causes cell cycle arrest in different phases [105, 191, 228]. In line with this 
theory, we have observed that ATP13A3 deficiency, by reducing cellular 
polyamine contents, suppressed vascular cell proliferation and caused 
downregulation of cyclin A, E and B mRNA expression in BOECs. The reduction 
of these cyclins, but not cyclin D, suggests a degree of repression on G1-S 
transition and DNA synthesis. Aside from affecting cell growth, polyamines 
were also revealed in the regulation of cell apoptosis. Flavonoid was previously 
reported causing DNA fragmentation in HL-60 cells by reducing putrescine and 
cells with higher putrescine levels were resistant to this stimulus [310]. 
Moreover, etoposide by causing polyamine depletion activated NF-κB and 
increased caspase activity in fibroblasts [311]. Coincide with these findings, I 
have also observed that ATP13A3 deficiency predisposed hPAECs to 
apoptosis (chapter3), suggesting a protective role of polyamine to endothelial 
cell viability. Another potential interpretation for the apoptosis driven by 




ATP13A3 deficiency is the overproduction of ODC. It was demonstrated that 
increased ODC contributed to the apoptosis of CEM T leukaemia cells [308]. 
Also, Ischemia can cause cardiomyocyte apoptosis by ODC upregulation [309]. 
Interestingly, here my preliminary data also show upregulated ODC in 
ATP13A3-deficient hPAECs while ornithine supplementation can exaggerate 
their apoptosis. However, DFMO co-administration only partially reversed the 
cell apoptosis, suggesting the basal apoptosis increase observed in ATP13A3 
deficient endothelial cells is more likely caused by the polyamine loss. In 
addition to cell growth and apoptosis, polyamines were also demonstrated 
essential for cell-cell junctions. Polyamine depletion was shown to induce 
permeability in human small intestine epithelial cells by affecting the expression 
of E-Cadherin [244] and occludins [245]. Similarly, here we also observed that 
loss of ATP13A3 in hPAECs exacerbated endothelial leakage in the presence 
of thrombin stimulation, indicating an important role of ATP13A3 in maintaining 
endothelial integrity under pathogenic conditions. 
 
  ATP13A3 was previously identified as a novel PAH associated gene [27]. 
Functional assessment of deleterious missense variants revealed L675V, 
M850I, V885M as severe pathogenic modifiers causing impairments on 
ATP13A3 mediated putrescine uptake. This provides strong evidence for the 
involvement of ATP13A3 genetic defects in PAH pathogenesis. The 
impairments of other two variants (R858H, L965P) on the putrescine transport 
were milder. The variable effects of ATP13A3 mutations suggest other 
modifiers may participate in disease progression. Interestingly, Lerche M et 
al.[109] has recently reported that an IFN-β induced PAH case in a multiple 
sclerosis patient with a nonsense ATP13A3 mutation (Glu514*). The fact that 
IFN-β withdrawal improved PAH symptoms in this patient suggests that 
additional factors, such as aberrant inflammation, may confer PAH 
development in ATP13A3 mutation carriers. One disadvantage of using the 
overexpression system for characterising the impact of mutations is that it may 




not fully represent the endogenous biological state. To overcome this, BOECs 
were generated from a PAH patient bearing a frameshift mutation (LK726X) in 
ATP13A3. Interestingly, LK726X frameshift mutation disrupted ATP13A3 
expression by causing NMD. As a result, mutant BOECs exhibited lower basal 
putrescine level and uptake capacity, predisposing cells to apoptosis under 
serum-free condition [27]. Similar to ATP13A3-deficient control BOECs, ODC 
protein expression was also significantly increased in LK726X BOECs, further 
indicating a regulatory role of ATP13A3 on ODC. Moreover, the polyamine 
synthesis pathway in LK726X BOECs was also activated, as manifested by the 
elevated mRNA expression of ODC1, AMD1, SRM, SMS.  The increased SRM 
and SMS mRNA may have exaggerated the putrescine loss by consuming 
more putrescine to produce spermidine and spermine. This may partially 
explain the basal reduction of putrescine but not spermidine or spermine 
observed in LK726X BOECs. However, it is noteworthy that cells derived from 
PAH-patients may have acquired some changes due to the somatic changes 
associated with the disease state leading to additional DNA damage. This may 
serve as a rational interpretation for the different transcriptional fingerprints 
observed in transient ATP13A3 loss (siRNA transfection) compared the chronic 
deficiency (genetic defects).  
  In summary, here I have demonstrated that ATP13A3 functions as a 
putrescine transporter with its disruption leading to endothelial dysfunctions. 
PAH associated mutations were shown to impair ATP13A3 mediated 
polyamine transport, with a frameshift mutation predisposed BOECs to 
apoptosis by affecting the polyamine homeostasis. These findings provide for 
the first time a pathogenic link between ATP13A3 genetic defects and PAH and 
shed lights for the underlying mechanism of polyamine dysregulation in the 
pathobiology of PAH.  
 




 Results III- Regulation of ATP13A3 by BMPs 
and inflammatory cytokines  
5.1 Introduction 
  Bone morphogenetic proteins (BMPs) are a group of at least 14 secreted 
ligands belongs to the transforming growth factor β (TGFβ) superfamily [79]. 
The first BMPs discovered were identified as calcification inducers in bone [312] 
while later studies have revealed more family members with a diverse range of 
functions, including embryogenesis and development [313], metabolism [314, 
315]and maintaining homeostasis of the cardiovascular system [79, 316]. 
These secreted ligands exert cell-specific effects primarily through autocrine 
and paracrine signalling while ligands such as BMP6, BMP9 and BMP10 also 
present in the circulation system [285, 317-319]. BMP signalling is initiated by 
the binding of - BMPs to cell surface heteromeric receptor complexes formed 
by type II and type I receptors [320, 321]. For BMPs, there are four known Type 
I receptors and four known Type II receptors, specific combinations of these 
defining the selectivity for BMPs [322]. This selectivity is further controlled by 
Type III accessory receptors, such as endoglin [323].  Upon binding of a 
dimeric BMP ligand to its specific receptor complex, the constitutively active 
kinase domain of the type II receptor [324] then transphosphorylates the type I 
receptor, which in turn catalyses C-terminal phosphorylation of the downstream 
canonical Smad1/5/8 (receptor-regulated Smads(R-Smads)) proteins. Once 
activated, the R-Smads form a complex with the nuclear chaperone Smad4 and 
then translocating into the nucleus where they control the transcriptional 
regulation of target genes [82, 325, 326].  
  The pathogenesis of PAH is hallmarked by reduced BMP signalling. Genetic 
analysis in PAH cohorts has revealed disease-associated mutations in several 
BMP-specific pathway members [27, 102, 103, 327]. Of note, pathogenic 
mutations in the gene encoding the bone morphogenetic protein type 2 receptor 




(BMPR2), a type II receptor for the BMP pathway was identified as the 
predominant genetic cause, accounting for nearly 80% of the familial PAH [328] 
and approximately 20% of sporadic cases [329]. Reduced BMPR2 expression 
in pulmonary vasculature is also observed in PAH patients without genetic 
defects [16], suggesting a broader role of the BMP pathway in disease 
pathobiology.  
  Cell surface receptors of the BMP/TGFβ pathway are constitutively 
internalised, degraded or recycled through the endo/lysosome system [330]. 
BMPR2 was demonstrated to be degraded through E3 ligase-mediated 
lysosomal degradation [331]. Chloroquine was shown to Inhibit this effect, 
resulting in increases expression of BMPR2 in hPAECs [332, 333]. Rab 11 was 
reported to mediate the recycling of TGFβ receptor Type II/I, or the receptor 
complex back to the plasma membrane [334], suggesting an essential role for 
the recycling endosome in TGFβ/BMP receptor trafficking. Intriguingly, 
ATP13A3 has been demonstrated to reside in the early/recycling endosome of 
Hela cells [141]. This points to a potential link between ATP13A3 and 
endosome functions. Moreover, microarray analysis following 4-hour TGFβ 
incubation revealed upregulated ATP13A3 expression in hPASMCs from 
HPAH patients bearing BMPR2 mutations [165], further suggesting a potential 
involvement of ATP13A3 in the TGFβ/BMP signalling pathway. Therefore, in 
this chapter, I will investigate the potential regulation of ATP13A3 by different 
BMP ligands in pulmonary vascular cells and assess the effects of ATP13A3 
deficiency on BMP downstream signalling.  
 
 





5.2.1 ATP13A3 and BMP signalling 
5.2.1.1 BMP9 and BMP10 selectively induce mRNA expression of 
ATP13A3, but not other P5-ATPases, in BOECs  
  To characterise the regulation of ATP13A3 by BMP ligands, BOECs were 
cultured with or without BMP9, BMP10 or BMP6 for 8 hours and assessed for 
mRNA expression of ATP13A1-5. ATP13A3 mRNA expression, consistent with 
previous observations, was significantly increased by 8-hour incubation of 
BMP9 in a dose-dependent manner (Figure 5-1 A). Although ATP13A3 was not 
altered by 0.3ng/ml BMP10, it was increased by BMP10 at 1ng/ml. BMP6, on 
the other hand, did not alter ATP13A3 expression (Figure 5-1 A). Interestingly, 
unlike ATP13A3, the transcription of ATP13A1 and ATP13A2 were only 
marginally increased by 20% and 15% respectively in response to 1ng/ml 
BMP9, but not by other BMP ligands (Figure 5-1 C, D). Both ATP13A4 and 
ATP13A5 were expressed at very low levels in vascular cells and there was no 
response to BMP ligands. Taken together, these results suggested a selective 
increase of ATP13A3 mRNA by BMP9 and BMP10.  
5.2.1.2 BMP9 and BMP10 induce ATP13A3 expression in BOECs via the 
ALK1 receptor  
  Given that BMP9 and BMP10 selectively induce ATP13A3 but not other P5-
ATPases in BOECs, I questioned which BMP receptors are involved in this 
effect. BMPR2 is abundantly expressed in BOECs and is partially responsible 
for the BMP9-dependent induction of ID2 mRNA in endothelial cells [322]. 
Although ID2 mRNA induction by 8-hour incubation of 1ng/ml BMP9 was 
significantly impaired by siBMPR2 transfection compared to siCP (Figure 5-2 
B), BMP9 induced ATP13A3 mRNA to the same extent in BOECs with or 
without BMPR2 deficiency (Figure 5-2 B). I then questioned whether ALK1, a 
type I receptor for BMP9 or BMP10, was involved in ATP13A3 induction by 
these BMP ligands. As shown in Figure 5.3, loss of ALK1 significantly impaired 




the induction of ATP13A3 mRNA by 1ng/ml BMP9. A similar effect was also 
seen in BOECs incubated with 1ng/ml BMP10, with a lower ATP13A3 mRNA 
expression in cells transfected with siALK1 (Figure 5-3).  
 
 
Figure 5-1 Selective up-regulation of ATP13A3 by BMP9 and BMP10 in 
BOECs 
mRNA expression of (A) ATP13A3, (B) ID1, (C) ATP13A1, (D) ATP13A2, in 
response to different concentrations of BMP9, BMP10 and BMP6. BOECs were 
serum restricted in 0.1% FBS overnight before treating with 0.3ng/ml or 1ng/ml 
BMP9 or BMP10, or 25ng/ml BMP6 for 8 hours (n=3). Data are presented as 
fold-change relative to 0.1%FBS. Mean ± SEM was shown. One-way ANOVA 
with Tukey’s post hoc test for multiple comparisons was used for data analysis. 











Figure 5-2 BMPR2 knockdown in BOECs does not affect the induction of 
ATP13A3 mRNA by BMP9 or BMP10 
Relative expression of (A) ATP13A3 (B) BMPR2, (C) ID1, and (D) ID2 in BOECs 
transfected with DharmaFECT1 (DH1) alone, siBMPR2 or non-targeting siRNA control 
(siCP) followed by treating with 0.1%FBS with or without the addition of 1ng/ml BMP9 
or 1ng/ml BMP10 (n=4).  Data are presented as fold-change relative to B2M and 
normalised to DH1. Mean ± SEM was shown. One-way ANOVA with Tukey’s post hoc 
test for multiple comparisons was used for data analysis. *P<0.05, compared to DH1. 
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Figure 5-3 ALK-1 deficiency impairs the induction of ATP13A3 mRNA by 
BMP9 or BMP10 in BOECs 
Relative expression of (A) ATP13A3 (B) ALK1, (C) ID1, and (D) ID2 in BOECs 
transfected with DharmaFECT1 (DH1) alone, siALK1 or non-targeting siRNA 
control (siCP) followed by treating with 0.1%FBS with or without the addition of 
1ng/ml BMP9 or 1ng/ml BMP10 (n=4).  Data are presented as fold-change 
relative to B2M and normalised to DH1. Mean ± SEM was shown. One-way 
ANOVA with Tukey’s post hoc test for multiple comparisons was used for data 









5.2.1.3 ATP13A3 depletion in endothelial cells did not affect BMP 
signalling  
  It is widely acknowledged that the dysregulated BMP signalling contributes 
to PAH pathogenesis [31, 79]. Receptors of the pathway are actively trafficking 
from the cell surface into cellular compartments, mediating BMP signalling 
transduction [330]. As ATP13A3 resides in the recycling endosome and its 
mRNA could be induced by BMP9/10, I assessed if ATP13A3 deficiency affects 
BMP signalling in endothelial cells. ATP13A3 deficiency in hPAECs did not alter 
the mRNA of the BMP type I (ALK1, ALK2) and type II (BMPR2) receptors 
(Figure 5-4). 8-hour BMP9 treatment induced a concentration-dependent 
induction of ATP13A3 mRNA expression (Figure 5-5 A). However, ATP13A3 
deficiency did not alter the BMP9 mediated ID2 response (figure 5.5 C). The 
ID1 response to 0.1ng/ml and 0.3ng/ml BMP9 was marginally reduced (10% 
and 15% respectively) by ATP13A3 deficiency, though no statistical 
significance was revealed (Figure 5-5 B).  
 
Figure 5-4 ATP13A3 deficiency does not altered mRNA expression of BMP 
receptors in hPAECs.  
mRNA expression of ATP13A3, BMPR2, ALK1 and ALK2 in hPAECs transfected with 
DH1, siATP13A3 or siCP. Data are presented as fold-change relative to DH1. Mean ± 
SEM was shown. One-way ANOVA with Tukey’s post hoc test for multiple 
comparisons was used for data analysis. *P<0.05, compared to siCP. 







Figure 5-5 ATP13A3 depletion in endothelial cells does not affect BMP 
signalling in hPAECs. 
mRNA expression of (A) ATP13A3, (B) ID1, (C) ID2 of hPAECs transfected with 
siATP13A3 in response to 0.1ng-1ng/ml BMP9 for 8 hours (n=4). Data are 
presented as fold-change relative to 0.1% FBS. Mean ± SEM was shown. One-
way ANOVA with Tukey’s post hoc test for multiple comparisons was used for 














5.2.2 ATP13A1-5 mRNA expression in response to different cytokine 
  Recently, a growing body of evidence has linked inflammation to the 
pathogenesis of PAH with perivascular inflammation observed in all forms of 
PAH. Therefore, cytokines such as Interleukin-1 beta (IL-1β) and Tumour 
necrosis factor alpha (TNFα), which have been reported to be elevated in the 
serum/plasma from PAH patients [74] were assessed for the regulation of 
ATP13A3. Transforming Growth Factor Beta (TGFβ) has previously been 
reported to upregulating ATP13A3 expression in hPASMCs from HPAH 
patients [165]. Therefore, TGFβ was also included for the assessment of P5-
ATPases regulation.  
 
5.2.2.1 Interleukin-1 beta selectively induced ATP13A3 expression, but 
not other P5-ATPases in hPASMCs 
  To assess the regulatory effects of different cytokines on ATP13A1-5, control 
hPASMCs were cultured with TNFα (0.05ng/ml, 1ng/ml), IL-1β (1ng/ml) or 
TGFβ (1ng/ml, 5ng/ml) for 4 hours and assessed for mRNA expression. IL-1β 
at 1ng/ml induced ATP13A3 mRNA by approximately 4-fold without affecting 
the expression levels of the other P5-ATPases. TNFα and TGFβ did not alter 
the expression of P5-ATPases in hPASMCs at 4-hour time point (Figure 5-6 A, 
B, C). To confirm that hPASMCs could respond to the cytokines mentioned 
above, ID1/PAI-1, Interleukin-6 (IL-6) and Interleukin-8 (IL-8) were used for 
assessing TGFβ, IL-1β and TNFα responses, respectively. As shown in Figure 
5-7, at 4-hour time point, ID1 expression was repressed by 50% with 5 ng/ml 
TGFβ treatment while IL-6 and IL-8 were induced by ~10 fold or ~7.5 fold with 
IL-1β (1ng/ml) and TNFα (1ng/ml) treatment respectively, indicating the 










Figure 5-6 P5-ATPase mRNA expression in response to different 
cytokines in hPASMCs 
mRNA expression of (A) ATP13A3, (B) ATP13A1 (C) ATP13A2 in hPASMCs 
cultured in 0.1% FBS supplemented DMEM with or without the presence of 
different concentrations of TNFα, IL-1β and TGFβ for 4 hours (n=3).  Data 
were presented as fold change relative to B2M and normalised to 0.1% FBS. 
Mean ± SEM was shown. One-way ANOVA with Tukey’s post hoc test for 












Figure 5-7 ID1, IL-6, IL-8, SERPINE-1 mRNA expression in response to 
different cytokines in hPASMCs 
mRNA expression of (A) ID1, (B) SERPINE1 (PAI-1) (C) Interleukin-6 (D) 
Interleukin-8 in hPASMCs cultured in 0.1% FBS supplemented DMEM with or 
without the presence of different concentrations of TNFα, IL-1β and TGFβ for 4 
hours (n=3).  Data were presented as fold change relative to B2M and 
normalised to 0.1% FBS. Mean ± SEM was shown. One-way ANOVA with 
Tukey’s post hoc test for multiple comparisons was used for data analysis. 
























































































































































































































































































































































































































TGF beta response 





  BMP signalling is critical for maintaining the function and structural integrity 
of the vasculature. In this chapter, I have shown that in BOECs, BMP9 and 
BMP10, but not BMP6, selectively increased ATP13A3 mRNA without affecting 
the expression of other P5-ATPases. It is well established that BMP9/10 
signalling via the BMPR2/ALK1 holds importance for the maintenance of 
vascular homeostasis [39, 322]. The fact that BMP6 did not affect ATP13A3 
expression suggests that the induction of ATP13A3 is more likely through ALK1 
rather than other BMP type I receptors, such as ALK2 or ALK3 [79]. 
Interestingly, BMPR2 silencing did not impair this BMP-driven ATP13A3 
induction, probably due to the compensation by other type II receptors, such as 
activin type II receptors [322]. In contrast, ALK1 depletion substantially 
attenuated the ATP13A3 induction by BMP9, indicating the involvement of 
ALK1 in ATP13A3 regulation. Whole genome analysis in an I/HPAH patient 
cohort revealed higher frequency (6/11) of heterozygous protein truncated 
variants in ATP13A3 [27], suggesting that ATP13A3 haploinsufficiency may 
contribute to the pathogenesis of PAH. Considering that BMP9 transcriptionally 
upregulates ATP13A3 in endothelial cells, it is rational to hypothesise that 
BMP9 may be therapeutically promising for PAH patients bearing ATP13A3 
mutations by enhancing the expression of the non-mutated ATP13A3 allele. 
Similar effects have been reported by our group that BMP9 blunted PAH 
phenotypes in Bmpr2+/R899X by selectively restoring Bmpr2 expression in 
endothelial cells [39]. However, a proof-of-concept study in the Atp13a3P452fs 
mouse model is required to validate the hypothesis. 
 
  Here I have shown that ATP13A3 knockdown did not alter the mRNA 
expression of BMPR2, ALK1 and ALK2. However, since the recycling of these 
receptors mainly affect their protein level and/or cellular localisation, this does 
not completely rule out a possible role for ATP13A3 in regulating these 
receptors, though ID1 and ID2 induction by various doses of BMP9 were 




unaffected by ATP13A3 deficiency in hPAECs. Further investigations are 
necessary to characterise the potential effects of ATP13A3 deficiency on the 
canonical Smad pathway, such as the phosphorylation of Smad1/5/8 and on 
non-canonical kinase pathway signalling. Also, a broader analysis of BMP 
target genes may reveal a subset of BMP9-responsive genes that are affected 
by ATP13A3 loss. As revealed by microarray analysis, ATP13A3 expression 
was upregulated by 4-hour TGFβ incubation in hPASMCs from HPAH patients 
harbouring BMPR2 mutation [165]. However, here I have shown that TGFβ did 
not induce ATP13A3 upregulation in control hPASMCs, suggesting extra 
modifiers such as reduced BMPR-II expression by leading to aberrant TGFβ 
responses may contribute to this effect.  
 
  Recently, a growing body of evidence has linked inflammation to the 
pathogenesis of PAH. My investigation of the regulation of ATP13A3 in the 
context of inflammatory cytokines revealed a selective upregulation of 
ATP13A3 by IL-1β in hPASMCs. It is noteworthy that IL-1β overproduction 
promotes PAH in MCT rat models [335]. Moreover, IL-1β was also shown 
mediating the proliferative response of vascular cells by upregulating FGF2 
[336]. In aortic smooth muscle cells, exogenous FGF2 treatment could 
upregulate polyamine transport and synthesis, resulting in the proliferative 
effect [337]. However, this study did not specify the polyamine transporter 
involved in the proliferative effect. Therefore, further investigation of the role of 











 Results IV- Atp13a3 in rodent models of 
pulmonary hypertension 
6.1 Introduction 
  Polyamines are a group of polycations dynamically involved in cell growth 
and apoptosis [104]. Polyamine dysregulation has previously been implicated 
in the pathogenesis of PAH with polyamines accumulation shown in the lungs 
of rats treated with both monocrotaline (MCT) and hypoxia [255]. Intriguingly, 
the two models seem to favour different mechanisms for this polyamine 
augmentation. In the MCT model, the activation of both ODC and AMD in rat 
lungs implicates the occurrence of aberrant polyamine biosynthesis. 
Intervention with DFMO, the irreversible inhibitor of ODC, alleviates the 
elevation of mPAP in this model, indicating a pathogenic role of ODC 
overproduction[255]. On the contrary, chronic hypoxia repressed lung ODC 
activity and hypoxic rats showed no response to a DFMO intervention [255]. 
This suggests a different mechanism may confer the polyamine elevation in 
hypoxic rat lungs [256]. Indeed, a later study revealed increased putrescine 
uptake in rat lung explants under hypoxic conditions [256]. Autoradiographs of 
[14C]-SPD uptake in rat lung tissues also demonstrated an accumulation of 
[14C]-SPD in the intimal and media layer of pulmonary arteries from hypoxia 
treated rats [257]. These findings suggest that hypoxia activates polyamine 
transport and thus contributes to the development of PAH. However, no 
polyamine transporters were identified in these studies.  
 
  ATP13A3, a putative polyamine transport [139, 147], has recently been 
identified as a novel PAH-associated gene [27]. However, no study to date has 
investigated the role of Atp13a3 in the context of PAH in an animal model. 
Previous studies revealed Atp13a3 as widely expressed across different mouse 
tissues, with the peak of expression observed in the embryonic phase [155, 




156]. Here, I will describe the expression pattern of Atp13a3 in lung tissues of 
MCT and Sugen/hypoxia (SU/Hx) rat models. More importantly, a genetically 
modified mouse model bearing the PAH-associated frameshift mutation 
(P452Lfs) will be described for the first time with respect to Atp13a3 expression, 
lung polyamine content and pulmonary hemodynamic changes. 
 
6.2 Result 
6.2.1 Monocrotaline treated rats display a reduced level of Atp13a3 in lung 
tissues 
  I first sought to assess Atp13a3 mRNA expression in the MCT rat model. 
Tissues from this model were kindly provided by Dr Elisabet Ferrer with 
hemodynamic assessment performed by Mr Stephen Moore. Briefly, rats were 
given a single injection of 40mg/kg MCT, after which they developed a 
progressive PAH phenotype over 28 days. Hemodynamic parameters were 
assessed, and tissues were harvested from animals at 7, 14, 21 and 28 days 
for the monitoring of disease development. As shown in figure 6-1 B, when 
compared to the saline group, rats injected with MCT displayed elevated right 
ventricular systolic pressure (RVSP) at day 14, with pressure continuing to rise 
by day 28. The hemodynamic changes paralleled the right ventricle hypertrophy, 
manifesting as an increased Fulton index at days 14, 21 and 28 (Figure 6-1 C). 
Left ventricular end-systolic pressure (LVesp), though fluctuating at week 2, 
remained similar between MCT and control rats. Interestingly, in the MCT group, 
the lung expression of Atp13a3 started to decrease at the 3-week time point 
and continued to drop to ~ 60% of the level of control rats by day 28 (Figure 6-
1 A). The reduction of Atp13a3 expression tracked the increase of RVSP and 
the Fulton index (starting from week2), indicating a potential link between 
Atp13a3 and the progression of MCT induced PAH. 
 
 






Figure 6-1 Atp13a3 expression is downregulated in MCT-rat lung tissues. 
(A) Relative expression of Atp13a3 in rat lung tissues at days 7 (W1), 14 (W2), 
21 (W3) and 28 (W4) after injection of MCT or vehicle (Control) (n=3-8 per 
group). mRNA expression was normalised to the arithmetic means of the Ct 
values for three housekeeping genes (3HK) B2m, Actb and Hprt. PAH disease-
associated phenotyping by assessing (B) Right ventricle systolic pressure 
(RVSP) and (C) Fulton index (RV/LV+S). (D) Left ventricular end-systolic 
pressure (LVesp). Paired t-test was used to compare data from MCT and 
control rats at each time point. *P<0.05, ***P<0.001 compared with control at 
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6.2.2 Atp13a3 is upregulated in both hypoxia and Sugen/hypoxia rat lungs 
  I next assessed Atp13a3 mRNA expression in two other well-established 
PAH model, the hypoxia rat model and the Sugen/hypoxia rat model. Lung 
tissues from these models were kindly provided by Dr Lu Long and Dr Xudong 
Yang. For the hypoxic-rat model, rats were subjected to hypoxia (10% O2) for 
three weeks. In the Sugen/hypoxia model (SU/Hx), rats were given weekly 
injection of SU-5416, a vascular endothelial growth factor (VEGF) receptor-2 
tyrosine kinase inhibitor, at day 0 followed by exposure to hypoxia (10% O2) for 
three weeks. Rats were then returned to normoxia for an additional five weeks 
over which time, a progressive increase in the severity of pulmonary 
hypertension occurs. As demonstrated in figure 6-2, chronic hypoxia (3-week) 
induced a ~2-fold increase of Atp13a3 mRNA in rat lung tissues. In those rats 
removed from hypoxia after 3 weeks and maintained in normoxia for a further 
5 weeks, Atp13a3 levels were similar to control animals. Interestingly, rats in 
SU/Hx group which underwent the same 8-week duration, exhibited 23.8% 
increase of lung Atp13a3 expression compared to the hypoxia/normoxia group 
(Figure 6-2), suggesting a potential link between Atp13a3 and endothelial injury. 
6.2.3 The Bmpr2R899X mutation does not lead to altered Atp13a3 
expression in mouse lung tissues 
  Bmpr2+/R899X knock-in mice have previously reported with impaired BMP 
signalling and spontaneously develop PAH at the age of 6 months [39]. Having 
demonstrated that BMP9 selectively induces the expression of ATP13A3 
mRNA in human endothelial cells (Chapter 5) I then assessed whether the 
Bmpr2+/R899X mutation altered Atp13a3 mRNA in lung tissues kindly provided 
by Dr Lu Long and Dr Xudong Yang. 
Unlike the previous findings in other established PAH models, Bmpr2+/R899X 
mice displayed a similar Atp13a3 mRNA level to their wild-type littermates 
(Figure 6-3). 
 






Figure 6-2 Atp13a3 expression in the lung tissues of hypoxia and the 
Sugen/hypoxia rat model Relative expression of Atp13a3 in lung tissues of hypoxia 
or Sugen/hypoxia rat models. The mRNA expression level was normalised to the 
arithmetic means of the Ct values for three housekeeping genes (3hk) B2m, Actb and 
Hprt (n=4). One-way ANOVA with Tukey’s post hoc test for multiple comparisons was 
used for data analysis. *P<0.05 compared with control. 
 
Figure 6-3 Atp13a3 expression in lung tissues of the Bmpr2R899X mouse 
Relative expression of Atp13a3 in lung tissues of Bmpr2 R899x mice compared to 
Wild-type littermates (n=3). The mRNA expression level was normalised to the 
arithmetic means of the Ct values for three housekeeping genes (3hk) B2m, Actb and 

























































6.2.4 Characterising of Atp13a3-P452Lfs mice 
6.2.4.1 Genotyping of Atp13a3-P452Lfs mice 
  Together with the introduction of the desired P452L frameshift mutation (C>-), 
one additional silent mutation was also created to prevent the Cas9 protease 
from “re-cutting” the engineered region. The introduction of these mutations 
created a de novo BseRI restriction enzyme digestion site which can be used 
for mouse genotyping. Following PCR amplification of the mutant region, 
amplicons were further digested with BseRI. As illustrated in figure 6-4 A, Wild 
type amplicons showed no digestion by BseRI, while heterozygous amplicons 
were partially digested. Amplicons from the homozygous mice were fully 
digested by BseRI, resulting in two distinct cleavage bands (Figure 6-4 A). The 
mouse genotypes were further confirmed by Sanger sequencing. 
 
Figure 6-4 Genotyping of Atp13a3 P452Lfs mice  
(A) Genomic DNA extracted from mouse tail tip biopsies was amplified by PCR for the 
region covering the P452Lfs mutation. The resulting amplicons were further digested 
with BseRI for genotyping. (B) Representative Sanger sequencing results of 
Atp13a3P452Lfs mice. The targeted P452Lfs C>- mutation is highlighted in the 
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6.2.4.2 Atp13a3-P452Lfs mice display reduced Atp13a3 protein and mRNA 
expression in lung tissues  
  The P452Lfs frameshift mutation creates a de novo premature stop codon 
(TGA), thus is likely to cause mRNA degradation through the nonsense-
mediated decay (NMD) pathway (Figure 6-4 B). Indeed, when compared to 
their wild type littermates, both heterozygous and homozygous mice showed a 
lower level of Atp13a3 mRNA and protein expression as revealed by qPCR and 
immunoblotting (Figure 6-6 A, B). In a homozygous Atp13a3-P452Lfs mouse, 
both mRNA and protein expression of Atp13a3 were reduced when compared 
to heterozygous mice. This indicates that this mutation leads to insufficiency of 
Atp13a3.  
6.2.4.3 Atp13a3-P452Lfs mice have lower levels of polyamines in lung 
tissues  
  I have shown that ATP13A3 deficiency in human pulmonary artery 
endothelial cells disrupts cellular polyamine homeostasis (Chapter 4). Having 
demonstrated that Atp13a3-P452Lfs mice display reduced Atp13a3 expression 
in lung tissue, I asked if the polyamine level was altered in these tissues. 
Interestingly, preliminary data show that in comparison to the wild type 
littermates, both heterozygous and homozygous Atp13a3-P452Lfs mice 
showed lower putrescine, spermidine and spermine levels in their lung tissues 
(Figure 6-7), suggesting a disruption of polyamine homeostasis in these mice. 
6.2.4.4 Atp13a3-P452Lfs mice exhibit elevated RVSP at 6-month age  
  I then moved on to assess if these are sufficient to induce the PAH associated 
hemodynamic changes in mice. The hemodynamic assessment was performed 
by Dr Ekaterina Legchenko. As shown in Figure 6-6, at 3-month age, no overt 
hemodynamic difference were revealed among mice (Figure 6-5A). However, 
when characterised at 6-month age, both heterozygous and homozygous male 
Atp13a3-P452Lfs mice exhibit significant higher right ventricle systolic pressure 
(RVSP) (Figure 6-6 A) without compromising the systemic arterial pressure or 




heart rate (Figure 6-6 B, C) when compared with their wild type littermates. 
Interestingly, only male mice developed increased RVSP while hemodynamic 




Figure 6-5 Atp13a3-P452Lfs mice exhibit increased RVSP at 6-month age  
(A) Right ventricle systolic pressure (RVSP) of male Atp13a3P452Lfs+/-, Atp13a3P452Lfs-/- 
mice and their wild type littermates was assessed at 3-month and 6-month age (n=5-
10). (B) Systemic arterial pressure (SAP) and (C) heart rate (HR) of the mice were also 
assessed at 6-month age. One-way ANOVA with Tukey’s post hoc test for multiple 
comparisons was used for comparison among genotypes. ****P<0.00001 compared 





















































Figure 6-6 Atp13a3-P452Lfs display impair Atp13a3 expression in lung 
tissues 
(A) Atp13a3 mRNA was assessed in lung tissues from 3-month old Atp13a3P452Lfs+/- 
(N=3), Atp13a3P452Lfs-/- (N=1) mice and their wild type littermates (Atp13a3WT N=2), 
Data are presented as Atp13a3 expression relative to the arithmetic means of the Ct 
values three housekeeping genes (3hk) B2m, Actb and Hprt. (B) Immunoblotting of 
Atp13a3 and α-Tubulin was performed using the lung tissues isolated from wild type, 
Atp13a3P452Lfs+/- and Atp13a3P452Lfs-/- mice (n=1)  
 
Figure 6-7 Atp13a3-P452Lfs mice display reduced polyamine levels in lung 
tissues 
(A) Putrescine (PUT), (B) Spermidine (SPD) and (C) Spermine (SPM) level in lung 
tissues of wild type (N=2), Atp13a3-P452Lfs heterozygous (N=2), homozygous (N=1) 
mice were measured by LC-MS. Data are presented as the relative level of polyamines 


























































































































































  In this chapter, I have shown different expression patterns of Atp13a3 mRNA 
in the MCT- and hypoxia-induced rodent PAH models. In the MCT-treated rat, 
lung polyamine levels are elevated as a consequence of upregulating de novo 
polyamine synthesis [255]. This may partially explain the downregulation of 
Atp13a3 mRNA, as increased polyamine content was reported to suppress 
polyamine transport through feedback regulation [213]. Contrary to the MCT 
PH rat model, Atp13a3 mRNA was upregulated in the lungs of the hypoxia-
induced rat PH model. This is consistent with the observation that hypoxia 
promotes polyamine transport in rat lung tissues [256] and further suggests that 
Atp13a3 could be mediating the increase in polyamine content.  
 
  Adding to this finding, by using In silico analysis (Pathwaynet online database) 
I have revealed a functional relationship between HIF1α and ATP13A3 [158]. 
HIF1α is a subunit of the transcriptional factor hypoxia-induced factor 1 (HIF1). 
In normoxia, HIF1α is constantly degraded through ubiquitin-mediated 
proteasomal degradation [159]. However, hypoxia stabilises HIF1α expression 
by suppressing ubiquitination. By then dimerising with HIF1β and mediating 
transcription, a set of target genes are transactivated [161]. Intriguingly, the 
promoter region of ATP13A2, another P5B ATPase, contains hypoxia response 
elements which can bind to HIF1α [162]. Pharmacological inhibition of HIF1α 
hydroxylation increases ATP13A2 expression by preserving HIF1α level [163]. 
Interestingly, the HIF1α pathway has been demonstrated to increase polyamine 
transport in cancer cells[338]. Considering the high homology shared between 
ATP13A3 and ATP13A2, it is possible that the stabilisation of HIF-1a in hypoxia 
is responsible for Atp13a3 upregulation and hence contributes to the 
development of PH by affecting polyamine transport. However further 
investigations are needed to validate this hypothesis. The different regulation 
of Atp13a3 in MCT versus hypoxia and Sugen-hypoxia may be partly related to 
the differences in the disease pathology in these models. Although the MCT 




challenge causes PH, it also causes hepatic and renal fibrosis [279, 339], which 
may have additional impacts on polyamine metabolism. Future investigations, 
such as rebalancing polyamine transport by overexpressing Atp13a3 in the 
MCT rat or administration of an Atp13a3 neutralising antibody in the hypoxia 
and Sugen-hypoxia models may be informative to understand the role of 
Atp13a3 and polyamine dysregulation in the pathogenesis of PAH. Moreover, 
the effects of Atp13a3 on polyamine homeostasis may be cell type dependent 
in the lung vasculature. Therefore, to delineate the cell-specific role of Atp13a3 
in these models is of great importance. 
 
  Here, by collaborating with Dr Ekaterina Legchenko, we have characterised 
for the first time that the Atp13a3 frameshift mutation (P452Lfs) predisposes 
mice to develop an elevated RVSP. Disruption of Atp13a3 is likely to confer the 
phenotypes as reduced Atp13a3 expression was observed in mutant mice. The 
fact that RVSP elevation was concluded in comparison with wild type 
littermates also rules out the possibility that background genetic variation may 
contribute to phenotypes. Interestingly, preliminary data suggest a lower 
polyamine content in the lung tissues from Atp13a3 P452L (+/- and -/-) mice 
compared to their wild type littermates. These findings, at first glance, differ 
from the elevated lung polyamine contents reported in MCT and hypoxia-
induced PH. However, it is noteworthy that these pathological-insult models 
may not fully recapitulate the pathobiology of human PAH as they could be a 
physiological response (hypoxia) or lead to multi-organ injury (MCT 
administration). On the contrary, genetic models provide a “cleaner” system for 
investigating PAH pathobiology especially those induced by genetic defects. 
The fact that the Atp13a3-P452Lfs mice spontaneously developed PAH-like 
hemodynamic changes strongly suggests that reduced polyamine content 
caused by the Atp13a3 mutation contributes to the development of PAH. This 
also coincides with my previous findings that ATP13A3 deficiency achieved by 
siRNA knockdown or mutation (L726X) induced endothelial cell apoptosis by 




disrupting polyamine homeostasis (Chapter 4). It is possible that the polyamine 
elevation observed in the established PH models is the “by-product” of 
advanced disease rather than the “cause” of PAH, for example, under hypoxic 
condition, rats may upregulate their lung polyamine transport in response to 
HIF1a stabilisation while MCT administration metabolically activates the 
polyamine synthesis by elevating ODC.  
 
  ODC is another aspect that worth further attention. As shown previously 
(Chapter 4), ATP13A3 deficiency induces ODC upregulation in endothelial cells 
and DFMO partially alleviate the apoptosis triggered by ornithine 
supplementation. This suggests that elevated ODC may be an important factor 
contributing to the development of PAH, especially when polyamine 
homeostasis is disrupted. Therefore, to investigate the ODC expression and 
activities in Atp13a3 P452L mutant mice and to assess the therapeutic value of 
targeting ODC by DFMO may be of importance in understanding the 
pathological role of Atp13a3 mutation. Additionally, it is also worth validating 
these findings in PAH patients. Recently, a lung metabolomics study has 
revealed elevated level of ornithine and putrescine in PAH patients [258]. 
Plasma metabolomics profiling also demonstrated increased levels of 
polyamine metabolites in idiopathic or heritable PAH patients, with N-acetyl-
putrescine being prognostic independent of the established prognostic markers 
[259]. Considering ATP13A3 is a polyamine transporter in vascular cells, 
analysing the potential links between ATP13A3 expression and polyamine level 
in lung tissues or plasma samples from PAH patients may help to decipher any 
potential broader role of ATP13A3 dysregulation in the pathogenesis of PAH. 




 Results V- Generation of the ATP13A3-
R858H iPSC lines  
7.1 Introduction 
  Since the discovery of heterozygous germline mutations in BMPR2, 
knowledge of the molecular genetic architecture of PAH patients has expanded 
greatly. To date, 16 genes [31] have been recognised as associated with PAH, 
among which BMPR2 remains the predominant genetic cause. However, 
insights from recently-identified genes might be anticipated to further the 
understanding of the pathobiology of PAH and reveal additional treatment 
targets.  
 
  Experimental animal models, especially genetically modified mice, held 
promise as tools for examining the pathogenesis of PAH-related gene 
mutations. However, owing to the anatomical and functional differences to 
human, genetic mouse models have not generally proven to be robust PAH 
models. Furthermore, those rat models driven by disease-initiating stimuli (i.e. 
hypoxia, monocrotaline, Sugen-hypoxia) have limitations with respect to 
extrapolating to human disease [270, 279, 339]. Additionally, age, sex and 
environmental exposure to disease modifying factors are heterogeneous 
contributors to the pathobiology of human PAH and hence, make it even harder 
for animal models to entirely recapitulate the human disease condition. 
Vascular cells derived from lung tissues or blood samples of the PAH patients 
complement the rodent model analyses. However, access to these resources 
can be limited, and following isolation, primary cells only survive for a restricted 
number of passages before they senesce or change their differentiation state. 
Also, these cells are generally isolated from patients with end-stage disease, 
where changes due to chronic disease may lead to responses[340, 341] that 
are not directly due to the genetic mutation. Therefore, additional models that 




can overcome these limitations and thus represent a complementary system to 
the above models will be beneficial for studying PAH. 
 
  Induced pluripotent stem cells (iPSC) reprogrammed from somatic cells can 
be propagated indefinitely and can be differentiated into endothelial [342] and 
smooth muscle-like cells[343, 344]. These properties make iPSCs an 
appropriate alternative for modelling PAH. Indeed, several groups have 
pioneered the use of patient-derived iPSCs in studying the reduced penetrance 
of BMPR2 mutations in PAH [345]. iPSCs generated by reprogramming skin 
fibroblasts of PAH patients that are then differentiated into endothelial cells 
share similar traits to hPAECs derived from the same patient [346]. Our group 
has also reported that control iPSCs engineered to harbour a BMPR2 mutation 
using CRISPR-Cas9 editing recapitulate some PAH phenotypes after 
differentiation into endothelial cells and smooth muscle cells [273, 347]. 
Collectively, these studies demonstrate the feasibility of studying PAH with 
iPSC models.  
 
  In this chapter, I will describe the generation of an iPSC line engineered with 
the CRISPR-CAs9 editing system to harbour an ATP13A3 missense mutation 
(R858H) identified in a PAH patient. Comparative phenotyping of the mutant 
iPSC line with the isogenic wild-type line it derived from following endothelial 














7.2.1 Generation of the C2-ATP13A3R858H iPSC line by CRISPR-Cas9 gene 
editing  
  To general the mutant iPSC line, a PAH-associated ATP13A3 missense 
mutation (R858H) was introduced into a control iPSC line (C2-ATP13A3WT) 
generated from BOECs from a healthy individual using the CRISPR-Cas9 gene 
editing system (Figure 7.1). A detailed method is described in Chapter 2.9. 
 
Figure 7-1 Strategy overview for introducing the ATP13A3-R858H mutation using 
the CRISPR-Cas9 system 
7.2.1.1 CRISPR-Cas9 nuclease vector efficiency test 
  Prior to the introduction of the ATP13A3 R858H mutation, CRISPR-Cas9 
guide RNAs (gRNA) were designed using the online platform, benchling 
(www.benchling.com), based on the algorithm considering the target efficiency 
and off-target possibility.  Two CRISPR nuclease vectors containing the 
gRNAs (listed in Chapter 2, Table2-11) targeting different loci of human 
ATP13A3 were then tested for their cleavage efficiencies in the control iPSC 
(C2-ATP13A3WT) line. The orange fluorescent protein (OFP) signal was 




















indicating the successful delivery of both vectors. ATP13A3-R858H CRISPR 
vector-2 exhibited a higher transfection efficiency than vector-1, as revealed by 
a larger OFP positive cell population. To further compare the two vectors, 
cleavage efficiency was assessed (detailed method described in Chapter 3). 
As shown in Figure 7-3, insertions and/or deletions (Indels) introduced by 
CRISPR cleavage were detected by the digestion of the mismatched amplicons 
with the cleavage detection enzyme, resulting in two cleaved bands (~200bp 
and ~250bp respectively). The ATP13A3-R858H CRISPR vector-2 yielded a 
higher cleavage efficiency (40%) than vector-1 (20%) (Figure 7-3). Taken 
together, these findings suggest that the desired human ATP13A3 genomic loci 
are “editable” by CRISPR-Cas9 nuclease and that vector-2 displayed higher 
cleavage efficiency than vector-1. 
 
Figure 7-2 Orange Fluorescent Protein (OFP) signal in control iPSCs (C2) 
electroporated with ATP13A3-R858H CRISPR-Cas9 nuclease vectors 
Control iPSCs (C2-ATP13A3WT) were electroporated with GeneArt CRISPR Nuclease 
Vectors-1/2 using Nucleofector® electroporation system (Lonza). At 24-hour and 48-
hours post-transfection, the OFP signal were visualised by fluorescence microscopy. 
Representative images are shown (20x, scale bar = 250 μm). PmaxGFP vector 








(Thermo Fisher scientifics) was transfected as a positive control into C2-ATP13A3WT 
iPSCs and visualised together with the ATP13A3-R858H CRISPR-targeted cells (N=3). 
 
 
Figure 7-3 Genomic Cleavage Detection Assay for ATP13A3-R858H 
CRISPR-Cas9 vectors in control iPSCs (C2) 
Representative gel image of cleavage detection assay (N=3). Following 
immunofluorescent imaging, transfected C2-ATP13A3WT iPSCs were harvested for 
genomic DNA and were PCR amplified using primers flanking the CRISPR-Cas9 
targeting regions (Chapter2, Table. 2.10.2.1). After re-annealing, samples were 
treated with or without cleavage detection enzyme and fractionated on a 2% agarose 
gel. Band densitometry was performed on each lane using Image J. The cleavage 
efficiency was calculated according to the following equations:  
ATP13A3-R858H CRISPR-Cas9 vector-1 cleavage efficiency= 
1 - (1 - fraction cleaved)1/2 = 1 - (1 - 0.36)1/2 = 20%. 
ATP13A3-R858H CRISPR-Cas9 vector-2 cleavage efficiency:  















7.2.1.2 Introducing the ATP13A3-R858H mutation into control iPSCs (C2) 
  To introduce the ATP13A3-R858H mutation into the C2-ATP13A3WT control 
iPSC line, 3 μg CRISPR nuclease vector and 3 μg linearised ATP13A3-R858H-
LNDA repair vector were co-transfected into cells by electroporation. As 
indicated in figure 7-8A, the introduction of the R858H mutation created a de 
novo Ndel digestion site and a neomycin resistance cassette. Following 
Geneticin (G418, 50 μg/ml) selection (details described in Chapter 2.9), forty-
eight remaining colonies were further genotyped by PCR amplifying the 1kb 
LHA fragments using the primers listed previously (Chapter2, Table2-11). NdeI 
digestion screening revealed three positive colonies with cleaved bands at 
900bp and 100bp (Figure 7-8 B), indicating the successful homology-directed 
integration. Genotyping samples of the three colonies were further sequenced 
by Sanger sequencing. All lines were confirmed as carrying the homozygous 
ATP13A3-R858H mutation (Figure 7-8 C). Following expansion, these iPSC 
lines were further tested for their efficiency to differentiate into endothelial cells. 
As a result, line 33 with an average efficiency of 40-55% iPSC-EC production 
was chosen for further functional assessment.  
 
7.2.2 Pluripotency assessment of the C2-ATP13A3R858H iPSC line 
  Following genotyping, iPSC lines with the confirmed ATP13A3R858H mutation 
were expanded into 6-well plates and maintained for further use. To assess the 
pluripotency of the mutant C2- ATP13A3R858H iPSC lines, immunostaining was 
performed to assess the endogenous level of the pluripotency markers, Nanog, 
OCT4, Tra-1-60. As shown in figure 7-9, all three pluripotency markers were 
abundantly expressed in the C2-ATP13A3R858H iPSCs, indicating the mutation 
does not affect pluripotent differentiation potential in these lines.  
 
 







Figure 7-4 Introducing the ATP13A3-R858H mutation into C2-ATP13A3WT 
control iPSCs (A) Schematic for the introduction of the ATP13A3-R858H 
mutation by CRISPR-mediated homology recombination. R858H G>C mutation 
introduced a de novo NdeI restriction enzyme site. (B) Representative gel 
image of the Ndel genotyping screening. Genomic DNA from emerging cell 
colonies were PCR amplified as described in chapter 2. PCR products with or 
without Ndel digestion were run on a 1.5% agarose gel. Samples in lane 1- 6 
were from correctly targeted iPSC colonies as the DNA product can be digested 
by NdeI. (C) Representative result from Sanger sequencing. ATP13A3 R858H 
(G>A) mutation as well as three silent mutations (C>A, G>C, T>C) are 
highlighted in the red rectangles.  
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Figure 7-5 Immunostaining of pluripotency markers in C2-ATP13A3R858H 
iPSC lines 
C2-ATP13A3R858H iPSCs were seeded into 24-well plates at a density of 
30,000/well and stained for the pluripotency markers Nanog, OCT4, TRA-1-60 
(Reprocell 1:100) (Green). Nuclei were counterstained with DAPI (Blue) before 
being visualised (20X magnification, scale bar = 50 μm) using a Leica DMI3000 



















7.2.3 Generation of C2-ATP13A3R858H iPSC-derived endothelial cells 
(iPSC-ECs) 
  To examine the potential contribution of ATP13A3 mutations to the 
pathogenesis of PAH, C2-ATP13A3R858H iPSCs were first assessed for their 
ability to differentiate into endothelial cells. At the end of the 10-day 
differentiation period, immunostaining revealed efficient expression of the 
endothelial-specific markers CD31, VE-cadherin, von Willebrand factor (VWF) 
in both the C2-ATP13A3WT control and C2-ATP13A3R858H mutant iPSC-derived 
endothelial cells, indicating the successful differentiation of iPSC-ECs (Figure 
7-10). 
 
7.2.4 Generation of C2-ATP13A3R858H iPSC-derived smooth muscle cells 
(iPSC-SMCs)  
  As described in Chapter 3, ATP13A3 is expressed at similar levels in human 
pulmonary arterial endothelial cells and smooth muscle cells. Therefore, I 
assessed C2-ATP13A3R858H iPSCs for their capacity to differentiate into smooth 
muscle cells and compared these to C2-ATP13A3WT iPSCs. At the end of this 
differentiation period, iPSC-SMCs were assessed for endogenous smooth 
muscle cell markers by immunostaining. As shown in figure 7-11, both C2-
ATP13A3WT control and C2-ATP13A3R858H iPSC derived smooth muscle cells 
abundantly expressed both smooth muscle actin (SMA) and myosin heavy 












Figure 7-6 Immunostaining of endothelial markers in C2-ATP13A3WT and 
C2-ATP13A3R858H iPSC-derived endothelial cells (iPSC-ECs) 
C2-ATP13A3WT and C2-ATP13A3R858H iPSC-ECs, following differentiation, 
were seeded into 4 chamber slides (Thermo fisher Scientific) at a density of 
50,000/well and stained for the endothelial markers: VE-Cadherin, CD31, von 
Willebrand factor (VWF) (BD Biosciences) (Green) overnight. Nuclei were 
counterstained with DAPI (Blue) before visualisation (20X magnification, scale 























Figure 7-7 Immunostaining of smooth muscle markers in C2-ATP13A3WT 
and C2-ATP13A3R858H iPSC-derived smooth muscle cells (iPSC-SMCs) 
C2-ATP13A3WT and C2-ATP13A3R858H iPSC-SMCs, following differentiation, 
were seeded into 4 chamber slides (Thermo fisher Scientific) at a density of 
50,000/well and stained with the smooth muscle markers: smooth muscle actin 
(SMA) and myosin heavy chain (MHC) (Sigma-Aldrich) (Green) overnight. 
Nuclei were counterstained with DAPI (Blue) before being visualised (20X 



















7.2.5 C2-ATP13A3R858H iPSC-ECs did not display a pro-apoptotic 
phenotype in comparison to C2-ATP13A3WT iPSC-ECs 
  As demonstrated in Chapter 3, ATP13A3 silencing by siRNA increased the 
rate of apoptosis in hPAECs. Therefore, to assess the impact of this missense 
ATP13A3 mutation on endothelial cell apoptosis, C2-ATP13A3R858H iPSCs and 
C2-ATP13A3WT control iPSCs were differentiated into endothelial cells in 
parallel and assessed for cell apoptosis following serum-free exposure. As 
shown in Figure 7-12, unlike ATP13A3 deficiency in hPAECs, C2-
ATP13A3R858H iPSC-ECs displayed similar Caspase3/7 Glo activity to C2-
ATP13A3WT control iPSC-ECs both under E+ complete media or serum-free 
EBM2 (Figure 7-12). 
 
7.2.6 The R858H missense mutation does not affect ATP13A3 expression 
or polyamine uptake capacity in the C2-ATP13A3R858H iPSCs 
  Since I have observed that C2-ATP13A3R858H iPSCs exhibited similar cellular 
apoptosis rates to C2-ATP13A3WT wild type iPSCs, I then questioned if the 
mutation affects ATP13A3 expression and cellular polyamine uptake. RNA 
samples were directly isolated from iPSC lines without further differentiation. 
qPCR data reveals a similar ATP13A3 mRNA level between the two iPSC lines, 
indicating the missense mutation (R858H) does not cause transcriptional 
disruption of ATP13A3 (figure 7-13). To assess the polyamine uptake capacity, 
both iPSC lines were cultured in iPSC culture media (recipe listed in chapter 2, 
appendix) with or without the addition of 1mM putrescine, 10 μM spermidine 
and 10μM spermine overnight. As shown in Figure 7-13, both C2-ATP13A3WT 
and C2-ATP13A3R858H iPSCs display similar cellular polyamine levels either in 
the basal condition or following polyamine supplementation. These suggest that 
the R858H mutation does not cause an overt impairment of cellular polyamine 
transport.  
 






Figure 7-8 Caspase3/7 Glo activities of iPSC-EC differentiated from C2-
ATP13A3R858H and C2-ATP13A3WT iPSCs 
C2-ATP13A3R858H iPSC-ECs and control C2-ATP13A3WT iPSC-ECs were 
seeded into 96-well plates at a density of 15,000/well before being exposed to 
either E+ complete media (Chapter 2, appendix) or serum-free EBM2 overnight. 
Cellular apoptosis was assessed by Caspase3/7 Glo (Promega) (N=4). Data 
are presented as fold-change normalised to the raw value of C2-ATP13A3WT 
control iPSC-ECs cultured in E+ complete media for each experiment. Two-
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Figure 7-9 ATP13A3 mRNA expression and polyamine uptake capacity of C2-
ATP13A3WT and C2-ATP13A3R858H iPSCs (A) ATP13A3 mRNA expression in C2-
ATP13A3WT and C2-ATP13A3R858H iPSCs (N=3). Data are presented as fold 
change relative to B2M and further normalised to C2 wild type (WT) in 0.1%FBS. C2-
ATP13A3WT and C2-ATP13A3R858H iPSCs were cultured in 0.1%FBS EBM2 with 
or without the addition of 1mM putrescine, 10μM spermidine and 10μM spermine 
overnight. Cellular (B) putrescine (C) spermidine and (D) spermine levels were 
measured using LC-MS (N=3) and data are presented as the polyamine peak area 
ratio relative to sample protein concentration, and further normalised to the C2-
ATP13A3WT (WT) control in 0.1%FBS. Two-tailed Student's t-test was used for 















































  In this chapter, I have demonstrated the generation of an iPSC subclone 
harbouring an ATP13A3 missense mutation (R858H). Comparison of this 
mutant iPSC line with the isogenic wild-type parental line enables the 
assessment of the functional impact of specific mutations without the 
confounding aspect of genetic and epigenetic variation between biological 
replicates from controls and disease patients. Atp13a3 was previously reported 
to be highly expressed during mouse embryonic development [156], indicating 
a potential role in organogenesis. Here, the introduction of the R858H mutation 
did not affect the pluripotency of the iPSC line as revealed by immunostaining 
of Nanog, OCT4 and Tra1-60. Additionally, the C2-ATP13A3R858H iPSC line 
was also able to successfully differentiate into endothelial and smooth muscle 
cells. However, unlike ATP13A3 knockdown in hPAECs, the ATP13A3-R858H 
mutation alone did not lead to exaggerated apoptosis in iPSC-ECs. One 
explanation would be that the R858H missense mutation causes a milder 
impairment on ATP13A3 function, without affecting its expression. Moreover, 
C2-ATP13A3R858H iPSCs also exhibit similar polyamine uptake capacity to the 
isogenic parental C2-ATP13A3WT control line. Of note, hPAECs overexpressing 
the ATP13A3-R858H mutation displayed a less robust reduction of putrescine 
uptake compared with the impact of the catalytically inactivated ATP13A3 
mutant (D498N), suggesting the R858H mutant might have a mild effect 
(Chapter 4).  
  So far, genetic studies [19, 27, 348] in F/HPAH cohorts have revealed an 
autosomal dominant transmission of gene variants with incomplete penetrance 
in PAH patients. Although BMPR2 mutations account for 70–80% of familial 
[328] and 10–20% of sporadic PAH cases [329], the disease penetrance only 
ranges between 14-42% [348, 349]. The heterozygous R858H mutation was 
identified from a PAH patient and chosen for the generation of the mutant iPSC 
line, which is a lengthy process. My parallel overexpression experiments have 
suggested that this may represent a mild mutation. If I were to generate a 




second mutant line, I would select one of those mutations identified as having 
a stronger effect in my in vitro assays. However, it is also possible that the 
R858H missense mutation serves as predisposing mutation, and additional 
disease-promoting stimuli are required for disease occurrence. Recently, 
Lerche M et al.[109]has reported that an IFN-β induced PAH case in a multiple 
sclerosis patient with a nonsense ATP13A3 mutation (Glu514*). The fact that 
withdrawing IFN-β improved PAH symptoms in this patient suggests that 
additional factors may confer PAH development in ATP13A3 mutation carriers. 
Interestingly, type I interferon was shown to induce the development of PAH in 
the mouse by activating Interferon Alpha and Beta Receptor Subunit 1 (IFNAR1) 
[350]. The IFNAR1 protein is rapidly turned over via internalization and 
recycling through the endocytic system [351]. Therefore, investigating a 
potential link between ATP13A3 and IFNAR1, especially in the presence of type 
I interferon may be informative in uncovering the underlying mechanism of 
ATP13A3 mutations penetrance in PAH pathobiology. This could be assessed 
in C2-ATP13A3R858H iPSCs and compared to the response in C2-ATP13A3WT 
iPSCs. Interestingly, I have demonstrated an upregulation of ATP13A3 mRNA 
by IL-1β in hPASMC (chapter 5). However, how this may affect polyamine 
dysregulation is still unknown, especially on the background of an ATP13A3 
mutation. Additionally, cells with or without genetic defects may respond to 
stimuli differently. For example, the transcriptional fingerprint of hPASMCs 
bearing BMPR2 mutation in response to TGFβ is distinct to control hPASMCs 
[165], with TGFβ–dependent upregulation of ATP13A3 mRNA transcription 
observed in mutant, but not in control hPASMCs (Chapter 5). Elevated plasma 
IL-1β level was also documented in PAH patients and correlated with worse 
clinical outcomes [74]. In addition, both in vivo [352, 353] and in vitro [354-356] 
data have suggested IL-1β as a potent inflammatory disease driver for PAH. 
Therefore, to investigate the response to IL-1β in C2-ATP13A3R858H iPSCs and 
in C2-ATP13A3WT iPSCs and how this affects cellular polyamine levels may 
lead to a further understanding of ATP13A3 mutation in PAH pathogenesis.   




 General Discussion and Future Work 
 
8.1 Summary of findings and limitations 
  Pulmonary arterial hypertension (PAH) is a devastating vascular disorder 
characterised by the progressive remodelling of small pulmonary arteries. 
Although the aetiologies of PAH can be diverse, genetic defects are a major 
cause, accounting for approximately one-third of the IPAH patient population 
[31, 357]. Recently, ATP13A3, the gene encoding an enigmatic cation 
transporter, was identified as a novel PAH associated gene [27]. My thesis 
focussed mainly on characterising the functions of ATP13A3 in the pulmonary 
vasculature and the underlying mechanism of how disease-associated 
mutations contribute to PAH pathogenesis. 
  Some prior evidence has suggested a tentative link between ATP13A3 and 
polyamines [139, 147]. Similar to that in Hela cells [141], ATP13A3 was shown 
to reside in the recycling endosome of endothelial cells. This is consistent with 
ATP13A3 being a cellular polyamine transporter as the endocytic system is 
proposed to be essential for polyamine trafficking [190]. Indeed, my studies of 
cellular polyamine measurement revealed ATP13A3 as mediating polyamine 
transporter in endothelial cells with a higher selectivity towards putrescine than 
spermidine and spermine (Chapter 4). In addition to transport, ATP13A3 
deficiency in endothelial cells also affects polyamine metabolism, manifesting 
by post-translational upregulation of ODC1.  
  Polyamines are essential for cell growth [104, 171] while their depletion 
causes cell cycle arrest [191]. In line with these findings, I observed that 
ATP13A3 deficiency, by reducing cellular polyamine content (Chapter 4), 
suppressed vascular cell proliferation and downregulated cyclin A, E and B 
mRNA expression in BOECs (Chapter 3). The reduction of these cyclins, but 
not cyclin D, suggests repression of G1-S transition and DNA synthesis. Aside 
from affecting cell proliferation, ATP13A3 loss also predisposed endothelial 




cells to apoptosis. One potential explanation for this finding includes the 
polyamine reduction via ATP13A3 loss as decreased polyamines may promote 
cell apoptosis under pathogenic insults [310][311]. ODC overproduction might 
also play a part in the apoptosis driven by ATP13A3 loss, since high ODC level 
was reported in cells undergoing apoptosis [308][309]. However, DFMO co-
administration only partially reversed this apoptotic phenotype, suggesting that 
EC apoptosis driven by ATP13A3 deficiency is more likely related to the 
polyamine deficiency rather than ODC overproduction. Moreover, I also 
observed that ATP13A3 loss exacerbated thrombin-dependent hPAECs 
monolayer permeability. Interestingly, studies have demonstrated polyamines 
as crucial factors for maintaining cell-cell junctions [244][245]. Therefore, 
further investigations of the impact of ATP13A3 loss on adherens or tight 
junction molecules, such as VE-Cadherin and Zo-1, may provide further 
mechanistic insights.  
  Having demonstrated that ATP13A3 deficiency can disrupt endothelial 
homeostasis, I next sought to characterise the functional impacts of PAH-
associated ATP13A3 mutations using a lentiviral overexpression system. 
Interestingly, L675V, M850I, V885M mutations exhibited substantial 
impairment on ATP13A3 mediated putrescine uptake while the impacts of 
R858H, L965P were milder. A disadvantage of using overexpression systems 
for characterising mutations is that it might not represent the endogenous 
biological state. As a surrogate, BOECs generated from a PAH patient bearing 
an ATP13A3 frameshift mutation (LK726X) were characterised. Importantly, 
LK26X, by reducing ATP13A3 expression via nonsense-mediated mRNA 
decay of the mutant transcript, recapitulated the pathological phenotypes such 
as reduced putrescine uptake and increased apoptosis observed in ATP13A3-
deficent BOECs. These findings reinforced the hypothesis that genetic defects 
in ATP13A3 participate in PAH pathobiology via the disruption of polyamine 
homeostasis. However, cells derived from PAH-patients may have acquired 
disease-associated somatic changes such as DNA damage [84, 340]. 




Therefore, to functionally assess specific mutations without confounding these 
aspects, an iPSC subclone harbouring an ATP13A3 missense mutation 
(R858H) was generated. However, R858H did not affect polyamine uptake 
capacity, nor did it exacerbate apoptosis in ATP13A3R858H iPSC-ECs. A likely 
explanation is that R858H impairs ATP13A3 function only mildly, supported by 
no disruption on ATP13A3 expression and a marginal reduction of putrescine 
uptake in hPAECs (Chapter 4). In this context, incomplete disease penetrance 
for ATP13A3 missense mutations, similar to BMPR2 [348], might mean that 
additional stimuli are required to reveal disease-associated phenotypes. Of 
note, IFN-β promoted PAH in a multiple sclerosis patient harbouring a 
nonsense ATP13A3 mutation (Glu514*) [109]. Therefore, the impact of IFN-β 
on the function of C2-ATP13A3R858H warrants further investigation. Collectively, 
the in vitro data generated in my studies have demonstrated that ATP13A3 is 
a polyamine transporter with a higher preference towards putrescine. ATP13A3 
deficiency or mutation, by affecting cell polyamine homeostasis, leads to 
endothelial dysfunction. These findings provide strong evidence for a 
pathogenic link between ATP13A3 genetic defects and PAH, providing new 
insights into the involvement of polyamine dysregulation in the pathobiology of 
PAH.  
  Adding to my in vitro data, in collaboration with Dr. Ekaterina Legchenko, we 
have observed elevated RVSP in mice with the Atp13a3P452Lfs/P452Lfs frameshift 
mutation compared to wild-type litter mates at 6 months of age. The mutant 
mice have reduced Atp13a3 expression in their lungs, suggesting a link 
between Atp13a3 loss of function and hemodynamic alterations. Although 
preliminary, I have also observed lower polyamine contents in the lungs of 
Atp13a3P452Lfs/P452Lfs and Atp13a3P452Lfs/+ mice compared to their wild type 
littermates. At first glance, these findings contradict the elevated lung 
polyamine contents reported in MCT [358]and hypoxia-induced PH [255]. 
However, the polyamine elevation observed in these PH models may represent 
a “by-product” of advanced disease due to upregulation of their lung polyamine 




transport (hypoxia) or polyamine synthesis (MCT). Conversely, genetic rodent 
models may provide a "cleaner" system for investigating the pathobiology of 
PAH and our data suggest that, Atp13a3P452Lfs/P452Lfs mice spontaneously 
develop PAH-like hemodynamic changes. Given that ATP13A3 deficiency 
(Chapter 4) increased ODC in endothelial cells and inhibition with DFMO 
alleviated the apoptosis triggered by ornithine, the regulation and therapeutic 
inhibition of Odc warrants investigation. Furthermore, polyamine dysregulation 
has been documented in human PAH via metabolomic profiling of human lung 
samples [258] or plasma samples [259], so analysis of plasma polyamine 
contents in PAH patients harbouring ATP13A3 mutations may be informative. 
This might also be assessed regarding correlation to ATP13A3 expression in 
blood-derived cells from these PAH patients to explore a potential broader role 
of ATP13A3 dysregulation in the pathogenesis of PAH.   
 
8.2 Conclusions and Future directions  
  In my studies, I have demonstrated that ATP13A3, residing in the recycling 
endosome, functions as a polyamine transporter in human vascular endothelial 
cells with putrescine as the preferred substrate. Deficiency of ATP13A3 induces 
endothelial dysfunction via the impairment of polyamine transport and 
subsequent ODC overproduction. PAH-associated ATP13A3 mutations 
compromise polyamine homeostasis and hence promote PAH. Notably, 
BOECs isolated from a PAH patient harbouring a frameshift ATP13A3LK726X 
mutation exhibited disease-associated phenotypes, possibly due to the 
disruption of cellular polyamine homeostasis. Collectively, these findings 
suggest a crucial role of ATP13A3 in maintaining vascular homeostasis with 








Based on the current findings, the investigation of ATP13A3 and its role in PAH 
might proceed in a number of directions.  
 
8.2.1 Biochemical characterisation of ATP13A3 
  Although I have demonstrated that ATP13A3 mediates polyamine uptake in 
vascular cells, a potential disadvantage of unlabelled polyamine 
supplementation combined with cellular polyamine measurement is that it does 
not exclude the possibility of compensation by polyamine metabolism. 
Therefore, further validation using supplementation with fluorescent-labelled 
(Bodipy-) or radioactive-labelled polyamines would further strengthen my 
findings.   
 
  Additionally, characterising the biochemical transport function of ATP13A3 
regarding to the aspartyl site autophosphorylation/dephosphorylation and the 
activation of ATP hydrolysis, both of which are heavily reliant on substrate 
binding, requires further study. These can be examined via [γ-32P] ATP based 
autophosphorylation assay using full-length ATP13A3 purified in a yeast 
overexpression system [141] or a luminescence ATPase activity assay using 
cell microsomal fractionation [148]. These two assays will enable a further 
comparison of the preferable polyamine for ATP13A3, and provide a means to 
screening additional transport substrates. Once developed, these together with 
the LC-MS based assay I have demonstrated earlier, may facilitate a more 
comprehensive functional assessment of the PAH associated mutations in 
ATP13A3.    
 
8.2.2 ATP13A3 in human pulmonary arterial smooth muscle cells 
  My current study has mainly focussed on investigating the role of ATP13A3 
in endothelial cells. However, hPASMC dysfunction also contributes to the 
pathogenesis of PAH. Preliminary data from my study suggests that ATP13A3 
deficiency reduces hPASMCs growth, but whether this is due to disrupted 




polyamine homeostasis is unclear. Notably, unlike endothelial cells, ODC 
protein was not increased by ATP13A3 deficiency in hPASMCs, which may 
indicate either a heavier reliance on the polyamine biosynthesis or a different 
substrate preference by ATP13A3 in hPASMC. Therefore, a comprehensive 
assessment of whether ATP13A3 mediates polyamine transport and its 
substrate specificity in hPASMCs would be informative. Interestingly, spermine 
was recently shown to induce hPASMC proliferation via the upregulation of 
spermine synthase (SMS) [360], so investigation of a potential link between 
ATP13A3 and SMS would also provide a further direction for exploring 
polyamine dysregulation in PAH.  
 
8.2.3 Atp13a3 P452Lfs mice 
  Promisingly, we observe an elevated RVSP in Atp13a3 P452Lfs mice at 6-
months of age. However, deeper phenotyping of these mice is required, 
including lung morphometric analysis of these mice to assess vessel 
remodelling. Moreover, as the hemodynamic elevation presents at 6-months of 
age, but not 3 months, it would be interesting to track the polyamine changes 
over time to establish if polyamine dysregulation might contribute to the disease 
phenotype. Furthermore, as observed in my in vitro study, ATP13A3 deficiency 
causes substantial upregulation of endothelial ODC, so determination of Odc 
expression in endothelial cells from the Atp13a3P452Lfs.mice would be of interest. 
If endothelial Odc is elevated, the therapeutic potential of targeting ODC by 
DFMO in these mice would be assessed. Finally, as BMP9 selectively induces 
ATP13A3 mRNA expression in BOECs, a proof-of-concept study to enhance 
the expression of the non-mutated Atp13a3 allele with BMP9 in heterozygous 
Atp13a3P452Lfs/+ mice and assess how it affects polyamine homeostasis and 
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Materials and buffer recipes 
Mouse Genomic DNA extraction reagents: 
Digestion buffer recipe:50mM Tris-HCl, pH 8.0; 5mM EDTA, pH 8.0; 100mM 
NaCl; 1% sodium dodecyl sulfate (SDS) 
 
RNA extraction from cells/tissues material 
Cell RNA extraction 
Silica membrane column: EconoSpin® All-In-One Mini Spin Columns for 
DNA/RNA extraction 
Buffer recipe: 
Cell lysis buffer: RLT buffer (Qiagen) 1:100 diluted with β-Mercaptoethanol. 
RNase-Free DNase solution (Qiagen): One vial of RNase-Free DNase 
dissolved in 550μl of nuclease-free water. 
Tissue RNA extraction 
TissueLyser II (Qiagen)，Stainless steel beads (Qiagen) 
5PRIME Phase Lock Gel tubes (Quantabio) 




EDTA-free protease inhibitor cocktail (Roche): Two tablets per 1 ml dH2O. 
Aliquoted 50μl/tube and stored at -20ºC.  
Lysis Buffer recipe: 
SDS Lysis buffer: 125mM Tris HCl pH 7.4, 2% SDS, 10% glycerol.  Aliquoted 
950μl/tube and store at -20°C. One aliquot (50μl) EDTA-free protease inhibitor 





Radioimmunoprecipitation buffer (RIPA buffer): 50mM Tris HCl pH7.4, 0.5% 
Sodium deoxycholate, 150mM NaCl, 0.1%SDS, 1% IGEPAL CA-630. Aliquoted 
950μl/tube and store at -20°C. One aliquot (50μl) EDTA-free protease inhibitor 
cocktail was added into one aliquot (950 μl) RIPA Lysis buffer before used.  
Buffer recipe for Western blotting: 
5x Sample loading buffer: 312.5mM Tris.HCl pH6.8, 10%SDS, 50%Glycerol, 
0.0075%(w/v) bromophenol blue, 25%(v/v) β-Mercaptoethanol 
Tris(tris(hydroxymethyl)aminomethane) buffered saline, Tween20 (TBS-T): 
10mM Tris.HCl, 150mM NaCl; pH7.4, 0.05% Tween 20 
Protein Electrophoresis buffer:  
25mM Tris, 192mM Glycine, 0.01%SDS 
Protein transfer buffer:  




Slides: 4-chambered Nunc™ Lab-Tek™ II Chamber Slides™ (Thermo Fisher 
Scientific) 
Slide coating buffer: Type I Rat Tail Collagen (BD biosciences) 1:100 (v/v) in 
0.02N acetic acid 
Buffer recipe: 
Fixation 
4% Paraformaldehyde solution: 
39% Formaldehyde solution (Sigma) 1:10 diluted with PBS buffer. 
Permeabilisation 
0.05% Saponin solution: 
0.05% (w/v) Saponin (Sigma) in 0.5% (w/v) BSA (sigma) in PBS buffer. 







Human induced pluripotent stem cell (iPSCs) 
Cell culture media recipes 
Chemically defined medium (CDM): 
Ham’s F-12 Nutrient Mixture (49.5%v/v, Thermo Fisher Scientific) 
Iscove’s Modified Dulbecco’s Medium (IMDM) (49.5%v/v, Thermo Fisher 
Scientific) 
Chemically defined lipid concentrates (1%v/v, Thermo Fisher Scientific) 
Transferrin from human serum (15μg/ml, Roche) 
Recombinant human insulin (7μg/ml, Roche) 
1-thioglycerol (450 μM, Sigma) 
Knockout Serum Replacement (KSR) medium:  
Advanced DMEM/F12 (79.5%v/v, Thermo Fisher Scientific) 
Knockout Serum Replacement (19.5% v/v, Thermo Fisher Scientific) 
MEM Non-Essential Amino Acids Solution (1%v/v, Thermo Fisher Scientific) 
L-glutamine (2mM, Thermo Fisher Scientific) 
FGF2(10ng/ml) 
CDM-BSA: CDM media supplemented with 5mg/ml bovine serum albumin 
(BSA, Sigma). 
CDM-PVA: CDM media supplemented with 1.2mg/ml polyvinyl alcohol(sigma) 
Feeder-dependent iPSC culture medium (25% media): 
CDM-BSA (25% v/v), KSR (50% v/v), Conditioned media from iMEFs cultured 
in CDM-BSA supplemented with 4ng/ml FGF-2 for 24 hours (25% v/v), Activin 
A(12.5ng/ml), FGF-2(15ng/ml), L-ascorbic acid(50ng/ml) 
Feeder-free iPSC culture medium (CDM-BSA/KSR, BK): 
CDM-BSA (50% v/v), KSR (50% v/v), Activin A(12.5ng/ml), FGF-2(15ng/ml), 
L-ascorbic acid (50ng/ml, Sigma) 
iPSC-ECs differentiation basal media(E+): 
EGM2-MV2 serum-free media (Promocell) supplemented with Chemically 





Sigma), Transferrin from human serum (15μg/ml, Roche) and Recombinant 
human insulin(7μg/ml, Roche) 
iPSC-ECs full growth media (E+ FGM): 
E+ media supplemented with 2% FBS(Lonza), 5ng/ml FGF2, 20ng/ml human 
VEGFA165, 10uM SB 431542 and 5uM DAPT. 
 
